ArticlePDF AvailableLiterature Review

Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects

  • University Politecnica delle Marche of Ancona

Abstract and Figures

Sexual enhancers increase sexual potency, sexual pleasure, or libido. Substances increasing libido alter the concentrations of specific neurotransmitters or sex hormones in the central nervous system. Interestingly, the same pathways are involved in the mechanisms underlying many psychiatric and neurological disorders, and adverse reactions associated with the use of aphrodisiacs are strongly expected. However, sexual enhancers of plant origin have gained popularity over recent years, as natural substances are often regarded as a safer alternative to modern medications and are easily acquired without prescription. We reviewed the psychiatric and neurological adverse effects associated with the consumption of herbal aphrodisiacs Areca catechu L., Argemone Mexicana L., Citrus aurantium L., Eurycoma longifolia Jack., Lepidium meyenii Walp., Mitragyna speciosa Korth., Panax ginseng C. A. Mey, Panax quinquefolius L., Pausinystalia johimbe (K. Schum.) Pierre ex Beille, Piper methysticum G. Forst., Ptychopetalum olacoides Benth., Sceletium tortuosum (L.) N. E. Brown, Turnera diffusa Willd. ex. Schult., Voacanga africana Stapf ex Scott-Elliot, and Withania somnifera (L.) Dunal. A literature search was conducted on the PubMed, Scopus, and Web of Science databases with the aim of identifying all the relevant articles published on the issue up to June 2020. Most of the selected sexual enhancers appeared to be safe at therapeutic doses, although mild to severe adverse effects may occur in cases of overdosing or self-medication with unstandardized products. Drug interactions are more concerning, considering that herbal aphrodisiacs are likely used together with other plant extracts and/or pharmaceuticals. However, few data are available on the side effects of several plants included in this review, and more clinical studies with controlled administrations should be conducted to address this issue.
Content may be subject to copyright.
Pharmaceuticals 2020, 13, 309; doi:10.3390/ph13100309
Pharmacology of Herbal Sexual Enhancers: A Review
of Psychiatric and Neurological Adverse Effects
Pietro Brunetti 1, Alfredo Fabrizio Lo Faro 1, Anastasio Tini 2, Francesco Paolo Busardò 1,* and
Jeremy Carlier 1,2
1 Unit of Forensic Toxicology, Section of Legal Medicine, Department of Excellence of Biomedical Sciences
and Public Health, Marche Polytechnic University, 60126 Ancona, Italy; (P.B.); (A.F.L.F.); (J.C.)
2 Unit of Forensic Toxicology, Section of Legal Medicine, Department of Anatomical, Histological, Forensic,
and Orthopedic Sciences, Sapienza University of Rome, 00198 Rome, Italy;
* Correspondence:; Tel.: +39-071-5964727
Received: 9 September 2020; Accepted: 12 October 2020; Published: 14 October 2020
Abstract: Sexual enhancers increase sexual potency, sexual pleasure, or libido. Substances
increasing libido alter the concentrations of specific neurotransmitters or sex hormones in the central
nervous system. Interestingly, the same pathways are involved in the mechanisms underlying many
psychiatric and neurological disorders, and adverse reactions associated with the use of
aphrodisiacs are strongly expected. However, sexual enhancers of plant origin have gained
popularity over recent years, as natural substances are often regarded as a safer alternative to
modern medications and are easily acquired without prescription. We reviewed the psychiatric and
neurological adverse effects associated with the consumption of herbal aphrodisiacs Areca catechu
L., Argemone Mexicana L., Citrus aurantium L., Eurycoma longifolia Jack., Lepidium meyenii Walp.,
Mitragyna speciosa Korth., Panax ginseng C. A. Mey, Panax quinquefolius L., Pausinystalia johimbe (K.
Schum.) Pierre ex Beille, Piper methysticum G. Forst., Ptychopetalum olacoides Benth., Sceletium
tortuosum (L.) N. E. Brown, Turnera diffusa Willd. ex. Schult., Voacanga africana Stapf ex Scott-Elliot,
and Withania somnifera (L.) Dunal. A literature search was conducted on the PubMed, Scopus, and
Web of Science databases with the aim of identifying all the relevant articles published on the issue
up to June 2020. Most of the selected sexual enhancers appeared to be safe at therapeutic doses,
although mild to severe adverse effects may occur in cases of overdosing or self-medication with
unstandardized products. Drug interactions are more concerning, considering that herbal
aphrodisiacs are likely used together with other plant extracts and/or pharmaceuticals. However,
few data are available on the side effects of several plants included in this review, and more clinical
studies with controlled administrations should be conducted to address this issue.
Keywords: aphrodisiac; sexual enhancer; plant; pharmacology; toxicology; psychiatry; neurology;
adverse effect
1. Introduction
Sexual drive is influenced by biological, psychological, and social factors, but it can also be
affected by medications and medical conditions. Many prescription drugs and narcotics (e.g.,
antidepressants, anxiolytics, antihistamines, antihypertensives, adrenergic receptor blockers,
antipsychotics, and opioids) can negatively impact sexual desire, inhibit erection, ejaculation, or
orgasm, and so on. Contrariwise, many aphrodisiac substances can improve sexual performance. In
particular, substances of natural origin have been used worldwide for millennia in traditional
medicines to boost sexual desire, sexual pleasure, or sexual behavior [1], and the use of psychoactive
and/or stimulant drugs during intercourse, i.e., chemsex, is on the rise [2]. Nowadays, sexual
Pharmaceuticals 2020, 13, 309 2 of 52
performance anxiety, which contributes to psychogenic erectile dysfunction, is estimated to affect 9
to 25% of men in the United States, and phytotherapy is often employed as a treatment [3]. In 2007,
approximately 56% of infertile couples had sought medical care worldwide [4] and many of these
couples had opted for supportive complementary and alternative medicines to treat infertility. In
2010, in the United States, approximately 29% of 428 infertile couples had utilized an alternative
treatment after 18 months of observation, 59% of which had taken herbal therapy [5]. Natural
substances are mistakenly believed to be a safer alternative to modern medications with no side
effects. They are also readily accessible on the Internet and specialized markets without a
prescription. Consequently, the use of herbal supplements to enhance sexual drive has become
increasingly popular, and more than 300,000 intoxications were reported to poison control centers
over the last 20 years [6,7].
According to Sandroni, aphrodisiacs can be classified into three categories according to whether
they increase potency (i.e., effectiveness of erection in males), sexual pleasure, or libido (i.e., sexual
desire) [8]. Potency-enhancing substances typically induce vasodilation, often through the nitric
oxide (NO) pathway, inducing hypotension and potentially harmful cardiovascular effects (e.g.,
sildenafil and L-arginine). Sexual pleasure-enhancing substances cause tumescence and lubrication
of the genital mucosa, therefore increasing sensation (e.g., cantharidin). Libido-enhancing substances
alter the concentrations of specific neurotransmitters (e.g., dopaminergic and serotoninergic
pathways) or sex hormones (e.g., pituitary hormones and testosterone) in the central nervous system
(CNS) [8]. For example, methamphetamine is a synthetic illicit psychomotor stimulant affecting the
mesolimbic dopamine pathway, which plays an essential role in motivation and the reward system.
A substantial body of evidence shows that acute methamphetamine use is associated with enhanced
positive sexual experiences and libido, with a greater likelihood of engaging in high-risk sexual
behaviors. Sexual behavior, however, may be impaired due to chronic methamphetamine exposure
The modulation of neurotransmission is also involved in the mechanisms underlying many
psychiatric and neurological disorders. For instance, although not fully understood, the
dysregulation of monoaminergic systems, especially the decrease in serotoninergic, dopaminergic,
and adrenergic neurotransmissions, seems to be the primary cause of depression [10]. Contrariwise,
mania is believed to be the consequence of an excess of the same monoamines in specific regions of
the brain [11]. Schizophrenia, however, mainly involves dopaminergic and glutamatergic
neurotransmissions [12]. In neurology, a deficit of dopamine due to the death of cells in the substantia
nigra is the primary cause of Parkinson’s disease, while Alzheimer’s disease is due to the
degeneration of the hippocampus and the raphe nuclei, affecting the cholinergic pathway [13]. The
drugs approved to treat psychiatric and neurological conditions mainly target these
neurotransmission pathways.
Considering the mechanism of action of sexual enhancers, psychiatric and neurological adverse
effects associated with their consumption are strongly expected. In 2014, Corazza et al. reviewed the
psychoactive effects of four popular sexual enhancers [6]. In March 2020, Srivatsav et al. reviewed
the efficacy and the safety profile of several common aphrodisiacs used in the treatment of erectile
dysfunction, but the study was not exhaustive and psychiatric and neurological adverse effects were
not addressed [14]. In this review, we aimed to summarize and interpret the findings of cases and
preclinical and clinical studies reporting psychiatric and neurological adverse effects associated with
the use of aphrodisiacs of plant origin. A preliminary screening of the literature allowed for the
identification of several plants with potential psychiatric or neurological complications, which were
therefore included in this review: Areca catechu L., Argemone Mexicana L., Citrus aurantium L.,
Eurycoma longifolia Jack., Lepidium meyenii Walp., Mitragyna speciosa Korth., Panax ginseng C. A. Mey,
Panax quinquefolius L., Pausinystalia johimbe (K. Schum.) Pierre ex Beille, Piper methysticum G. Forst.,
Ptychopetalum olacoides Benth., Sceletium tortuosum (L.) N. E. Brown, Turnera diffusa Willd. ex. Schult.,
Voacanga africana Stapf ex Scott-Elliot, and Withania somnifera (L.) Dunal.
Pharmaceuticals 2020, 13, 309 3 of 52
2. Results
Of 5255 potentially relevant reports, 4758 were excluded because they did not describe
psychiatric or neurological adverse effects or because they were not written in English, French, or
Italian language. No relevant reports were found for A. Mexicana, E. longifolia, L. meyenii, T. diffusa, V.
africana, and W. somnifera, which were therefore excluded from the results. A total of 137 records were
included in the final review; species-by-species search results are detailed in a flow diagram in Figure
1. A general description of each species including their traditional and modern uses, active
ingredients with their mechanism of action and pharmacokinetics, and general toxicity, is provided
in the discussion. Psychiatric and neurological adverse events reported in the literature are displayed
in Table 1; study conditions and co-exposures are also detailed.
Figure 1. Species-by-species flow diagram of literature search.
Pharmaceuticals 2020, 13, 309 4 of 52
Table 1. Reports of psychiatric and neurological adverse events associated with herbal aphrodisiacs.
Ingredients Co-Exposure Study, Participants, Age, and Sex Neurological/Psychiatric Effects References
Areca catechu
Fluphenazine decanoate,
procyclidine, flupentixol
Case reports of acute intoxications with
Areca catechu L. in two schizophrenic
men aged 51 and 45; both patients
consumed a high quantity of betel nuts
for 2 weeks
Rigidity, bradykinesia, akathisia, and
tremors [15]
Tobacco, alcohol, cannabis,
Survey study on 11 participants aged
27–70 (average = 52), 9 males and 2
females; chewed 6 nuts/week (range =
4–6 days)
Mood swings, anxiety, irritability, reduced
concentration, reduced energy, sleep
disturbance, craving, tolerance, and
Tobacco, salbutamol, tea, coffee,
Longitudinal pilot study on 100
participants, 26 users with a mean
(±SD) age of 40.0 (±9) years, 11 males
and 15 women
Enhancement of physiological tremor [17]
Tobacco, alcohol
Cross-sectional study on 310 pregnant
women, 292 users, mean age of 26 years
(range = 25–27); took 5–10 nuts during
Addiction [18]
Survey study on 59 participants, 47
males and 12 females, median age of
43.0 years (range = 12–70); 1–50 years of
Craving and dependence [19]
Cross-sectional study on 851
participants, aged 16–35, 314 users, 242
tobacco + users, and 295 regular
cigarette smokers; <6–>10 years of
Tolerance and withdrawal [20]
Tobacco, alcohol
Intercountry Asian BQ Consortium
study on 2078 participants who took
any A. catechu products/day for a
minimum of 6 months
Tolerance, withdrawal, craving, and
dependence syndrome [21]
Pharmaceuticals 2020, 13, 309 5 of 52
Tobacco, alcohol
Survey study on 41 participants with a
mean (±SD) age of 40.34 (±9.23) years,
27 males and 14 females; took 5 to more
than 31 BQ/day
Relaxation, stimulation, addiction, and
withdrawal symptoms [22]
carbamazepine, levetiracetam,
phenobarbital, phenytoin,
sodium valproate, other
medications (not specified)
Observational study on 152 participants
with epilepsy, 50 users with a mean age
of 28.4 (95% CI: 25.3, 31.6) years, 23
males and 27 women; chewed 1–20
nuts/day for more than 5 years
Drowsiness [23]
Tobacco and alcohol-
Epidemiological studies of dependence
on 4031 participants
Case report of two women
Dependence, tolerance, withdrawal,
attentional bias, impaired work, impaired
time perception, and increased arousal
Poor concentration, lethargy,
despondency, and episodes of paranoia (1
Survey study on 200 participants, 171
males and 29 females aged 22–45 years;
chewed 4.3 nuts/day
Addiction [25]
Nicotine, arecaidine (1.46
µg/mL in urine), N-
methylnipecotate, cotinine
Cross-sectional survey on 113
participants with a mean (±SD) age of
40.0 (±12.6) years, 104 males and 9
Craving for BQ, addiction, depression, and
drowsiness [26]
Arecoline Methscopolamine
Cholinergic REM induction test on 34
participants: 14 bipolar patients with a
mean (±SD) age of 30 (±6.1) years, 6
males and 8 females; 15 HC volunteers
with a mean (±SD) age of 26.8 (±4.4)
years, 8 males and 7 females; and 5
subjects with a personal or family
history of affective disorders, age
ranged between 23 and 35 years, 2
males and 3 females; administered with
0.5 mg of arecoline
Shorter REM latency in patients with
primary affective disorders (1st and 3rd) [27]
Pharmaceuticals 2020, 13, 309 6 of 52
Pilot dose–response study on 24
participants, 8 bipolar subjects and 16
HC monozygotic twins; administered
with 1 or 12 mg of arecoline IP and 4 or
12 mg SC
Nausea, vomiting, increased anger,
confusion, depression, fatigue and tension,
decreased elation, friendliness, and vigor
Arecoline REM induction test on 97
participants: 20 MDD patients with a
mean age of 46.6 years (range 22–83), 8
males and 12 females; 19 MDD+ANX
patients with a mean age of 40.0 years
(range 21–47), 7 males and 12 females;
18 ANX patients with a mean age of
32.2 years (range 22–51), 8 males and 10
females; 14 ANX+MDD patients with a
mean age of 32.8 years (range 23–38), 4
males and 10 females; and 26 healthy
controls with a mean age of 36.4 years
(range 20–87), 11 males and 15 females;
administered with 0.5 mg of arecoline
Rapid REM induction in MDD and
MDD+ANX patients compared to healthy
Methyl atropine
Animal study on 265 Sprague Dawley
rats; administered with 2 mg/kg of
Decreased locomotory activity [30]
Cognitive and behavioral study on 12
participants with AD, mean age of 65.5
years (range 54–79), 4 males and 8
females; administered with 0.5 and 12
mg/h of arecoline for 1 to 6 h
Decreased knowledge memory,
psychomotor retardation, dysphoria, and
difficulty with verbal expression
Arecoline REM induction test on 30
participants: 10 with atypical
depression with a mean (±SD) age of
33.5 (±7.8) years, 4 males and 6 females,
and 20 HC with a mean (±SD) age of
34.5 (±13.8) years, 10 males and 10
Rapid REM induction in atypical
depressives without a history of panic
attacks or anxiety disorders compared to
Pharmaceuticals 2020, 13, 309 7 of 52
females; administered with 0.5 mg of
Catecholamine and ACTH responses to
an arecoline study on 31 participants: 15
MSA patients with a mean (±SD) age of
57.9 (±1.8) years, 8 males and 7 females;
6 PAF patients with a mean (±SD) age
of 52.3 (±1.8) years, 2 males and 4
females; and 10 HC with a mean (±SD)
age of 58.5 (±4) years, 7 males and 3
females; administered with 0.3 mg of
Mild vertigo, nystagmus, nausea,
exacerbation of tremor, and alteration in
Randomized, double-blind, placebo-
controlled study on 111 participants: 40
placebo-receiving subjects, including 20
depressed patients with a mean (±SD)
age of 39 (±12) years and 20 HC with a
mean (±SD) age of 28 (±6) years; 38
subjects receiving 0.5 mg of arecoline,
including 21 depressed patients with a
mean (±SD) age of 38 (±9) years and 17
HC with a mean (±SD) age of 28 (±6)
years; and 33 subjects receiving 1.0 mg
of arecoline, including 18 depressed
patients with a mean (±SD) age of 42
(±11) years and 15 HC with a mean
(±SD) age of 34.5 (±13.8) years
Shorter REM latency in depressed patients [34]
Cholinergic REM induction test on 48
participants: 33 MDD children with a
mean (±SD) age of 10.5 (±1.5) years, 26
males and 7 females and 15 HC
children with a mean (±SD) age of 10.2
(±1.6) years; administered with 0.5 mg
of arecoline over 60 min
Shorter REM latency in depressed children [35]
Pharmaceuticals 2020, 13, 309 8 of 52
Animal study on 63 male albino Wistar-
derived rats; administered with 0.5, 1.5,
or 3.5 mg/kg of arecoline SC before test
Accelerated decay of memory after chronic
administration [36]
Animal study on 96 female Sprague
Dawley rats; administered with 40 or 80
µg of arecoline
Decreased locomotory activity [37]
Citrus aurantium
Chlordiazepoxide, valproic
acid, diazepam, sodium
pentobarbital, d-limonene
Animal study on 176 adult male Swiss
mice; administered with 0.5 or 1.0
mg/kg of EO (90.4% of d-limonene) and
1.0 mg/kg of four different fractions of
leaves extract orally
Increased hypnotic effect and enhanced
sleeping time induced by pentobarbital [38]
Randomized, triple-blind, clinical study
on 156 postmenopausal women: 52 CA-
receiving women with a mean (±SD)
age of 53.65 (±3.55) years, 52 lavender-
receiving women with a mean (±SD)
age of 54.21 (±3.86) years, and 52
placebo-receiving women with a mean
(±SD) age of 52.12 (±3.49) years; took 2 ×
500 mg/day of CA powder for 6 weeks
Headache, nausea, and hypnosis [39]
Randomized, triple-blind, clinical study
on 156 postmenopausal women: 52 CA-
receiving women with a mean (±SD)
age of 53.65 (±3.55) years, 52 lavender-
receiving women with a mean (±SD)
age of 54.21 (±3.86) years, and 52
placebo-receiving women with a mean
(±SD) age of 52.12 (±3.49) years; took 2 ×
500 mg/day of CA powder for 6 weeks
Headache and nausea [40]
Rosa damascena Mill.
Randomized, double-blind clinical
study on 99 female students with a
mean (±SD) age of 22.33 (±2.38) years,
equally parted into two intervention
Headache, nausea, and vomiting [41]
Pharmaceuticals 2020, 13, 309 9 of 52
groups and a control group; inhaled EO
of CA blossom at 0.5%
speciosa Korth.
Cross-sectional study on 433
participants with a mean (±SD) age of
45.7 (±13.6) years, 350 males and 83
females; 149 regular users chewed 12
leaves/day, 168 occasional users
chewed 4 leaves/day, and 116 controls
Dizziness, freshness, sprightliness, fatigue,
shaking hands, headaches, decreased sexual
drive, poor concentration, distractedness,
difficulty sleeping, irritability, poor thinking
ability, impaired memory, laziness, and
social withdrawal
Case report of a kratom intoxication of
a 43-year-old male with chronic pain
and opioid withdrawal; took kratom tea
four times daily for 3.5 years
Withdrawal, drowsiness, and generalized
tonic-clonic seizure [43]
Datura stramonium L.,
cannabinoids, tricyclic
antidepressants, oxycodone
Case report of a kratom intoxication of
a 64-year-old male, found with 167 ± 15
ng/mL of mitragynine in urine
Seizures and coma [44]
heroin, cannabis, amphetamine,
mitragynine (67.5–75 mg/day)
Cross-sectional survey on 136
participants: 72 short-term users and 64
long-term users, age range = 36–65
years, 135 males and 1 female; took 3 ×
250 mL/day of kratom tea for 3.5 years
Loss of weight, tiredness, dose-dependent
stimulation/sedation, intense craving,
withdrawal, chronic fatigue, insomnia,
frequent sweating, and sudden nerve pain
Case report of a 44-year-old kratom
addicted male with a previous history
of alcohol and cocaine dependence;
took from 2 × 4 g/day to 4 × 10 g/day for
3 years
Wellbeing, euphoria, increased
productivity, industriousness, relaxation,
tolerance, withdrawal symptoms of
cravings, anxiety, restlessness, and itch
Cross-sectional study on 530 MS users,
528 males and 2 females (age not
reported); took MS tea 1–10 times daily
for 4–5 years
Increased alertness, dizziness, sedation, hot
sensation, hallucination, vomiting, hostility,
aggression, excessive tearing, inability to
work, aching of muscles and bones, jerky
movement of limbs, loss of appetite, weight
loss, insomnia, malaise, and restlessness
Amphetamine, haloperidol,
Retrospective study on 52 participants
with a median age of 30.5 years (range:
Seizure, nausea, alteration of consciousness,
contraction, confusion, headache, dizziness, [48]
Pharmaceuticals 2020, 13, 309 10 of 52
codeine, depressants, unknown
chemical substance
2 days–81 years), 84.6% males and
15.4% females
syncope, myalgia, insomnia, fatigue, loss of
appetite, agitation, tremor, ataxia, dystonia,
and neonatal withdrawal
Wild dagga, wormwood,
alprazolam, synthetic
cannabinoid, synthetic
tryptamine, alcohol,
methamphetamine, risperidone
14 kratom exposures reported to the
Texas Poison Center Network of 11
males and 3 females aged between 18
and 48 years
Agitation, nausea, vomiting, confusion,
tremor, diaphoresis, drowsiness,
hallucinations, mydriasis, and abdominal
Qualitative study on 34 male
participants: 22 regular users chewed
10–80 leaves/day for 3–50 years; 6
occasional users chewed 1–20
leaves/day for 1–6 years; 3 non-users;
and 3 ex-users
Loss of appetite, craving to eat kratom,
withdrawal, compulsion, impaired control,
preoccupation, loss of weight,
muscle/bone/back/joint aches,
cramps/numbness, anxiety, depressed
mood, dysphoria, moodiness, annoyance,
restlessness, irritability, autonomic nervous
system hyper/hypoactivity, chills, sneeze,
cough, illness/catch cold, sleepy, yawning,
watering eyes, runny nose, sticky mouth,
disturbances of behaviors and cognitive
functions, and fatigue
Mitragynine (291.9 mg/day)
Cross-sectional survey on 293 male
kratom users with a mean age of 28.9
years, 153 medium-term users and 140
long-term users; up to ≥3 × 350 mL/day
of kratom fresh juice
Sleeping difficulty, decreased appetite,
nausea, vomiting, muscle spasm, sweating,
fever, abdominal pain, headaches, hot
flashes, hiccups, shakiness or tremors,
severe muscle
pain and cramps, nervousness, sadness,
restlessness, anger, tension, depressed
mood, and craving
Qualitative study on 168 kratom users:
109 males, 13 females, and 44 others
(sex not specified)
Warmth/tingling, nausea/stomachache,
alternating chills/sweats,
dizziness/unsteadiness, vomiting, itching,
numbness in mouth/throat, visual
alterations, and sedation
Pharmaceuticals 2020, 13, 309 11 of 52
Alcohol, other botanicals,
benzodiazepines, narcotics,
660 calls about kratom exposure
received by U.S. poison centers, the
median age was 28 years (range = 2
months–69 years, data available for 604
subjects), 472 males and 186 females
(data available for 658 subjects)
Agitation, irritability, drowsiness, and
nausea [53]
Cross-sectional study on 526 kratom
users with a mean age of 51.8 years;
took 3–17 leaves/day
Craving-fatigue syndrome, mood
symptoms, insomnia, and physical sickness [54]
Tramadol, codeine, morphine
Case reports of two kratom-addicted
subjects, a 60-year-old female who took
0.25 ounces of kratom every 4 h for
several months, and a 57-year-old male
Dependence, tolerance, irritability,
increased pain, anxiety, edginess, and leg
Retrospective study on 150 male
participants with a mean (±SD) age of
34.4 (±11.2) years; took up to ≥4 × 350
mL/day of kratom fresh juice
Withdrawal symptoms, anxiety, and
depression [56]
Case report of a maternal (a 29-year-old
female) and neonatal kratom exposure;
took 3 × 18-20 g/day of kratom powder
Anxiety and maternal and neonatal
withdrawal [57]
Case report of a female infant’s NAS,
her mother took 3–4 kratom teas/day
during her pregnancy
Excessive sucking, irritability, sleeplessness,
and withdrawal [58]
Case report of a kratom overdose and
management of withdrawal of a 24-
year-old man with Asperger syndrome,
depression, and long-term substance
dependence; took 600 mg/day of
Unresponsiveness, seizures, and
withdrawal [59]
Case report of a kratom intoxication of
a 19-year-old male with ADHD; took
several pills (2–8 g) per day for several
Seizures [60]
Pharmaceuticals 2020, 13, 309 12 of 52
Case report of a 52-year-old kratom-
addicted female with a long-standing
history of MDD; took 1 tablespoon 4–6
times per day for 9 months
Increased depression, anxiety, suicidal
thoughts, exacerbation of chronic pain
issues, dysphoria, nausea, muscle aches,
sweating, goose bumps, and insomnia
Cross-sectional study on 95 male
participants: 70 kratom users with a
mean (±SD) age of 28.8 (±5.3) who took
3 glasses of kratom tea/juice daily, and
25 healthy controls with a mean (±SD)
age of 25 (±7.6)
Visual memory and new learning
impairment [62]
Cross-sectional study on 150 male
kratom users with a mean (±SD) age of
34.4 (±11.2) years; took up to ≥3
glasses/day for more than 6 years
Auditory, visual, tactile, and olfactory
hallucinations, persecutory, reference,
control and grandiose delusion thought
broadcasting, and withdrawal
Alcohol, clonazepam, cocaine
Brief report on 2321 kratom exposures,
of which 4 cases of NAS and 2 deaths
were reported, and 4 deaths for which
kratom was listed as a cause or
contributing factor to the death
Agitation, drowsiness, confusion, seizure,
withdrawal, hallucinations, respiratory
depression, coma, and cardiac or respiratory
Alcohol, other unknown
Case reports of kratom intoxications
with 4 males with a mean age of 43.5
years (range = 44–67); case 2 took 4 × 10
g/day of kratom over 24 h
Seizure, sedation, withdrawal symptoms,
and dependence syndrome [65]
Opiate, methamphetamine,
Cross-sectional survey on 163 regular
kratom male users with a mean (±SD)
age of 37.1 (±10.9) years; took 1–3
glasses/day of kratom tea for more than
6 years
Weight loss, physical pain, loss of appetite,
fatigue, craving for opioid, insomnia, and
Case reports of two kratom
intoxications: a 27-year-old male with
bipolar disorder and schizophrenia
who took 5 g/day of kratom for 3 years,
and a 26-year-old female with no
Restlessness, generalized body aches,
overwhelming anxiety, thoughts of suicide,
hallucinations, and withdrawal symptoms
Pharmaceuticals 2020, 13, 309 13 of 52
history of mental health disorders who
took 2–3 pills/day (20–30 g of
kratom/day) for 2 years
Case report of a 22-year-old male with
ADHD and kratom use disorder; took
kratom tea every 2 h daily (30 g at
maximum dosage) for 2 years
Tolerance, irritability, and withdrawal
symptoms [68]
Case report of a 27-year-old male with a
history of ANX, ADHD,
benzodiazepine, and opioid use
disorders; took up to 4 × 8 mL/day
bottles of kratom for 1.5 years
Tonic-clonic seizures [69]
Alcohol, antidepressants,
benzodiazepines, cannabis,
cocaine, hallucinogens, opioids
(prescribed or illicit), tobacco
Online anonymous cross-sectional
survey on 2798 kratom users with a
mean(±SD) age of 40.2(±11.8) years,
1099 males and 1699 females; took up to
3 × 1–6 g/day of kratom
Sickness, dizziness, alertness, anxiety,
sleepiness, and withdrawal symptoms [70]
Cross-sectional quantitative study on
356 participants, 137 kratom users and
219 non-users aged between 18 and ≥37
years, 212 males and 144 females
Addiction, withdrawal symptoms, and
impaired social functioning [71]
Animal study on 36 male mice from the
ICR strain: 18 mitragynine-treated mice
administered with 5, 10, or 15 mg/kg IP
of for 28 days; 6 scopolamine-treated
mice; and 12 HC
Impaired working memory function and
reduction in locomotory activity [72]
7-hydroxymitragynine (0.15
mg/L in blood, 2.20 mg/L in
urine), zopiclone, citalopram,
Fatal mitragynine intoxication of a
middle-aged male, found with 1.06 and
3.47 mg/L of mitragynine in blood and
urine, respectively
CNS depression [73]
Morphine, methamphetamine,
Animal study on male C57BL/6 mice;
administered with 1, 5, 10, or 20 mg/kg
IP 30 min before or immediately after
Decreased activity in the δ, θ, and β, but not
α band in the hippocampus and withdrawal [74]
Pharmaceuticals 2020, 13, 309 14 of 52
locomotor and consolidation tests, 30
mg/kg IP for 14 days for the withdrawal
induction and for 28 days for the
chronic study
Morphine, penicillin G
procaine, propofol, xylazine,
ketamine, naltrindole,
Animal study on 39 male Fischer 334
rats; administered with 25, 50, 100, or
150 µg of mitragynine and 2.5, 5, 10, or
20 µg of 7-hydroxymitragynine
Increased morphine self-administration
after 7-hydroxymitragynine treatment [75]
Morphine, urethane, xylocaine
Animal study on 60 male Sprague
Dawley rats and other set of animals
used for in vivo electrophysiological
studies; administered with 1.0, 5.0 and
10.0 mg/kg of mitragynine IP
Impaired acquisition of spatial learning and
significant synaptic depression in the
hippocampal region at high mitragynine
Panax ginseng C.
A. Mey
Fluvoxamine, venlafaxine
Case report of a 47-year-old female with
chronic depression; took 200 mg of
ginseng extract within 24 h
Hypomania [77]
Case report of a 26-year-old male with
history of suicidal thoughts; took 250
mg/day of Chinese ginseng for two
Restless, insomnia, agitation,
disorganization [78]
Contraceptive pill, ginsenosides
Placebo-controlled, clinical study on 20
participants with (mean (±SD) age of
20.6 (±4.2), 10 males and 10 females;
administered with placebo and 5 × 200,
400, or 600 mg of ginseng extract with a
7-day wash-out between
Decreased speed attention [79]
Ginkgo biloba L., contraceptive
Placebo-controlled, clinical study on 20
participants with a mean (±SD) age of
20.6 (±4.2), 10 males and 10 females;
administered with placebo and 5 × 200,
400, or 600 mg of ginseng extract with a
7-day wash-out between
Decreased speed attention [80]
Pharmaceuticals 2020, 13, 309 15 of 52
Case report of ginseng intoxication of a
MDD 56-year-old woman; took 300
mg/day of root extract for 2 weeks
Hyperactivity, insomnia, dysphoria, and
verbal and physical aggressiveness [81]
Ginkgo biloba L., vitamins and
minerals, cold-liver oil,
primrose oil, caffeine, alcohol
Randomized, double-blind, placebo-
controlled clinical study on 70 post-
menopausal females, 12 ginseng-
receiving subjects with a mean (±SD)
age of 58.4 (±1.0) years and 14 placebo-
receiving subjects with a mean (±SD)
age of 57.4 (±0.7) years; administered
with 2 × 100 mg/day of ginseng extract
for 12 weeks
Slight depression (one case) [82]
Ginsenosides (27–30%)
Single-blind, placebo-controlled clinical
study on 14- and a 17-year-old ADHD
males; administered with 2 × 250
mg/day of ginseng extract
Mild sedation [83]
Rg1, Rb1, Rg3, Re, Rc, Rb2, Rd,
Rf, Rh1, Rg2s, other minor
ginsenosides, escitalopram,
venlafaxine, paroxetine,
duloxetine, citalopram,
bupropion, fluvoxamine,
imipramine, trazodone
Open-label study on 35 MDD females
with a mean (±SD) age of 45.1 (±9.5)
years; administered with 2 g at day 1 of
red ginseng extract titrated at 3 g/day
for 4 weeks and maintained for another
4 weeks
Headache, insomnia, and hypersomnia [84]
Case reports on two ginseng
intoxications of 23- and a 79-years-old;
took ginseng ≅ 15 and ≅ 20 g/day,
Racing thoughts, anxiety, irritable mood,
labile affect, disorganized thought process,
constant distraction, and auditory
Chemotherapies, ginsenosides,
Open-label study on 30 patients with
cancer-related fatigue and under
chemotherapy with a median age of 58
(range = 48–68) years, 15 males and 15
females; administered with 2 × 400
mg/day ginseng root extract for 4 weeks
Pain, nausea, cognitive disturbance, and
seizure [86]
Pharmaceuticals 2020, 13, 309 16 of 52
Multivitamins, herbal
Case report of a 42-year-old female with
no history of psychiatric issue or illicit
drug use
Psychosis and confusion [87]
- Case report of a ginseng intoxication
(age, sex, and dose not specified) Mania [88]
Randomized, double-blind, placebo-
controlled clinical study on 74 opioid-
addicted participants under methadone
maintenance treatment, 48 males with a
mean age of 40.64 years and 26 females
with a mean age of 39.0 years;
administered with 4 × 250 mg of root
Sleepiness and agitation [89]
Case report of a 47-year-old male with
no history of psychiatric disorder; took
600 mg/day ginseng to increase energy
and sexual activity
Nervousness, aggressive behaviors,
irritability, increased psychomotor activity,
decreased sleep, and excessive talkativeness
Eicosapentaenoic acid,
docosahexaenoic acid, Rg1,
Rb1, Rg3
Open-label study on 40 ADHD children
with a mean (±SD) age of 8 (±1.45) years
31 males and 9 females; administered
with 3 mg/day ginseng extract for 12
Transitory headache (one case) [91]
quinquefolius L.
Phenelzine, bee pollen, other
natural medications
Case report of a 42-year-old female with
chronic depression, but no history of
manic episodes
Mania and hallucinations [92]
Ginkgo biloba L., ritalin, efamol
Open-label study on 36 ADHD children
with a mean (±SD) age of 10.2 (±3.7);
administered with 2 × 200 mg/day of
ginseng extract for 4 weeks
Increased impulsiveness, hyperactivity and
aggressiveness, headache, and tiredness [93]
Tamoxifen, other estrogenic
botanical supplements
Multicenter, prospective study on 788
with breast cancer; 103 used ginseng
after cancer diagnosis
Fatigue [94]
Pharmaceuticals 2020, 13, 309 17 of 52
johimbe (K.
Schum.) Pierre
ex Beille
Corynanthine (5, 20 mg/kg)
Animal study on 101 male Sprague
Dawley rats; administered with 5 or 20
mg/kg of yohimbine IP
Decrease in spontaneous locomotor activity,
overreaction to external stimuli, violent
tremors, convulsions, abnormal posture,
and decrease in body temperature
Doxapram, 4-aminopyridine
Animal study on 82 red deer (Cervus
elaphus L.), administered with 0.063,
0.124, 0.125, 0.128, 0.189, 0.20, 0.21, 0.23,
0.24, 0.25, or 1.00 mg/kg of yohimbine
Rapid reaction to external stimuli, anxiety,
and nervousness [96]
Desipramine, bupropion,
Three case reports of manic symptoms
following yohimbine administration of
three psychiatric patients: a 41-year-old
male who took 10 mg of yohimbine
orally, and 20- and 43-year-old females
who took 20 mg of yohimbine in two
sessions and one session, respectively
Tremors, nausea, generalized restlessness,
diaphoresis, and palpitations [97]
Randomized, double-blind, placebo-
controlled study on 59 participants: 39
drug-free patients with agoraphobia
and panic attacks—11 males with a
mean (±SD) age of 36.8 (±8.2) years and
29 females with a mean (±SD) age of
38.8 (±10.1) years; and 20 HC—9 males
with a mean (±SD) age of 33.3 (±7.3)
years and 11 females with a mean (±SD)
age of 43.3 (±7.4) years; administered
with 4 × 5 mg of yohimbine capsules
Anxiety, nervousness, hot and cold flashes,
restlessness, tremors, and piloerection
Acetylsalicylic acid
Case report of an acute yohimbine
intoxication of a 16-year-old female;
took 250 mg of powdered yohimbine
Weakness, generalized paresthesia, loss of
coordination, dissociative state, severe
headache, dizziness, tremors, decreased
hearing, nausea, diaphoresis, and
intermittent palpitations
Pharmaceuticals 2020, 13, 309 18 of 52
Randomized, double-blind, placebo-
controlled study on 88 participants: 68
agoraphobic subjects with panic attacks
or panic disorder—19 males with a
mean (±SD) age of 38 (±9) years and 49
females with a mean (±SD) age of 40
(±1) years; and 20 HC—9 males with a
mean (±SD) age of 34 (±8) years and 11
females with a mean (±SD) age of 43
(±7) years; administered with 4x5 mg of
yohimbine capsules
Increased rate of panic attacks, anxiety [100]
Animal study on male hooded Lister
rats; administered with 2.5 or 5 mg/kg
of yohimbine IP for acute exposure
evaluation and 2.5 or 5 mg/kg daily for
5 days for chronic exposure evaluation
Decreased locomotory activity and
increased anxiety [101]
Randomized, double-blind, placebo-
controlled study on 65 participants: 45
depressed subjects with a mean (±SD)
age of 41 (±13) years—17 males and 28
females; and 20 HC with a mean (±SD)
age of 39 (±9) years—9 males and 11
females; administered with 4 × 5 mg of
yohimbine capsules
Drowsiness, nervousness, anxiety, fear,
sadness, depression, nausea, tremors, hot
and cold flashes, and muscle aches
Animal study on 12 male Sprague
Dawley rats; administered with 5
mg/kg IP weekly for 6 weeks
Profound hypothermia [103]
Animal study on six unrestrained
bonnet macaques (Macaca radiata É.
Geoffroy); administered with 0.10, 0.25,
0.50, or 0.75 mg/kg (0.93–9.74 mg) of
yohimbine orally
Distress symptoms, freezing behaviors,
clonic jaw movements, excessive yawning,
and sexual arousal
Pharmaceuticals 2020, 13, 309 19 of 52
Randomized double-blind placebo-
controlled study on 53 participants: 38
subjects with panic disorders with a
mean (±SD) age of 35 (±2) years—11
males and 27 females; and 15 HC with a
mean (±SD) age of 30 (±3) years—5
males and 10 females; administered
with 0.4 mg/kg of yohimbine over 10
Anxiety and panic attacks [105]
Glyburide, alcohol
Case report of an acute yohimbine
intoxication of a diabetic 63-year-old
man; took 100 × 2 mg of yohimbine
tablets in about 90–120 min
Anxiety and alertness [106]
Tolazoline, xylazine
Animal study on four healthy horses—
three mares and one gelding;
administered with 0.025 mg/kg of
yohimbine every 2 min until a maximal
dose of 2.0 mg/kg
Agitation, muscular tremors, mild
excitement, and reduction in xylazine-
mediated sedation
Clinical study on eight narcoleptic
participants, four males with a mean
age of 43.5 years (range 22–64) and four
females with a mean age of 26 years
(range 21–39); administered with 2.7,
5.4 mg of yohimbine tablets twice daily
up to 16.2 mg/day
Insomnia, tremors, and flushing [108]
Fluoxetine, TCAs, propranolol,
Four case reports of a 44-, two 45-, and
a 53-year-old males with PTSD; took
“high” quantity of over-the-counter
Sexual arousal, sweating, shaking, panic
attacks, and flashbacks [109]
[15O] H2O
PET scans in a single-blind fixed-order
study on nine participants with a mean
age of 30.7 years—three males and six
females; administered with 0.15 mg/kg
Panic attack (one subject) and increased
anxiety [110]
Pharmaceuticals 2020, 13, 309 20 of 52
up to a maximum dose of 10 mg of
yohimbine over 3 min
Morphine, U-50,488, SNC80
Animal study on 318 male OF1 mice
and male Sprague Dawley rats;
administered with 2 and 4 mg/kg of
yohimbine IP
Blockage of opioid-mediated spinal
antinociception [111]
benzodiazepines, [11C]
Animal study on three adult male
rhesus monkeys; administered with 0.4
mg/kg of yohimbine
Increased binding potential for BDZ
receptors in the hippocampus and anxiety [112]
Randomized, double-blind, placebo-
controlled study on 17 participants: 8
methadone-maintained subjects with a
mean (±SD) age of 38 (±2.6) years—6
males and 2 females; and 9 male HC
with a mean (±SD) age of 30 (±3.7)
years; administered with 4 mg/kg of
yohimbine over 10 min
Precipitation of withdrawal and craving
symptoms in methadone patients [113]
Xylazine, ketamine,
buprenorphine, gentamicin,
Animal study on 73 male Long–Evans
rats; administered with 1.25 or 2.5
mg/kg of yohimbine IP after extinction
and 0.625 mg/kg after 21–51 days of
Reinstatement of extinguished
methamphetamine seeking behavior [114]
Cocaine, clonidine, RS-79948,
Animal study on 14 adult squirrel
monkeys (Saimiri sciureus L.);
administered with 0.1 and 0.56 mg/kg
of yohimbine IP before the
reinstatement test
Reinstatement of extinguished cocaine
seeking behavior [115]
Randomized double-blind placebo-
controlled study on 13 male
participants with a mean (±SD) age of
24.9 (±2.2) years; administered with 0.4
mg/kg of yohimbine IV, procedure
repeated after 14 days
Increased restlessness, anxiety, and
impaired mood [116]
Pharmaceuticals 2020, 13, 309 21 of 52
Animal study on 12 adult male Sprague
Dawley rats; administered with 0.1, 1.0,
or 10.0 mg/kg of yohimbine IP
Suppression of P13 and N40 auditory
circuitry components at high doses and
increment of amplitude at low/moderate
Case report of an acute yohimbine
intoxication of a 37-year-old male body
builder; took 5 g of yohimbine, found
with 5240, 2250, 1530, and 865 ng/mL in
blood 3, 6, 14, and 22 h, respectively,
after ingestion and 50 mg/L in urine at
General malaise, vomiting, loss of
consciousness, and tonic-clonic seizures [118]
Randomized double-blind placebo-
controlled study on 24 claustrophobic
participants, 12 yohimbine-receiving
subjects and 12 placebo-receiving
patients, 79% females with a mean
(±SD) age of 24.46 (±8.65) years (males
not reported); administered with 2 × 5.4
mg of yohimbine pills, procedure
repeated after 14 days
Significant improvement in peak fear at the
one-week follow-up behavioral assessment [119]
Xylazine, ketamine,
pentobarbital, chloral hydrate,
cefazoline, heparin, heroin
Animal study on 22 male Sprague
Dawley rats; administered with 1.25
and 2.5 mg/kg of yohimbine IP 30 min
before reinstatement sessions
Stress and reinstatement of extinguished
heroin seeking behavior [120]
Randomized, double-blind, placebo-
controlled study on 24 male
participants: 12 athletes with an average
age of 29 years and 12 untrained HC
with an average age of 29.5 years;
administered with 0.4 mg/kg of
yohimbine IV
Anxiety [121]
Nicotine, acamprosate Randomized, double-blind, placebo-
controlled study on 35 participants: 12 Increase in alcohol craving symptoms [122]
Pharmaceuticals 2020, 13, 309 22 of 52
acamprosate-receiving subjects with a
mean (±SD) age of 44.4 (±1.6) years—11
males and 1 female; and 13 placebo-
receiving patients with a mean (±SD)
age of 44.1 (±1.9) years—11 males and 2
females; administered with 0.4 mg/kg
of yohimbine IV
Clonidine, 2-[18F]-fluoro-2-
Randomized, double-blind, placebo-
controlled study on 22 participants, 11
patients with IBS with a mean (±SD) age
of 40.5 (±12.9) years and 11 HC with a
mean (±SD) age of 37.3 (±10.6) years;
administered with 40 mg of yohimbine
Increased anxiety and reduced brain activity
in the anterior cingulate cortex, amygdala,
dorsal brainstem, and posterior insula
Nicotine, ketamine, xylazine,
buprenorphine, bupivacaine,
Animal study on 84 Long–Evans
juvenile rats; administered with 0.3 and
0.6 mg/kg of yohimbine IP before
operative sessions
Increased nicotine self-administration [124]
Alcohol, d-Phe CRF
Animal study on 60 rats (strain not
reported); administered with 1.25
mg/kg of yohimbine IP before alcohol
self-administration and reinstatement
Increased alcohol self-administration and
reinstatement of alcohol seeking behavior [125]
Caffeine, diphenhydramine,
Two fatal case reports of acute
yohimbine intoxication of 23- and 37-
year-old males; found 7400 ng/mL in
iliac blood and 5400 ng/mL in heart
blood, respectively
Seizures, elevated vitals, and death [126]
Pioglitazone, naltrexone,
Animal study on 193 genetically
selected msP male rats; administered
with 1.25 mg/kg of yohimbine IP 1 h
after naltrexone and before the
reinstatement session
Reinstatement of alcohol seeking behavior [127]
Pharmaceuticals 2020, 13, 309 23 of 52
Nicotine, caffeine,
Randomized, double-blind, placebo-
controlled study on 119 participants: 62
cocaine-dependent subjects with a
mean (±SD) age of 41.1 (±10.0) years—
32 males and 30 females; and 57 HC
with a mean (±SD) age of 33.1 (±12.6)
years—32 males and 30 females;
administered with 21.6 mg of
yohimbine capsule
Increase in anxiety and craving in cocaine-
dependent subjects [128]
Animal study on 768 AB strain wild
zebrafish larvae, 640 yohimbine-
receiving animals; administered with
10, 25, 50, 100, or 200 mg/L of
yohimbine solution, and 128 HC
anxiogenic at high concentrations [129]
MDMA, SCH-23390, atropine,
ketamine, xylazine
Animal study on 67 male Sprague
Dawley rats; administered with 2.0
mg/kg before reinstatement test and 5.0
mg/kg daily for 10 days for chronic
Anxiogenic effects and reinstatement of
extinguished MDMA seeking behavior [130]
Double-blind, placebo-controlled study
on 16 healthy women aged between 18
and 32 years: 5 yohimbine + naltrexone-
receiving patients, and 11-placebo-
receiving patients; administered with 16
mg of yohimbine orally alone and co-
administered with 50 mg of naltrexone
Agitation, restlessness, anxiety, headaches,
nausea, light-headedness, vomiting,
weakness, lethargy, tremors, blockage of
analgesia in ipsilateral forehead, and
increase in electrically evoked pain in
Nicotine, THC
Randomized, double-blind, placebo-
controlled study on 95 participants: 39
cocaine-dependent subjects with a
mean (±SD) age of 41 (±1.7) years—12
males and 27 females; and 56 HC with a
mean (±SD) age of 33 (±1.7) years—32
Increased impulsivity in HC and slower hit
reaction time in female cocaine-dependent
Pharmaceuticals 2020, 13, 309 24 of 52
males and 34 females; administered
with 21.6 mg of yohimbine prior to two
cocaine exposure sessions
Randomized, double-blind, placebo-
controlled study on 103 participants
with a mean (±SD) age of 24.79 (±0.36)
years—51 males and 52 females
randomly assigned to four
experimental groups (placebo,
yohimbine, hydrocortisone, yohimbine
+ hydrocortisone); administered with 20
mg of yohimbine orally
Decreased memory generalization in
females (both yohimbine and yohimbine +
hydrocortisone groups)
Randomized, double-blind, placebo-
controlled study on 39 participants: 13
yohimbine-receiving patients and 10
placebo-receiving patients—13 males
and 10 females aged between 18 and 52
years; 5 yohimbine + naltrexone-
receiving females and 11 placebo-
receiving females aged between 18 and
32 years; administered with 16 mg of
yohimbine alone and co-administered
with 50 mg of naltrexone orally
Nausea, headache, malaise, pain, anxiety,
and sexual arousal [134]
Randomized, double-blind, placebo-
controlled study on 42 health
participants with a mean (±SD) age of
21.29 (±3.27): 21 yohimbine-receiving
subjects and 21 placebo-receiving
subjects—19 males and 23 females;
administered with 20 mg of yohimbine
orally 45 min before behavioral test
Anxiety, nervousness, nausea, decreased
motor and temporal impulsivity, and
increased reflection impulsivity
Alcohol, kavain (450.1 mg/L),
dihydrokavain (456 mg/L)
Alternated, double-blind, placebo-
controlled study on 24 participants with
Body sway and decreased reaction time
tasks [136]
Pharmaceuticals 2020, 13, 309 25 of 52
methysticum G.
a mean age of 26.7 years (range = 18–
53), 10 males and 13 females; 12 subjects
received 500 mL of kava juice and 12
received placebo
Cross-over study on 24 participants
with stress-induced insomnia, 9 males
with a mean age of 43.7 years (range
23–65) and 15 females with a mean age
of 44.6 (range 30–65) years;
administered with 120 mg/day of
standardized kava extract for 6 weeks
Dizziness, vivid dreams, and dry mouth [137]
Randomized, double-blind, placebo-
controlled study on 38 participants with
a previous history of GAD and a mean
(±SD) age of 51.7 (±11.6) years—7 males
and 31 females; administered 140
mg/day of standardized kava extract for
1 week and 280 mg/day for the next 3
Bad taste in mouth, difficulty achieving
orgasm, drowsiness, dry mouth, increased
appetite, muscle twitching, nausea, spasms
or drawing of muscles, sweating, tingling or
numbness, and trembling
Benzodiazepines, fluoxetine,
Case report of a kava intoxication of a
45-year-old female with a family history
of essential tremor; took 65 mg/day of
kava extract for 10 days
Slow saccades, hypophonic speech,
generalized postural and tremor at rest,
severe generalized rigidity in axial and
appendicular muscles, severe akinesia, gait
disturbance with lack of balance, and
inability to walk
Randomized, double-blind, placebo-
controlled study on 141 participants
with neurotic anxiety: 71 subjects with a
mean age of 48.8 (range 18–69) years,
administered with 3 × 50 mg/day of
standardized kava extract for 4 weeks;
and 70 placebo-receiving subjects with
a mean age of 48.2 (range 18–69)
years—36 males and 105 females
Withdrawal, aggravation of anxiogenic
symptoms, and tiredness [140]
Pharmaceuticals 2020, 13, 309 26 of 52
Saccade and cognitive study on 28
participants: 11 kava-intoxicated
subjects with a mean (±SD) age of 38.1
(±10.3) years and 17 kava-users with a
mean (±SD) age of 33.1 (±7.0) years;
took 75–375 g of kava powder
Ataxia, tremors, sedation, disorientation,
and blepharospasm [141]
Kavain (55%)
Randomized, prospective, open study
on 68 perimenopausal females: 15 kava-
receiving subjects with a mean (±SD)
age of 51.5 (±1.1) years were
administered with 100 mg/day of
calcium plus kava for 3 months; 19
kava-receiving subjects with a mean
(±SD) age of 51.1 (±0.8) years were
administered with 200 mg/day of
calcium plus kava for 3 months; and 34
HC with a mean (±SD) age of 50.2 (±0.6)
Nausea [142]
Flunitrazepam, flumazenil
Animal study on 40 male sleep-
disturbed Wistar rats; administered
with 10, 30, or 300 mg/kg of a 96%
ethanol kava extract
Hypnosis (shorter sleep latency, increase in
the total non-REM time) [143]
Case report of an acute kava
intoxication of a 37-year-old male; took
a “too strong” kava tea
Leg weakness, severe vertigo, nausea,
vomiting, diaphoresis, and dizziness [144]
Hypericum perforatum L.,
alcohol, caffeine
Randomized, double-blind, placebo-
controlled study on 24 participants with
MDD and a mean (±SD) age of 42.9
(±8.8) years—20 males and 38 females;
took 3 × 2.66 g/day of herbal kava
tablets for 10 months
One case of withdrawal [145]
Dihydrokavain (26%), kavain
(21%), dihydromethysticin
Randomized, double-blind, placebo-
controlled study on 28 participants with
GAD and a mean (±SD) age of 30.1
Increased females’ sex drive and difficulty
to reach the orgasm in males [146]
Pharmaceuticals 2020, 13, 309 27 of 52
(18%), methysticin (14%),
yangonin (13%),
Desmethoxyyangonin (8%)
(±12.4) years—7 males and 21 females;
administered with 120 and 240 mg/day
of kavalactones in 3 g tablets of
standardized extract of kava roots
Dihydrokavain (26%), kavain
(21%), dihydromethysticin
(18%), methysticin (14%),
yangonin (13%),
desmethoxyyangonin (8%)
Randomized, double-blind, placebo-
controlled study on 58 participants with
GAD and a mean (±SD) age of 30.1
(±8.8) years, 20 males and 38 females;
administered with 120 or 240 mg/day of
kavalactones in 3 g tablets of
standardized extract of kava roots
Significant reduction in anxiety and
headaches [147]
Anxiolytics, antidepressants,
antinausea, antipsychotics,
painkillers, stimulants,
sedatives, meth/amphetamine,
cannabis, cocaine, ecstasy,
hallucinogens, opiates,
benzylpiperazine, synthetic
Survey study on 434 participants with a
mean (±SD) age of 34.54 (±14.62)
years—36.41% males and 63.59%
females, 26 kava-users
Driving-impairment [148]
Animal study on adult wild-type short-
fin outbred zebrafish with a 1:1 male-to-
female ratio; administered with 10, 20,
or 50 mg/L of water extract from
powdered kava roots for 20 min and 7.5
mg/L for 1 week
Sedation and immobility [149]
Methysticin DMSO
Animal study on 18 AD model mice—
12 APP/Psen1 strain and 6 wild-type
mice; administered with 6 mg/kg of
methysticin once a week for 52 weeks
Reduced movements [150]
olacoides Benth.
Diazepam, pentylenetetrazol
Animal study on CF1 strain male adult
mice parted in eight groups (15–30
animals); administered with 30, 100, or
300mg/kg of ethanolic extract for 30
Reduced locomotion [151]
Pharmaceuticals 2020, 13, 309 28 of 52
MK801, DMSO, scopolamine,
Animal study on 66 CF1 strain male
adult albino mice; administered with 50
or 100 mg/kg of standardized ethanolic
and 100–800 mg/kg once a day for 21
Impairment of both short- and long-term
memories [152]
tortuosum (L.) N.
E. Brown
Randomized, double-blind, placebo-
controlled study on 21 participants with
a mean (±SD) age of 54.6 (±6.0), 9 males
and 12 females; administered with 25
mg/day of standardized extract
(Zembrin®) for 3 weeks
Headache, blurred vision, poor hearing,
nausea, vomiting, appetite increase, muscles
rigidity, drowsiness, confusion,
concentration difficulty, memory problems,
depression, anxiety, and ataxia
AD—Alzheimer’s disease; ADHD—attention deficit and hyperactivity disorder; ADD—attention deficit disorder; BQ—betel quid; CA—Citrus aurantium; CNS—
central nervous system; CPZ—cuprizone; EO—essential oil; HC—healthy controls; IBS—irritable bowel syndrome; IP—intraperitoneally; IV—intravenously;
MDD—major depressive disorder; MS—Mitragyna speciosa; MSA—multiple system atrophy; NAS—neonatal abstinence syndrome; NPDS—United States National
Poison Data System; PAF—pure autonomic failure; PTSD—post-traumatic stress disorder; REM—rapid eye movement; SSRIs—selective serotonin reuptake
inhibitors; SNRIs—serotonin and noradrenaline reuptake inhibitors; ST—Sceletium tortuosum; SUD—substances use disorder; TCA—tricyclic antidepressant;
TeCA—tetracyclic antidepressant.
Pharmaceuticals 2020, 13, 309 29 of 52
3. Discussion
3.1. Areca catechu L. (Betel Nut)
Betel nut is one of the most widely used addictive substances in the world and represents the
fourth most consumed drug after nicotine, ethanol, and caffeine [23,154]. The fruit, obtained from the
palm tree, Areca catechu L., is commonly chewed in Southeast Asia and the South Pacific islands
[155,156] for its antiparasitic, digestive, euphoric, and aphrodisiac effects [157,158]. There are two
main ways to prepare areca nut for chewing: wrapping a split unripe nut with lime paste (calcium
oxide) in a betel tree leaf or inserting a piece of Piper betel L. inflorescence with lime paste into an
unripe areca nut [22,154,159].
The betel nut contains a variety of active alkaloids responsible for its effects. The content of major
alkaloids arecoline, arecaidine, guvacoline, and guvacine in the fresh nut is approximately 0.30–
0.63%, 0.31–0.66%, 0.03–0.06%, and 0.19–0.72%, respectively, although it may vary with maturation
[160–163]. Due to the presence of calcium oxide, arecoline and guvacoline are hydrolyzed to
arecaidine and guvacine, respectively, in basic conditions [163,164]. Areca alkaloids mediate the
autonomic responses of the parasympathetic nervous system and the synaptic transmission in the
peripheral nervous system [164–166], and impact various aspects of brain function and regulation
[167,168]. Arecoline is a partial muscarinic (M) agonist and possesses a higher affinity for M receptors
than guvacoline [24,169]. High arecoline doses produce nicotinic cholinergic effects [170]. As tertiary
amines, arecoline and, to a lesser extent, arecaidine have a deep brain penetration [165,169]. It was
demonstrated that arecoline enhances cognition and memory and significantly improves several
behavioral disorders in patients with Alzheimer’s disease or schizophrenia, through the activation of
postsynaptic M1 receptors [24,162,171]. In addition, improvements in positive and negative
symptoms of psychosis have been observed in schizophrenic areca nut chewers [155,172,173]. It is
believed that arecoline reduces the dopaminergic hyperactivity underlying the positive symptoms of
psychosis throughout the modulation of M1, M2, and M4 receptors, and induces dopamine release
in the prefrontal cortex, the striatum, and the ventral tegmental area, ameliorating the negative
symptoms [169,174,175]. Furthermore, the release of dopamine and other catecholamines causes
stimulant and libido-enhancing effects [3,156,166,176,177]. These effects, coupled with the inhibition
of monoamine oxidase A (MAO-A) caused by aromatic phenolic compounds of the plant, may also
explain the antidepressant properties of the areca nut [24,169].
High betel nut doses can cause typical muscarinic and extrapyramidal symptoms such as
salivation, diaphoresis, diarrhea, gastrointestinal upset, emesis, vertigo, myosis, tremor,
hyperthermia, bradycardia, and asthma attacks [156,158,166,168,176,178,179]. Furthermore, if betel
nut is taken in high quantities, transient extrapyramidal symptoms including rigidity, bradykinesia,
and jaw tremor may occur [24,176,180]. These effects are probably due to guvacine and arecaidine,
which are strong inhibitors of γ-aminobutyric acid (GABA) reuptake and contribute to the reduction
in spontaneous activity and body excitability [181–183]. However, it was also demonstrated that areca
alkaloids reduce GABA affinity for the GABAA receptor, and arecaidine and guvacine effects on
GABA signaling may cause epileptic seizures [23,169,180,184]. The main risks associated with the
chronic consumption of betel nut are related to its metabolism. Indeed, areca alkaloids are converted
into DNA alkylating nitrosamines, which cause cell proliferation and oxidative stress-dependent
neurotoxicity, leading to oral carcinogenicity and exacerbating neurodegenerative disease symptoms
[24,158,183,185]. Albeit its use is culturally well accepted, the betel nut is a strongly addictive
substance and multiple adverse effects were reported (Table 1). Tolerance and
nicotine/amphetamine-like withdrawal syndrome, characterized by insomnia, mood swings,
irritability, and anxiety, may appear after repeated intakes [16,167,179].
3.2. Citrus
urantium L. (Bitter Orange)
Citrus aurantium L., also called Seville orange, sour orange, or bitter orange, is a small tree
belonging to the Rutaceae family. It is native to Eastern Africa, Arabia, and Syria, but is also cultivated
in Spain, Italy, and North America [186]. Bitter orange tree’s leaves, flowers, fruits peels, and seeds
Pharmaceuticals 2020, 13, 309 30 of 52
have been used for centuries to treat tachycardia, rheumatism, insomnia, anxiety, epilepsy, and
gastrointestinal disorders and to enhance sexual desire [187–189].
The bitter orange tree contains vitamins, minerals, terpenoids, and flavonoids [190]. The most
abundant flavonoids are hesperetin and naringenin, which possess, together with terpenoids,
carotenoids, and ascorbic acid, a free radical-scavenging ability and inhibit proinflammatory
mediators release, exerting a powerful antioxidant activity and reducing tumoral cell proliferation
[191,192]. Terpenoids such as d-limonene, α-pinene, β-myrcene, linalyl acetate, and linalool are the
main volatile components of the plant [193,194], and are distilled or extracted from blooms, leaves,
and orange peel to obtain essential oils (EOs) [195]. These substances, especially d-limonene, modify
the cell membrane of microbes and denature enzymes responsible for their germination and
sporulation, showing antimicrobic and antifungal properties [191,196]. For these reasons, bitter
orange tree’s EOs are widely sold as flavoring and preservative agents in foods and drinks [190,197].
Recently, a great interest in these EOs has been observed in the context of alternative medicines such
as aromatherapy. It was demonstrated that these substances, after vaporization and inhalation, are
effective for treating different forms of anxiety, sleep, and libido, and reduce seizures in animal
models [38,39,198–201]. The mechanism of action of the plant’s ingredients, however, is not fully
elucidated. Anxiolytic and hypnotic effects are seemingly due to the combination of the action of the
plant’s aroma on the limbic system through olfaction and the direct action of terpenes on GABAergic
and serotoninergic (5-HT1A) receptors [39,202,203].
Adverse effects are mild and transient; psychiatric and neurological effects are reported in Table
1. The US Food and Drug Administration confirmed that oral administration of bitter orange extracts
is safe [39], and its derivatives have gained popularity as dietary supplements over the last few years
[200,204]. Standardized derivatives containing 4–6% synephrine, an ephedrine-like alkaloid naturally
occurring in C. aurantium and possessing α- and β-adrenergic properties, are available [3,40,205].
Although synephrine has become one of the most popular stimulants in weight loss products,
cardiovascular adverse effects including increased blood pressure, tachycardia, ventricular
fibrillation, transient collapse, myocardial infarction, and cardiac arrest have been reported [206].
Headache and gastrointestinal symptoms have also been reported.
3.3. Mitragyna speciosa Korth. (Kratom)
Kratom is an herbal preparation obtained from the leaves of Mitragyna speciosa Korth, an
evergreen plant of the Rubiaceae family that grows spontaneously in Southeast Asia, mainly in
Thailand and Malaysia [207]. In these countries, the plant has been exploited for centuries for its
stimulant and narcotic properties and is commonly self-administrated by manual laborers to combat
fatigue and improve productivity [51]. Mitragyna leaves are traditionally chewed, smoked, or boiled
with hot water and served as a tea [208]. New preparations such as capsules, resins, or tinctures are
now available on the Internet and are purchased in Europe and in America for recreational use or as
herbal products [209,210].
More than 40 alkaloids were isolated from kratom. The alkaloids’ content is variable and
depends on plant age, season, and geographical location [211]. Mitragynine is the most abundant
active compound and accounts for up to 66% of the total mass of crude alkaloids extract. Other major
alkaloids are paynantheine, which is the second most abundant alkaloid (10% of total content),
speciogynine, and speciociliatine. Among the various minor alkaloids, 7-hydroxymitragynine is of
particular interest due to its important role in mediating the analgesic effect of mitragynine [157].
Both mitragynine and its oxidized metabolite 7-hydroxymitragynine are partial agonists of µ-opioid
receptors (MOR) and competitive antagonists of κ- and δ-opioid receptors (KOR and DOR), which
are involved in analgesia. However, mitragynine affinity for opioid receptors is lower than that of
morphine, while 7-hydroxymitragynine affinity is approximately 46 and 13 times higher than that of
mitragynine and morphine, respectively [212]. The possible stimulant and libido-enhancing effects
of mitragynine may be due to the blockade of serotonergic 5-HT2A receptors and the postsynaptic
stimulation of α2 adrenergic receptors 2R) in the CNS [212]. Recently, LaBryer et al. hypothesized
that kratom may have restored testosterone, luteinizing hormone (LH), follicle-stimulating hormone
Pharmaceuticals 2020, 13, 309 31 of 52
(FSH), and prolactin levels in a patient with hypogonadotropic hypogonadism [213]. Mitragynine
also binds adenosine A2A receptors, dopamine D2 receptors, and serotonin receptors 5-HT2C and 5-
HT7, but the physiological significance of these interactions is unclear [214]. Data showed that low
kratom doses (1–5 g) induce stimulating effects, involving the release of neurotransmitters by
reversible blockade of calcium channels. At higher doses (>15 g), it can cause sedative/narcotic effects,
and the plant can be used as a general analgesic, as an opium substitute, or to treat opium withdrawal
symptoms [215].
Studies have found that 7-hydroxymitragynine is the main contributor to the plant’s toxicity and
the development of addiction symptoms. In 2014, Singh et al. [51] reported a cross-sectional survey
investigating the correlation between frequency and quantity of kratom consumption, and the risk of
addiction development and the severity of withdrawal symptoms and craving in regular user [216].
Cessation of kratom use produced physical withdrawal symptoms similar to those of opiate
addiction including pain, sleep disorders, muscle spasms, watery eyes, runny nose, hot flashes, fever,
decreased appetite, diarrhea, and craving. Psychological withdrawal symptoms reported by users
included restlessness, tension, anger, and depression [217] (Table 1).
3.4. Panax
inseng C. A. Mey (Asian Ginseng) and Panax
uinquefolius L. (American Ginseng)
Ginseng is a perennial herbaceous plant of the family Araliaceae. Over twelve ginseng species
were identified, although mainly Asian or Korean ginseng (P. ginseng) and American ginseng (P.
quinquefolius) have been used for their therapeutic properties. Asian ginseng grows in East Asian
mountains, while American ginseng is an endangered species that grows in deciduous forests of the
west half of North America. Asian ginseng is an emblematic plant of traditional Chinese medicine,
and is listed in the Shennong Ben Cao Jing, the most ancient Chinese book of herbal medications. A
variety of pharmacological effects are attributed to ginseng. For example, it is used to improve
intelligence, to treat impotence, to treat hemorrhage, to relax, and to slow aging [218]. American
ginseng medical use is more recent and has gained popularity in Western countries over recent
decades. Ginseng health benefits were demonstrated in many clinical studies in various fields: it has
shown aphrodisiac, anti-inflammatory, anticancer (lung, liver, intestine, and stomach), antidiabetic,
cardioprotective, gastroprotective, antiamnestic, and antioxidative (heart and kidney) properties
[219]. The fresh root of ginseng can be directly chewed after peeling or soaked in wine for drinking
and chewing. In China and Korea, it is boiled with chicken to prepare energy drinks, teas, and candies
Asian and American ginseng contain a variety of pharmacologically active triterpene saponins,
named ginsenosides. Ginsenosides are classified into two groups depending on the hydroxylation of
their steroid core structure: the 20(S)-protopanaxadiol (PPD) and 20(S)-protopanaxatriol (PPT)
groups. Rb1, Rb2, Rb3, Rc, and Rd are the main PPD-type ginsenosides, and Rg1 and Re are the main
PPT-type ginsenosides. A total of 32 ginsenosides, including the abovementioned compounds, are
found in in both American and Asian ginseng, but the two plants also possess specific ginsenosides.
The presence of Rf, a PPD/PPT ratio lower than 2, and a Rb1/Rg1 ratio lower than 5 usually identify
Asian ginseng. The content of ginsenosides is affected by seasons, geographical distribution, and
processing (fresh ginseng, steamed ginseng or white ginseng, and sun-dried ginseng or red ginseng)
[220]. After oral administration, ginsenosides are mainly metabolized in the gastrointestinal tract and
the liver, undergoing successive deglycosylations: Rg3 is a metabolite of Rb1, Rb2, Rb3, Rc, and Rd,
and is further metabolized to Rh2; Rg2 is a metabolite of Re; and Rh1 is a metabolite of both Rg1 and
Rg2. Ginsenosides have low oral bioavailability, owing to their low membrane permeability and their
degradation in the gastrointestinal tract [219]. Rg1 induces NO synthesis in endothelial cells and
perivascular nerves, and increases vascular smooth muscle sensitivity to NO, prolonging the erection
in males and enhancing sexual potency. In addition, P. ginseng was proved to increase testosterone,
LH, and FSH in healthy volunteers through Rg1 and Rb1, enhancing libido. Re increases extracellular
dopamine and acetylcholine in rat brains, while Rb1 increases choline reuptake at the synapses. Rb1,
Rb2, Rc, Re, Rf, and Rg1 are agonists of GABAA receptors and Rc is also an agonist of GABAB
receptors. These modulations of several neurotransmission pathways may have an effect at different
Pharmaceuticals 2020, 13, 309 32 of 52
levels of the hypothalamus–pituitary–testis axis [221]. Mancuso and Santangelo recently reviewed
the effects of ginsenosides on the immune system (e.g., modulation of the immune response, anti-
inflammatory effects), the nervous system (e.g., regulation of the stress axis, improvement of memory
and learning functions), and the cardiovascular system (e.g., improvement of cardiac performance,
cardioprotective effects) [222].
American and Asian ginseng present a good safety profile with a few cases of mild
gastrointestinal and sleep disorders. Psychiatric and neurological side effects are rare, and causality
is difficult to ascertain [77,79,80,82–87,89–94]. In fact, most clinical studies with ginseng or
ginsenosides reported no psychiatric or neurological side effects or statistically insignificant effects
compared to placebo, and were not included in Table 1 [223–227]. A few cases of headache following
ginseng administration were reported without placebo control [84,91]. Insomnia, agitation, and
fatigue were more frequent [82–84,89,94], but still uncommon. More interestingly, several cases of
manic-like effects, such as confusion, agitation, irritation, nervousness, anxiety, and bizarre behavior,
without history of psychiatric disorder, were reported following ginseng use
[77,78,81,85,87,88,90,228]. These cases, however, were isolated and generally resulted from high
ginseng doses or with the concomitant use of other substances (e.g., phenelzine, cannabis, herbal
supplements); mania was not reported in clinical studies using ginseng alone or in combination. In
fact, ginseng toxicity mainly comes from drug interactions with cytochromes P450 (CYPs) CYP3A4
and CYP2D6 inhibitors and serotoninergic drugs, intensifying sedative effects or inducing cognitive
disorders or a serotonin syndrome [229–231].
3.5. Pausinystalia johimbe (K. Schum.) Pierre ex Beille (Yohimbe)
Pausinystalia johimbe (K. Schum.) Pierre ex Beille, also known as yohimbe, is an evergreen tree of
the Rubiaceae family that mainly grows in the tropical region of the African West coast, where the
bark has been consumed as an aphrodisiac for the treatment of erectile dysfunction [157,232].
The bark of the plant contains several structurally related indole alkaloids, yohimbine being the
most abundant one (10–15% of total content), followed by its stereoisomers α-yohimbine, β-
yohimbine, ψ-yohimbine, corynanthine, allo-yohimbine, and yohimbic acid [233,234]. Yohimbine is
marketed as a pharmaceutical prescribed for the treatment of erectile impotence and has been used
in multiple clinical trials as a probe to identify abnormal physiological and affective responses to
increased noradrenergic signaling, especially in patients with panic disorders [235,236]. Yohimbine
is a potent selective α2R antagonist with weaker α1R antagonist activity that blocks the presynaptic
feedback inhibition of noradrenaline release, prolonging the excitatory effects of noradrenaline at
postsynaptic α1R and β-receptors [237,238]. Yohimbine has a relatively short half-life due to an
extensive hepatic metabolism, which produces two main hydroxylated metabolites, 11- and 10-
hydroxyyohimbine, that are rapidly excreted in urine [239,240]. There is increasing interest in botanic
dietary supplements containing yohimbine extracts in the context of sexual and body enhancement
Yohimbine readily passes the blood–brain barrier after absorption, causing an increase in
sympathetic tone and blood pressure through the blockade of central medullary α2R [242], and
provokes noradrenergic perturbation in limbic forebrain structures like amygdala and locus
coeruleus, leading to mood and behavior alterations (Table 1). Due to these potential cardiac and
neurological adverse effects, yohimbine was used in patients with difficulties to reach orgasm, with
erectile dysfunction, or with low libido, mainly before the emergence of phosphodiesterase 5 (PDE5)
inhibitors (e.g., sildenafil), which present a better safety profile [243,244]. The yohimbine mechanism
of action is currently unclear. There is evidence suggesting that yohimbine increases libido by
blocking α2R in the locus coeruleus, which is involved in the control of the erection. Peripherally, it
was suggested that yohimbine enhances NO release from cavernosal endothelial cells, producing a
relaxation of smooth muscle cells and consequent erection, increasing sexual potency [3,6,237].
Moderate to severe adverse effects like sweating, flushing, hypertension, tachycardia, palpitations,
bronchospasm, chest pain, and atrial fibrillation are reported after deliberate or accidental ingestion,
while lethal intoxications are extremely rare [245,246].
Pharmaceuticals 2020, 13, 309 33 of 52
3.6. Piper methysticum G. Forst. (Kava)
Native to Western Pacific islands where the shrub is traditionally called “ava”, “wati”, or
“yagona”, kava (Piper methysticum G. Forst) grows in humid and shaded areas of tropical regions.
This is a perennial Piperaceae with a massive rhizome weighing up to a dozen kilograms [19]. Kava is
considered as a sacred beverage in Pacific islands [247]. The plant has also been used in traditional
medicine, first as a treatment for venereal diseases, then later as a sedative and treatment for anxiety
and sleep disorders, to decrease fatigue, and to relieve pain [248].
Eighteen active compounds named kavalactones were identified in kava, but only six, i.e.,
methysticin, dihydromethysticin, kawain, dihydrokawain, desmethoxyyangonin, and yangonin,
have been the focus of kava studies as they account for up to 96% of organic extracts (acetonic or
ethanolic extraction). Kava also contains a variety of other non-lactone compounds, i.e., flavokawains
A, B, and C, 5,7-dimethoxyflavanone, cinnamic acid bornyl ester, flavanones, fatty acids, and a
chalcone. Kava effects may be the result of a synergy of the six major kavalactones [249]. Kava extracts
produce a similar activity profile as that of benzodiazepines, which interact with GABA receptors,
inhibit the MAO-B, and inhibit dopamine and noradrenaline reuptake in the CNS, inducing libido-
enhancing properties [250]. In vitro studies of the hippocampus and other brain regions suggest that
the sedative effects of kavalactones may be mediated by an increase in GABAA receptor binding sites
[251,252]. It was demonstrated that several kavalactones are potent inhibitors of several CYP
metabolic enzymes [253]. Oral pharmacokinetics of kawain (100 mg/kg) were determined in rats with
and without co-administration of kava extract (256 mg/kg). The results showed that kawain was well
absorbed, and more than 90% of the dose was eliminated within 72 h, mainly in urine [254].
Data on kava’s safety profile obtained from clinical trials in patients with anxiety suggest
generally good tolerability and safety for short-term use (1–4 weeks) at therapeutic doses. However,
the use of kava at frequent and high doses can cause hepatotoxicity through the modulation of
various CYP, which is also the cause of potential drug interactions [255], dermopathy [256], and
cognitive disorders [257]. Sedation with drowsiness and dizziness is commonly reported in clinical
trials with administration of kava or methysticin (Table 1), which may impair driving performances
3.7. Ptychopetalum olacoides Benth. (Muirapuama)
Ptychopetalum olacoides Benth. is a popular Amazonian tree belonging to the Olacaceae family. It
is also known in Brazil as marapuama or muirapuama [258]. The native communities have used its roots
and barks as a treatment for depression, sexual dysfunction, and as a “nerve tonic” [259]. Roots are
usually prepared in alcoholic infusion, but other formulations have also been employed (e.g., mixture
of extracts, solutions, pills) [260].
Muirapuama root bark produces a volatile oil containing α-pinene, α-humulene, β-pinene, β-
caryophyllene, camphene, and camphor. Fatty acids such as uncosanoic, tricosanoic, and
pentacosanoic acids account for up to 20% of the total lipophilic components of the plant [261]. Other
compounds detected in muirapuama are fatty acid esters of sterols, coumarin, free fatty acids, and
free sterol; a small quantity of β-sitosterol was also detected [262]. Based on ethnopharmacological
data, it can be hypothesized that muirapuama interacts with the dopaminergic system, increasing
libido; the noradrenergic system, inducing antidepressant effects; and the serotonergic system,
modulating appetite. The antinociceptive effects of the plant were investigated in thermal and
chemical models of nociception in mice. Data showed that the maximal effect was reached 6 h after
administration of a low dose of muirapuama extract and produces significant and long-lasting (up
12 h) effects in both chemical and thermal tests of nociception in mice. In addition, higher doses,
either acutely or subchronically (15 days), did not cause a worsening of adverse effects [263]. A few
neurological side effects were reported in preclinical studies, including impairment of both short-
and long-term memory and reduced locomotion [151,152] (Table 1).
Pharmaceuticals 2020, 13, 309 34 of 52
3.8. Sceletium tortuosum (L.) N. E. Brown (Kanna)
Kanna, or Channa, is the traditional name of a succulent, perennial plant belonging to the
Aizoaceae family (earlier Mesembrynantheaceae) that is indigenous to South Africa, where it is
consumed by local tribes to relieve thirst and hunger and combat fatigue [264,265]. The dried aerial
parts of the plant are commonly chewed or consumed as teas, decoctions, and tinctures and
sometimes smoked or snuffed [266].
Kanna’s main active compounds are mesembrine, mesembrenol, mesembrenol, and
mesembrenone, which are synthesized in the plant through the condensation of phenylalanine and
tyrosine amino acids. Kanna alkaloids inhibit serotonin reuptake and PDE4A, potentially enhancing
sexual potency and libido [267–269]. In fact, the plant is widely sold over the Internet and specialized
herbal shops to increase sexual performance, although its mechanism of action and effects were not
clearly demonstrated. This dual inhibitory effect has been studied for the development of compounds
for the treatment of cognition impairment, motor dysfunction, depression, and neurodegeneration
[270]. Mesembrenone is the most potent inhibitor of PDE4A, while mesembrine is more selective
towards the serotonin receptor. In addition, mesembrine is also an agonist of GABAA, δ2-opioid, µ-
opioid, cholecystokinin-1, E4-prostaglandin, and melatonin-1 receptors at high doses, and shows
antinociceptive effects in animal models [266,270–273]. Recently, S. tortuosum has been marketed for
the treatment of mild depression and to improve mood [274]. Zembrin®, a standardized
hydroalcoholic extract, was found to be safe and well-tolerated in preclinical studies with mild
adverse effects (Table 1) and is widely sold as a dietary supplement [275]. Another commercially
available product is Trimesemine™, a highly-concentrated mesembrine extract (3% mesembrine
(w/w)) that shows a great upregulation of the expression of vesicular monoaminetransporter-2
(VMAT-2), increasing monoamines release as the primary pharmacological effect [276,277]. Kanna
alkaloids are metabolized in the liver to O,N-demethylated or dehydroxylated compounds, which
are then excreted as glucuronides or sulfates conjugates [277,278].
3.9. Other Plants
Little evidence was found on the psychiatric and neurological side effects of several sexual
enhancers that were originally included in this review: A. Mexicana, E. longifolia, L. meyenii, T. diffusa,
V. africana, and W. somnifera.
The safety of maca (Lepidium meyenii Walp.) and ashwagandha or Indian ginseng (Withania
somnifera (L.) Dunal) is well-documented. Maca is an edible herbaceous plant of the Andes Mountains
and has been used for centuries for improving male and female sexual function. A renewed interest
for maca has been observed from the 1990s onwards, and pills, capsules, flour, liquor, and extracts
are now massively produced and exported [279]. The plant, however, presents a good safety profile
[279], and only one case of a manic-like episode following consumption in a patient without history
of psychiatric disorders was reported [280]. Ashwagandha is an evergreen shrub of the family
Solanaceae, which is cultivated in hot and dry areas of tropical and subtropical regions of the world.
Ashwagandha has numerous applications in traditional Indian medicines and has been used for more
than 5000 years as an aphrodisiac, antioxidant, antimicrobial, adaptogenic, diuretic, tonic, narcotic,
immuno-stimulant, anti-inflammatory agent, anti-stress, antiulcer, among many other purposes.
Positive effect in insomnia, anxiety, chronic stress, weight management, thyroid gland function,
telomerase, cardio-respiratory endurance, muscle strength, recovery of male and female sexual
function, and senescence was demonstrated in preclinical and clinical studies [164]. Excellent
tolerability is generally reported after using ashwagandha for weeks at therapeutic doses, with
statistically insignificant adverse effects compared to placebo [281,282].
Other plants have been little studied, although some of them are well-known remedies that have
been used for many years. Further investigation is necessary to clearly understand the possible
neurological and psychiatric effects caused by these plants. For example, damiana (Turnera diffusa
Willd. Ex. Schult.), a Central American shrub of the family Passifloraceae, has been traditionally used
for centuries as a stimulant and aphrodisiac, to spark male sexual drive and increase performance,
and is still widely marketed [283]. Recently, the plant also proved to induce anxiolytic and
Pharmaceuticals 2020, 13, 309 35 of 52
antidepressant effects in preclinical studies [283,284]. However, no psychiatric or neurological side
effects related to damania were reported. Another interesting example is Voacanga africana Stapf ex
Scott-Elliot, a shrub/small tree of tropical Africa whose seeds have been recently commercialized as
a poison, stimulant, aphrodisiac, and ceremonial psychedelic [285]. Although the plant contains a
variety of indole alkaloids related to ibogaine, a well-known psychoactive substance from iboga
(Tabernanthe iboga Baill.) that has also been used as an aphrodisiac [286], there is no evidence of
positive effects on sexual function. In addition, although Voacanga africana alkaloids may modulate
neuronal excitability and have positive effects in Alzheimer’s disease [287,288], no neurological or
psychiatric complications related to the plant were reported. There is also little information on the
side effects of the Mexican poppy (Argemone mexicana L.) and Tongkat Ali (Eurycoma longifolia Jack.).
Other herbal aphrodisiacs that were not included in this literature review are commonly used,
but data on their safety profile are also limited [14].
3.10. General Discussion
The psychiatric and neurological side effects caused by the consumption of herbal aphrodisiacs
are mild, with mostly no consequences at therapeutic doses. Although rare, psychiatric side effects
were mostly reported and included anxiety, depression, psychosis, and mania. Neurological effects
included seizures, extrapyramidal symptoms, and withdrawal symptoms. Dizziness, sleepiness,
fatigue, agitation, insomnia, and headaches were reported. As expected, all the plants involved are
libido-enhancing aphrodisiacs altering neurotransmission, although ginseng (P. ginseng and P.
quinquefolius) and yohimbe (P. johimbe), and kanna (S. tortuosum) also enhance sexual potency.
Kratom (M. speciosa) and yohimbe presented the highest rate of side effects, but yohimbe’s general
toxicity is mainly cardiovascular, due to its effects on the NO pathway. These mild effects were not
anticipated, considering the mechanism of action of these plants. However, they did not come as a
complete surprise, because these plants have been used for centuries or millennia in traditional
medicines and modern medicine has considerably benefited from these ingredients and preparations
Few clinical reports and few data were found for the side effects of bitter orange (C. aurantium),
muirapuama (P. olacoides), and kanna (S. tortuosum), and only preclinical reports were found for
muirapuama. There were no reports on the side effects of damania (T. diffusa), the Mexican poppy
(A. mexicana), and Tongkat Ali (E. longifolia). Although several of these plants have been used for
centuries in traditional medicines, they have not been as extensively studied as the other plants
included in this review. Therefore, this result was not surprising. Psychiatric and neurological side
effects included headaches and hypnotic effects and were mild. Although the consumption of these
plants appears safe, further studies should be conducted to better understand their positive and
negative effects.
Herbal aphrodisiacs are readily available on the Internet and specialized shops and markets.
Aside from sexual enhancement, these plants often have many other therapeutic applications and
can be a part of the everyday diet of individuals. In addition, self-medication is frequent, as they are
available without a prescription, and plant extracts provided by retail herbal stores may also be
mislabeled or adulterated (e.g., heavy metals, pharmaceuticals) [290]. Consequently, these plants are
often taken concomitantly with contaminants, medications, and other herbal therapies or dietary
supplements: drug interactions represent the most significant health risks of herbal aphrodisiacs and
psychiatric and neurological adverse effects have been reported [230]. Medical doctors should be
aware of the potential drug interactions with aphrodisiacs and dietary supplements when prescribing
a pharmaceutical drug.
3.11. Limitations
Considering the paucity of data and the frequent co-exposure to other psychoactive substances,
conclusions can be hardly drawn regarding the psychiatric/neurological adverse effects of several of
the plants included in this article. In particular, more clinical studies with controlled administrations,
to have a better grasp on doses and co-exposures, should be conducted to address this issue.
Pharmaceuticals 2020, 13, 309 36 of 52
Another limitation is the choice of the keywords used for the literature search. The review
focused on selected plants and their active ingredients, which were included after a preliminary
screening of the literature. Other less common herbal aphrodisiacs might have eluded the search.
Additionally, only articles written in English, Italian, and French were included in the review,
and reports written in another language were excluded. This limitation is particularly relevant
considering the prevalence of traditional Ayurvedic, Unani, and Chinese medicines in East Asia and
diasporas [291].
4. Materials and Methods
A comprehensive literature search was conducted using the PubMed, Scopus, and Web of
Science bibliographic databases to identify scientific reports on the psychiatric and neurological
complications associated with the use of A. catechu, A. mexicana, C. aurantium, E. longifolia, L. meyenii,
M. speciosa, P. ginseng, P. quinquefolius, P. johimbe, P. methysticum, P. olacoides, S. tortuosum, T. diffusa,
V. africana, and W. somnifera. Database-specific search features with truncations (represented by an
asterisk in this article) and multiple keywords (represented by quotation marks in this article) were
employed. The search terms employed were addict*, anxiety, anxious, “brain disorder *”, cognit *,
depression, depressive, hallucin *, insomnia *, mania *, manic, mental, panic, “personality disorder
*”, psychiatry *, psychosis, psychotic, or schizoph * in combination with the following terms for each
A. catechu: “Areca catechu”, “areca palm”, “areca nut palm”, “betel palm”, “Indian nut”, “Pinang
palm”, arecaidine, or arecoline;
A. Mexicana: “Argemone mexicana”, “Mexican poppy”, “flowering thistle”, sanguinarine,
dihydrosanguinarine, dehydrocorydalmine, jatrorrhizine, columbamine, or oxyberberine;
C. aurantium: “Citrus aurantium”, “bitter orange”, “Seville orange”, “bigarade orange”, or
“marmalade orange”;
E. longifolia: “Eurycoma longifolia”, “tongkat ali”, “pasak bumi”, “Malaysian ginseng”,
eurycomanol, eurycomanone, or eurycomalactone;
L. meyenii: “Lepidium meyenii”, maca, or “Peruvian ginseng”;
M. speciosa: “Mitragyna speciose”, kratom, biak, mitragynine, or hydroxymitragynine;
P. ginseng and P. quinquefolius: “Panax ginseng”, “Panax quinquefolius”, ginseng, or
P. johimbe: “Pausinystalia johimbe”, yohimbe, ajmalicine, allo-yohimbine, corynantheine,
pseudoyohimbine, raubasine, yohimbine;
P. olacoides: “Ptychopetalum olacoides”, “muira puama”, or muirapuamine;
S. tortuosum: “Sceletium tortuosum”, kanna, channa, kougoed, mesembrine, mesembrenone,
mesembrenol, or tortuosamine;
T. diffusa: “Turnera diffusa”, damania, or damianin;
V. Africana: “Voacanga africana”, voacamine, or voacangine;
W. somnifera: “Withania somnifera”, ashwagandha, “Indian ginseng”, or “poison gooseberry”.
Further studies were retrieved from the reference list of selected articles and reports from
international institutions such as the World Health Organization (WHO), the US Drug Enforcement
Administration (DEA), and the European Monitoring Centre for Drugs and Drug Addiction
Records reporting the psychiatric and/or neurological adverse effects associated with the use of
the selected plant species in humans were included; only articles written in English, French, and
Pharmaceuticals 2020, 13, 309 37 of 52
Italian were included. Databases were screened up until June 2020 and references were
independently reviewed by three of the authors to determine their relevance to the present article.
5. Conclusions
Most of the sexual enhancers of plant origin included in this review appeared to be safe at
therapeutic doses, and few psychiatric and neurological side effects were reported. Yohimbe mainly
was involved in intoxication cases, but its cardiovascular toxicity is more concerning than its
psychiatric and neurological adverse effects. In addition, causality was often difficult to determine,
especially in case reports and self-reports, in which co-administration of other substances and herbal
formulations is prevalent. Interactions with pharmaceuticals or other herbal supplements are more
common and may pose a significant health threat.
The mechanisms underlying psychiatric and neurological disorders are multifaceted, often
involving multiple CNS pathways and receptors, and are not fully understood. Similarly, herbal
aphrodisiacs often contain multiple active ingredients with multiple mechanisms of action that are
yet to be fully characterized. Consequently, the mechanisms underlying the psychiatric and
neurological side effects associated with herbal aphrodisiac use is little-known.
Other sources of aphrodisiacs affecting the CNS are available, such as synthetic or semi-synthetic
drugs and natural substances of animal origin, which may also induce psychiatric or neurological
effects. Although aphrodisiacs are mainly obtained from plants, these substances may also be worthy
of investigation. It is also important to consider that plants that do not induce psychiatric or
neurological adverse effects are not necessarily harmless, and could exhibit another type of toxicity
(e.g., cardiovascular, hepatic, and renal toxicity), which was not the focus of the present review.
Author Contributions: P.B. and J.C. designed the study; A.F.L.F. and F.P.B. approved the design. P.B., A.F.L.F.,
A.T. and J.C. collected and organized the data and drafted the manuscript. All the authors contributed to the
revision of the manuscript and approved the final content. All authors have read and agreed to the published
version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: In this section you can acknowledge any support given which is not covered by the author
contribution or funding sections. This may include administrative and technical support, or donations in kind
(e.g., materials used for experiments).
Conflicts of Interest: The authors declare no conflict of interest.
1. Leonti, M.; Casu, L. Ethnopharmacology of love. Front. Pharmacol. 2018, 9, 567,
2. Giorgetti, R.; Tagliabracci, A.; Schifano, F.; Zaami, S.; Marinelli, E.; Busardò, F.P. When “Chems” Meet Sex:
A Rising Phenomenon Called “ChemSex.” Curr. Neuropharmacol. 2017, 15, 762–770,
3. Pyke, R.E. Sexual Performance Anxiety. Sex. Med. Rev. 2020, 8, 183–190, doi:10.1016/j.sxmr.2019.07.001.
4. Boivin, J.; Bunting, L.; Collins, J.A.; Nygren, K.G. International estimates on infertility prevalence and
treatment seeking: Potential need and demand for medical care. Hum. Reprod. 2007, 22, 1506–1512,
5. Smith, J.F.; Eisenberg, M.L.; Millstein, S.G.; Nachtigall, R.D.; Shindel, A.W.; Wing, H.; Cedars, M.; Pasch,
L.; Katz, P.P. The use of complementary and alternative fertility treatment in couples seeking fertility care:
Data from a prospective cohort in the United States. Fertil. Steril. 2010, 93, 2169–2174,
6. Corazza, O.; Martinotti, G.; Santacroce, R.; Chillemi, E.; Di Giannantonio, M.; Schifano, F.; Cellek, S. Sexual
enhancement products for sale online: Raising awareness of the psychoactive effects of yohimbine, maca,
horny goat weed, and ginkgo biloba. BioMed Res. Int. 2014, 2014, 1–13, doi:10.1155/2014/841798.
Pharmaceuticals 2020, 13, 309 38 of 52
7. Rao, N.; Spiller, H.A.; Hodges, N.L.; Chounthirath, T.; Casavant, M.J.; Kamboj, A.K.; Smith, G.A. An
Increase in Dietary Supplement Exposures Reported to US Poison Control Centers. J. Med. Toxicol. 2017, 13,
227–237, doi:10.1007/s13181-017-0623-7.
8. Sandroni, P. Aphrodisiacs past and present: A historical review. Clin. Auton. Res. 2001, 11, 303–307,
9. Guarraci, F.A.; Bolton, J.L. “Sexy stimulants”: The interaction between psychomotor stimulants and sexual
behavior in the female brain. Pharmacol. Biochem. Behav. 2014, 121, 53–61, doi:10.1016/j.pbb.2013.11.006.
10. Rot, M.A.H.; Mathew, S.J.; Charney, D.S. Neurobiological mechanisms in major depressive disorder. Can.
Med. Assoc. J. 2009, 180, 305–313, doi:10.1503/cmaj.080697.
11. Kato, T. Current understanding of bipolar disorder: Toward integration of biological basis and treatment
strategies. Psychiatry Clin. Neurosci. 2019, 73, 526–540, doi:10.1111/pcn.12852.
12. Martel, J.C.; McArthur, S.G. Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands
and Concepts in Schizophrenia. Front. Pharmacol. 2020, 11, 1003, doi:10.3389/fphar.2020.01003.
13. Hirao, K.; Pontone, G.M.; Smith, G.S. Molecular imaging of neuropsychiatric symptoms in Alzheimer’s and
Parkinson’s disease. Neurosci. Biobehav. Rev. 2015, 49, 157–170, doi:10.1016/j.neubiorev.2014.11.010.
14. Srivatsav, A.; Balasubramanian, A.; Pathak, U.I.; Rivera-Mirabal, J.; Thirumavalavan, N.; Hotaling, J.M.;
Lipshultz, L.I.; Pastuszak, A.W. Efficacy and Safety of Common Ingredients in Aphrodisiacs Used for
Erectile Dysfunction: A Review. Sex. Med. Rev. 2020, 8, 431–442, doi:10.1016/j.sxmr.2020.01.001.
15. Deahl, M. Betel nut-induced extrapyramidal syndrome: An unusual drug interaction. Mov. Disord. 1989, 4,
330–332, doi:10.1002/mds.870040406.
16. Winstock, A.R.; Trivedy, C.R.; Warnakulasuriya, S.; Peters, T.J. A dependency syndrome related to areca
nut use: Some medical and psychological aspects among areca nut users in the Gujarat community in the
UK. Addict. Biol. 2000, 5, 173–179, doi:10.1080/13556210050003766.
17. Hafeman, D.; Ahsan, H.; Islam, T.; Louis, E. Betel quid: Its tremor-producing effects in residents of
Araihazar, Bangladesh. Mov. Disord. 2005, 21, 567–571, doi:10.1002/mds.20754.
18. Senn, M.; Baiwog, F.; Winmai, J.; Mueller, I.; Rogerson, S.; Senn, N. Betel nut chewing during pregnancy,
Madang province, Papua New Guinea. Drug Alcohol Depend. 2009, 105, 126–131,
19. Bhat, S.J.S.; Blank, M.D.; Balster, R.L.; Nichter, M.; Nichter, M. Areca nut dependence among chewers in a
South Indian community who do not also use tobacco. Addiction 2010, 105, 1303–1310, doi:10.1111/j.1360-
20. Mirza, S.S.; Shafique, K.; Vart, P.; Arain, M.I. Areca nut chewing and dependency syndrome: Is the
dependence comparable to smoking? A cross sectional study. Subst. Abus. Treat. Prev. Policy 2011, 6, 23,
21. Lee, C.H.; Chiang, S.L.; Ko, A.M.-S.; Hua, C.H.; Tsai, M.H.; Warnakulasuriya, S.; Ibrahim, S.O.; Sunarjo;
Zain, R.B.; Ling, T.Y.; et al. Betel-quid dependence domains and syndrome associated with betel-quid
ingredients among chewers: An Asian multi-country evidence. Addiction 2014, 109, 1194–1204,
22. Lin, C.C.; Tamí-Maury, I.M.; Ma, W.F.; Lam, C.; Tsai, M.H.; Lin, M.T.; Li, C.I.; Liu, C.S.; Li, T.C.; Chiu, C.F.;
et al. Social and Cultural Context of Betel Quid Consumption in Taiwan and Implications for Prevention
and Cessation Interventions. Subst. Use Misuse 2017, 52, 646–655, doi:10.1080/10826084.2016.1246572.
23. Mateen, F.J.; Carone, M.; Tshering, L.; Dorji, C.; Dema, U.; Grundy, S.J.; Pokhrel, D.R.; Nirola, D.K. Areca
catechu (palm tree) nut chewing and seizures: An observational study. Epilepsy Behav. 2017, 74, 76–80,
24. Osborne, P.G.; Ko, Y.C.; Wu, M.T.; Lee, C.H. Intoxication and substance use disorder to Areca catechu nut
containing betel quid: A review of epidemiological evidence, pharmacological basis and social factors
influencing quitting strategies. Drug Alcohol Depend. 2017, 179, 187–197,
25. Papke, R.L.; Bhattacharyya, I.; Hatsukami, D.K.; Moe, I.; Glatman, S. Betel Nnut (areca) and Smokeless
Tobacco Use in Myanmar. Subst. Use Misuse 2020, 55, 1385–1394, doi:10.1080/10826084.2019.1624774.
26. Tsai, M.H.; Li, T.C.; Li, C.I.; Gritz, E.R.; Lam, C.; Chiu, C.F.; Liu, C.S.; Lai, C.C.; Hsu, W.Y.; Tamí-Maury, I.;
et al. Development and preliminary validation of a mandarin Chinese language questionnaire measuring
betel quid dependency among adults in Taiwan. Psychiatry Res. 2019, 271, 153–160,
Pharmaceuticals 2020, 13, 309 39 of 52
27. Sitaram, N.; Nurnberger, J.I.; Gershon, E.S.; Gillin, J.C. Cholinergic regulation of mood and REM sleep:
Potential model and marker of vulnerability to affective disorder. Am. J. Psychiatry 1982, 139, 571–576,
28. Nurnberger, J.I.; Jimerson, D.C.; Simmons-Alling, S.; Tamminga, C.; Nadi, N.S.; Lawrence, D.; Sitaram, N.;
Gillin, J.C.; Gershon, E.S. Behavioral, physiological, and neuroendocrine responses to arecoline in normal
twins and “well state” bipolar patients. Psychiatry Res. 1983, 9, 191–200, doi:10.1016/0165-1781(83)90043-4.
29. Dubé, S.; Kumar, N.; Ettedgui, E.; Pohl, R.; Jones, D.; Sitaram, N. Cholinergic REM induction response:
Separation of anxiety and depression. Biol. Psychiatry 1985, 20, 408–418, doi:10.1016/0006-3223(85)90043-5.
30. Overstreet, D.H. Selective breeding for increased cholinergic function: Development of a new animal model
of depression. Biol. Psychiatry 1986, 21, 49–58, doi:10.1016/0006-3223(86)90007-7.
31. Tariot, P.N.; Cohen, R.M.; Welkowitz, J.A.; Sunderland, T.; Newhouse, P.A.; Murphy, D.L.; Weingartner,
H. Multiple-Dose Arecoline Infusions in Alzheimer’s Disease. Arch. Gen. Psychiatry 1988, 45, 901–905,
32. Wager, S.; Robinson, D.; Goetz, R.; Nunes, E.; Gully, R.; Quitkin, F. Cholinergic REM sleep induction in
atypical depression. Biol. Psychiatry 1990, 27, 441–446, doi:10.1016/0006-3223(90)90554-F.
33. Polinsky, R.J.; Brown, R.T.; Curras, M.T.; Baser, S.M.; Baucom, C.E.; Hooper, D.R.; Marini, A.M. Central
and peripheral effects of arecoline in patients with autonomic failure. J. Neurol. Neurosurg. Psychiatry 1991,
54, 807–812, doi:10.1136/jnnp.54.9.807.
34. Gillin, J.C.; Sutton, L.; Ruiz, C.; Kelsoe, J.; Dupont, R.M.; Darko, D.; Risch, S.C.; Golshan, S.; Janowsky, D.
The Cholinergic Rapid Eye Movement Induction Test With Arecoline in Depression. Arch. Gen. Psychiatry
1991, 48, 264–270, doi:10.1001/archpsyc.1991.01810270076011.
35. Dahl, R.E.; Ryan, N.D.; Perel, J.; Birmaher, B.; Al-Shabbout, M.; Nelson, B.; Puig-Antich, J. Cholinergic REM
induction test with arecoline in depressed children. Psychiatry Res. 1994, 51, 269–282, doi:10.1016/0165-
36. Molinengo, L.; Orsetti, M.; Pastorello, B.; Scordo, I.; Ghi, P. The action of arecoline on retrieval and memory
storage evaluated in the staircase maze. Neurobiol. Learn. Mem. 1995, 63, 167–173,
37. Chau, D.T.; Rada, P.; Kosloff, R.A.; Taylor, J.L.; Hoebel, B.G. Nucleus accumbens muscarinic receptors in
the control of behavioral depression: Antidepressant-like effects of local m1 antagonist in the porsolt swim
test. Neuroscience 2001, 104, 791–798, doi:10.1016/S0306-4522(01)00133-6.
38. Carvalho-Freitas, M.I.R.; Costa, M. Anxiolytic and sedative effects of extracts and essential oil from Citrus
aurantium L. Biol. Pharm. Bull. 2002, 25, 1629–1633, doi:10.1248/bpb.25.1629.
39. Kamalifard, M.; Farshbaf-Khalili, A.; Namadian, M.; Ranjbar, Y.; Herizchi, S. Comparison of the Effect of
Lavender and Bitter Orange on Sleep Quality in Postmenopausal Women: A Triple-Blind, Randomized,
Controlled Clinical Trial. Women Health 2018, 58, 851–865, doi:10.1080/03630242.2017.1353575.
40. Farshbaf-Khalili, A.; Kamalifard, M.; Namadian, M. Comparison of the Effect of Lavender and Bitter
Orange on Anxiety in Postmenopausal Women: A Triple-Blind, Randomized, Controlled Clinical Trial.
Complement. Ther. Clin. Pract. 2018, 31, 132–138, doi:10.1016/j.ctcp.2018.02.004.
41. Heydari, N.; Abootalebi, M.; Tayebi, N.; Hassanzadeh, F.; Kasraeian, M.; Emamghoreishi, M.; Akbarzadeh,
M. The Effect of Aromatherapy on Mental, Physical Symptoms, and Social Functions of Females With
Premenstrual Syndrome: A Randomized Clinical Trial. J. Fam. Med. Prim. Care 2019, 8, 2990–2996,
42. Assanangkornchai, S.; Muekthong, A.; Sam-Angsri, N.; Pattanasattayawong, U. The use of Mitragynine
speciosa (“Krathom”), an addictive plant, in Thailand. Subst. Use Misuse 2007, 42, 2145–2157,
43. Boyer, E.W.; Babu, K.M.; Adkins, J.E.; Mccurdy, C.R.; Halpern, J.H. Self-treatment of opioid withdrawal
using kratom (Mitragynia speciosa korth). Addiction 2008, 103, 1048–1050, doi:10.1111/j.1360-
44. Nelsen, J.L.; Lapoint, J.; Hodgman, M.J.; Aldous, K.M. Seizure and Coma Following Kratom (Mitragynina
speciosa Korth) Exposure. J. Med. Toxicol. 2010, 6, 424–426, doi:10.1007/s13181-010-0079-5.
45. Vicknasingam, B.; Narayanan, S.; Beng, G.T.; Mansor, S.M. The informal use of ketum (Mitragyna speciosa)
for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution
therapy. Int. J. Drug Policy 2010, 21, 283–288, doi:10.1016/j.drugpo.2009.12.003.
Pharmaceuticals 2020, 13, 309 40 of 52
46. McWhirter, L.; Morris, S. A case report of inpatient detoxification after kratom (Mitragyna speciosa)
dependence. Eur. Addict. Res. 2010, 16, 229–231, doi:10.1159/000320288.
47. Ahmad, K.; Aziz, Z. Mitragyna speciosa use in the northern states of Malaysia: A cross-sectional study. J.
Ethnopharmacol. 2012, 141, 446–450, doi:10.1016/j.jep.2012.03.009.
48. Trakulsrichai, S.; Tongpo, A.; Sriapha, C.; Wongvisawakorn, S.; Rittilert, P.; Kaojarern, S.; Wananukul, W.
Kratom Abuse in Ramathibodi Poison Center, Thailand: A Five-Year. J. Psychoact. Drugs 2012, 45, 404–408,
49. Forrester, M.B. Kratom exposures reported to Texas poison centers. J. Addict. Dis. 2013, 32, 396–400,
50. Saingam, D.; Assanangkornchai, S.; Geater, A.F.; Balthip, Q. Pattern and consequences of krathom
(Mitragyna speciosa Korth.) use among male villagers in southern Thailand: A qualitative study. Int. J.
Drug Policy 2013, 24, 351–358, doi:10.1016/j.drugpo.2012.09.004.
51. Singh, D.; Müller, C.P.; Vicknasingam, B.K. Kratom (Mitragyna speciosa) dependence, withdrawal
symptoms and craving in regular users. Drug Alcohol Depend. 2014, 139, 132–137,
52. Swogger, M.T.; Hart, E.; Erowid, F.; Erowid, E.; Trabold, N.; Yee, K.; Parkhurst, K.A.; Priddy, B.M.; Walsh,
Z. Experiences of Kratom Users: A Qualitative Analysis. J. Psychoact. Drugs 2015, 47, 360–367,
53. Anwar, M.; Law, R.; Schier, J. Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to
Poison Centers—United States, 2010–2015. MMWR. Morb. Mortal. Wkly. Rep. 2016, 65, 748–749,
54. Saingam, D.; Assanangkornchai, S.; Geater, A.F.; Lerkiatbundit, S. Factor analytical investigation of
krathom (mitragyna speciosa korth.) withdrawal syndrome in Thailand. J. Psychoact. Drugs 2016, 48, 76–85,
55. Buresh, M. Treatment of kratom dependence with buprenorphine-naloxone maintenance. J. Addict. Med.
2018, 12, 481–483, doi:10.1097/ADM.0000000000000428.
56. Singh, D.; Narayanan, S.; Müller, C.P.; Swogger, M.T.; Rahim, A.A.; Leong Bin Abdullah, M.F.I.;
Vicknasingam, B.K.; Marc, T.S. Severity of Kratom (Mitragyna speciosa Korth.) Psychological Withdrawal
Symptoms. J. Psychoact. Drugs 2018, 50, 445–450, doi:10.1080/02791072.2018.1511879.
57. Mackay, L.; Abrahams, R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can.
Fam. Physician 2018, 64, 121–122.
58. Murthy, P.; Clark, D. An unusual cause for neonatal abstinence syndrome. Paediatr. Child Health 2019, 24,
12–14, doi:10.1093/pch/pxy084.
59. Diep, J.; Chin, D.T.; Gupta, S.; Syed, F.; Xiong, M.; Cheng, J. Kratom, an Emerging Drug of Abuse: A Case
Report of Overdose and Management of Withdrawal. A A Pract. 2018, 10, 192–194,
60. Tatum, W.O.; Hasan, T.F.; Coonan, E.E.; Smelick, C.P. Recurrent seizures from chronic kratom use, an
atypical herbal opioid. Epilepsy Behav. Case Rep. 2018, 10, 18–20, doi:10.1016/j.ebcr.2018.04.002.
61. Khazaeli, A.; Jerry, J.M.; Vazirian, M. Treatment of Kratom Withdrawal and Addiction With
Buprenorphine. J. Addict. Med. 2018, 12, 493–495, doi:10.1097/ADM.0000000000000435.
62. Singh, D.; Narayanan, S.; Müller, C.P.; Vicknasingam, B.; Yücel, M.; Ho, E.T.W.; Hassan, Z.; Mansor, S.M.
Long-Term Cognitive Effects of Kratom (Mitragyna speciosa Korth.) Use. J. Psychoact. Drugs 2019, 51, 19–
27, doi:10.1080/02791072.2018.1555345.
63. Abdullah, M.F.I.; Singh, D.; Swogger, M.T.; Rahim, A.A.; Vicknasingam, B. The prevalence of psychotic
symptoms in kratom (Mitragyna speciosa Korth.) Users in Malaysia. Asian J. Psychiatr. 2019, 43, 197–201,
64. Eggleston, W.; Stoppacher, R.; Suen, K.; Marraffa, J.M.; Nelson, L.S. Kratom Use and Toxicities in the United
States. Pharmacotherapy 2019, 39, 775–777, doi:10.1002/phar.2280.
65. Meireles, V.; Rosado, T.; Barroso, M.; Soares, S.; Gonçalves, J.; Luís, Â.; Caramelo, D.; Simão, A.; Fernández,
N.; Duarte, A.; et al. Mitragyna speciosa: Clinical, Toxicological Aspects and Analysis in Biological and
Non-Biological Samples. Medicines 2019, 6, 35, doi:10.3390/medicines6010035.
66. Saref, A.; Suraya, S.; Singh, D.; Grundmann, O.; Narayanan, S.; Swogger, M.T.; Prozialeck, W.C.; Boyer, E.;
Chear, N.J.Y.; Balasingam, V. Self-reported prevalence and severity of opioid and kratom (Mitragyna
speciosa korth.) side effects. J. Ethnopharmacol. 2019, 238, 111876, doi:10.1016/j.jep.2019.111876.
Pharmaceuticals 2020, 13, 309 41 of 52
67. Stanciu, C.N.; Gnanasegaram, S.A.; Ahmed, S.; Penders, T. Kratom Withdrawal: A Systematic Review with
Case Series. J. Psychoact. Drugs 2019, 51, 12–18, doi:10.1080/02791072.2018.1562133.
68. Schmuhl, K.K.; Gardner, S.M.; Cottrill, C.B.; Bonny, A.E. Home induction and outpatient treatment of
kratom use disorder with buprenorphine-naloxone: A case report in a young adult. Subst. Abus. 2020, 41,
311–314, doi:10.1080/08897077.2019.1671945.
69. Afzal, H.; Esang, M.; Rahman, S. A Case of Kratom-induced Seizures. Cureus 2020, 12, e6588,
70. Garcia-Romeu, A.; Cox, D.J.; Smith, K.E.; Dunn, K.E.; Griffiths, R.R. Kratom (Mitragyna speciosa): User
demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020, 208,
107849, doi:10.1016/j.drugalcdep.2020.107849.
71. Singh, D.; Narayanan, S.; Suraya, S.; Saref, A.; Grundmann, O.; Prozialeck, W.C.; Corazza, O.; Swogger,
M.T.; Griffin, O.; Balasingam, V. Public Perceptions toward Kratom (Mitragyna Speciosa) Use in Malaysia.
J. Psychoact. Drugs 2020, 52, 282–288, doi:10.1080/02791072.2020.1738603.
72. Apryani, E.; Hidayat, M.T.; Moklas, M.A.A.; Fakurazi, S.; Idayu, N.F. Effects of mitragynine from
Mitragyna speciosa Korth leaves on working memory. J. Ethnopharmacol. 2010, 129, 357–360,
73. Karinen, R.; Fosen, J.T.; Rogde, S.; Vindenes, V. An accidental poisoning with mitragynine. Forensic Sci. Int.
2014, 245, e29–e32, doi:10.1016/j.forsciint.2014.10.025.
74. Yusoff, N.H.M.; Suhaimi, F.W.; Vadivelu, R.K.; Hassan, Z.; Rümler, A.; Rotter, A.; Amato, D.; Dringenberg,
H.C.; Mansor, S.M.; Navaratnam, V.; et al. Abuse potential and adverse cognitive effects of mitragynine
(kratom). Addict. Biol. 2016, 21, 98–110, doi:10.1111/adb.12185.
75. Hemby, S.E.; Mcintosh, S.; Leon, F.; Cutler, S.J.; Mccurdy, C.R. Abuse liability and therapeutic potential of
the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict. Biol. 2019, 24,
874–885, doi:10.1111/adb.12639.
76. Hassan, Z.; Suhaimi, F.W.; Ramanathan, S.; Ling, K.H.; Effendy, M.A.; Müller, C.P.; Dringenberg, H.C.
Mitragynine (Kratom) impairs spatial learning and hippocampal synaptic transmission in rats. J.
Psychopharmacol. 2019, 33, 908–918, doi:10.1177/0269881119844186.
77. Vadnal, R.; Parthasarathy, L.; Parthasarathy, R. The Use of Ginseng as an Adjunct in Treatment-Resistant
Depression. Nutr. Neurosci. 1998, 1, 83–85, doi:10.1080/1028415x.1998.11747216.
78. Joshi, K.G.; Faubion, M.D. Mania and Psychosis Associated with St. John’s Wort and Ginseng. Psychiatry
(Edgmont) 2005, 2, 56–61.
79. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. Dose dependent changes in cognitive performance and mood
following acute administration of Ginseng to healthy young volunteers. Nutr. Neurosci. 2001, 4, 295–310,
80. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. Differential, dose dependent changes in cognitive performance
following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young
volunteers. Nutr. Neurosci. 2001, 4, 399–412, doi:10.1080/1028415X.2001.11747376.
81. Vázquez, I.; Agüera-Ortiz, L.F. Herbal products and serious side effects: A case of ginseng-induced manic
episode. Acta Psychiatr. Scand. 2002, 105, 76–77.
82. Hartley, D.E.; Elsabagh, S.; File, S.E. Gincosan (A combination of ginkgo biloba and panax ginseng): The
effects on mood and cognition of 6 and 12 weeks’ treatment in post-menopausal women. Nutr. Neurosci.
2004, 7, 325–333, doi:10.1080/10284150400015557.
83. Niederhofer, H. Panax ginseng may improve some symptoms of attention-deficit hyperactivity disorder. J.
Diet. Suppl. 2009, 6, 22–27, doi:10.1080/19390210802687221.
84. Jeong, H.G.; Ko, Y.H.; Oh, S.Y.; Han, C.; Kim, T.; Joe, S.H. Effect of Korean Red Ginseng as an adjuvant
treatment for women with residual symptoms of major depression. Asia Pac. Psychiatry 2015, 7, 330–336,
85. Norelli, L.J.; Xu, C. Manic psychosis associated with Ginseng: A report of two cases and discussion of the
literature. J. Diet. Suppl. 2015, 12, 119–125, doi:10.3109/19390211.2014.902001.
86. Yennurajalingam, S.; Reddy, A.; Tannir, N.M.; Chisholm, G.B.; Lee, R.T.; Lopez, G.; Escalante, C.P.;
Manzullo, E.F.; Hume, S.F.; Williams, J.L.; et al. High-Dose Asian Ginseng (Panax Ginseng) for Cancer-
Related Fatigue: A Preliminary Report. Integr. Cancer Ther. 2015, 14, 419–427,
Pharmaceuticals 2020, 13, 309 42 of 52
87. Yadav, P.; Stigall, K.; Johnson, H.E.; Rayapati, A.O.; Chopra, N. Functional foods: How functional are they?
A case report of supplement-induced psychosis. Int. J. Psychiatry Med. 2016, 51, 479–485,
88. Bostock, E.; Kirkby, K.; Garry, M.; Taylor, B.; Hawrelak, J.A. Mania associated with herbal medicines, other
than cannabis: A systematic review and quality assessment of case reports. Front. Psychiatry 2018, 9, 208,
89. Farnia, V.; Alikhani, M.; Ebrahimi, A.; Golshani, S.; Bahmani, D.S.; Brand, S. Ginseng treatment improves
the sexual side effects of methadone maintenance treatment. Psychiatry Res. 2019, 276, 142–150,
90. Görgülü, S. Manic Episode Associated with Ginseng: A Case Report. Int. J. Med. Rev. Case Rep. 2020, 4, 111
113, doi:10.5455/ijmrcr.manic-episodes-ginseng.
91. Lee, J.; Lee, A.; Kim, J.-H.; Shin, Y.M.; Kim, S.-J.; Cho, W.D.; Lee, S.I. Effect of omega-3 and Korean red
ginseng on children with attention deficit hyperactivity disorder: An open-label pilot study. Clin.
Psychopharmacol. Neurosci. 2020, 18, 75–80, doi:10.9758/CPN.2020.18.1.75.
92. Jones, B.D.; Runikis, A.M. Interaction of ginseng with phenelzine. J. Clin. Psychopharmacol. 1987, 7, 201–202,
93. Lyon, M.R.; Cline, J.C.; De Zepetnek, J.T.; Shan, J.J.; Pang, P.; Benishin, C. Effect of the herbal extract
combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: A pilot
study. J. Psychiatry Neurosci. 2001, 26, 221–228.
94. Ma, H.; Sullivan-Halley, J.; Smith, A.W.; Neuhouser, M.L.; Alfano, C.M.; Meeske, K.; George, S.M.;
McTiernan, A.; McKean-Cowdin, R.; Baumgartner, K.B.; et al. Estrogenic botanical supplements, health-
related quality of life, fatigue, and hormone-related symptoms in breast cancer survivors: A HEAL study
report. BMC Complement. Altern. Med. 2011, 11, 109, doi:10.1186/1472-6882-11-109.
95. Papeschi, R.; Sourkers, T.L.; Youdim, M.B. The effect of yohimbine on brain serotonin metabolism, motor
behavior and body temperature of the rat. Eur. J. Pharmacol. 1971, 15, 318–326, doi:10.1016/0014-
96. MacKintosh, C.G.; Van Reenen, G. Comparison of yohimbine, 4-aminopyridine and doxapram antagonism
of xylazine sedation in deer (Cervus elaphus). N. Z. Vet. J. 1984, 32, 181–184,
97. Price, L.H.; Charney, D.S.; Heninger, G.R. Three cases of manic symptoms following yohimbine
administration. Am. J. Psychiatry 1984, 141, 1267–1268, doi:10.1176/ajp.141.10.1267.
98. Charney, D.S.; Heninger, G.R.; Breier, A. Noradrenergic Function in Panic Anxiety. Arch. Gen. Psychiatry
1984, 41, 751–763, doi:10.1001/archpsyc.1984.01790190025003.
99. Linden, C.H.; Vellman, W.P.; Rumack, B. Yohimbine: A new street drug. Ann. Emerg. Med. 1985, 14, 1002–
1004, doi:10.1016/s0196-0644(85)80249-3.
100. Charney, S.; Woods, S.W.; Goodman, K.; Heninger, R. Neurobiological Mechanisms of Panic Anxiety:
Biochemical and Behavioral Correlates of Yohimbine-Induced Panic Attacks. Am. J. Psychiatry 1987, 144,
1030–1036, doi:10.1176/ajp.144.8.1030.
101. Johnston, A.L.; Baldwin, H.A.; File, S.E. Measures of anxiety and stress in the rat following chronic
treatment with yohimbine. J. Psychopharmacol. 1988, 2, 33–38, doi:10.1177/026988118800200106.
102. Heninger, G.R.; Charney, D.S.; Price, L.H. alpha 2-Adrenergic receptor sensitivity in depression. The
plasma MHPG, behavioral, and cardiovascular responses to yohimbine. Arch. Gen. Psychiatry 1988, 45, 718–
726, doi:10.1001/archpsyc.1988.01800320028003.
103. Dilsaver, S.C.; Davidson, R.K. Chronic treatment with amitriptyline produces subsensitivity to the
hypothermic effects of yohimbine. Prog. Neuro-Psychopharmacology Biol. Psychiatry 1989, 13, 211–215,
104. Rosenblum, L.A.; Coplan, J.D.; Friedman, S.; Bassoff, T. Dose-response effects of oral yohimbine in
unrestrained primates. Biol. Psychiatry 1991, 29, 647–657, doi:10.1016/0006-3223(91)90134-8.
105. Charney, D.S.; Woods, S.W.; Krystal, J.H.; Nagy, L.M.; Heninger, G.R. Noradrenergic neuronal
dysregulation in panic disorder: The effects of intravenous yohimbine and clonidine in panic disorder
patients. Acta Psychiatr. Scand. 1992, 86, 273–282, doi:10.1111/j.1600-0447.1992.tb03266.x.
106. Friesen, K.; Palatnick, W.; Tenenbein, M. Benign course after massive ingestion of yohimbine. J. Emerg. Med.
1993, 11, 287–288, doi:10.1016/0736-4679(93)90048-C.
Pharmaceuticals 2020, 13, 309 43 of 52
107. Kollias-Baker, C.A.; Court, M.H.; Williams, L.L. Influence of yohimbine and tolazoline on the
cardiovascular, respiratory, and sedative effects of xylazine in the horse. J. Vet. Pharmacol. Ther. 1993, 16,
350–358, doi:10.1111/j.1365-2885.1993.tb00182.x.
108. Wooten, V. Effectiveness of yohimbine in treating narcolepsy. South. Med. J. 1994, 87, 1065–1066,
109. Southwick, S.M.; Morgan, C.A., III; Charney, D.S.; High, J.R. Yohimbine use in a natural setting: Effects on
posttraumatic stress disorder. Biol. Psychiatry 1999, 46, 442–444, doi:10.1016/S0006-3223(99)00107-9.
110. Cameron, O.G.; Zubieta, J.K.; Grunhaus, L.; Minoshima, S. Effects of yohimbine on cerebral blood flow,
symptoms, and physiological functions in humans. Psychosom. Med. 2000, 62, 549–559,
111. Morales, L.; Perez-Garcia, C.; Alguacil, L.F. Effects of yohimbine on the antinociceptive and place
conditioning effects of opioid agonists in rodents. Br. J. Pharmacol. 2001, 133, 172–178,
112. Matsunaga, T.; Tsukada, H.; Nishiyama, S.; Sekine, Y.; Kakiuchi, T.; Iyo, M.; Mori, N. Yohimbine increases
the binding potential for [11 C] flumazenil in the monkey brain. J. Neural Transm. 2001, 108, 1375–1382,
113. Stine, S.M.; Southwick, S.M.; Petrakis, I.L.; Kosten, T.R.; Charney, D.S.; Krystal, J.H. Yohimbine-induced
withdrawal and anxiety symptoms in opioid-dependent patients. Biol. Psychiatry 2002, 51, 642–651,
114. Shepard, J.D.; Bossert, J.M.; Liu, S.Y.; Shaham, Y. The anxiogenic drug yohimbine reinstates
methamphetamine seeking in a rat model of drug relapse. Biol. Psychiatry 2004, 55, 1082–1089,
115. Lee, B.; Tiefenbacher, S.; Platt, D.M.; Spealman, R.D. Pharmacological blockade of α2-adrenoceptors
induces reinstatement of cocaine-seeking behavior in squirrel monkeys. Neuropsychopharmacology 2004, 29,
686–693, doi:10.1038/sj.npp.1300391.
116. Ehlert, U.; Erni, K.; Hebisch, G.; Nater, U. Salivary α-amylase levels after yohimbine challenge in healthy
men. J. Clin. Endocrinol. Metab. 2006, 91, 5130–5133, doi:10.1210/jc.2006-0461.
117. Keedy, S.K.; Connor, M.M.; Beenken, B.; Dorflinger, J.; Abel, M.; Erwin, R.J. Noradrenergic antagonism of
the P13 and N40 components of the rat auditory evoked potential. Psychopharmacology 2007, 190, 117–125,
118. Giampreti, A.; Lonati, D.; Locatelli, C.; Rocchi, L.; Campailla, M.T. Acute neurotoxicity after yohimbine
ingestion by a body builder. Clin. Toxicol. 2009, 47, 827–829, doi:10.1080/15563650903081601.
119. Powers, M.B.; Smits, J.A.J.; Otto, M.W.; Sanders, C.; Emmelkamp, P.M.G. Facilitation of fear extinction in
phobic participants with a novel cognitive enhancer: A randomized placebo controlled trial of yohimbine
augmentation. J. Anxiety Disord. 2009, 23, 350–356, doi:10.1016/j.janxdis.2009.01.001.
120. Banna, K.M.; Back, S.E.; Do, P.; See, R.E. Yohimbine stress potentiates conditioned cue-induced
reinstatement of heroin-seeking in rats. Behav. Brain Res. 2010, 208, 144–148, doi:10.1016/j.bbr.2009.11.030.
121. Sommer, M.; Braumann, M.; Althoff, T.; Backhaus, J.; Kordon, A.; Junghanns, K.; Ehrenthal, D.; Bartmann,
U.; Hohagen, F.; Broocks, A. Psychological and neuroendocrine responses to social stress and to the
administration of the alpha-2-receptor antagonist, yohimbine, in highly trained endurance athletes in
comparison to untrained healthy controls. Pharmacopsychiatry 2011, 44, 129–134, doi:10.1055/s-0031-
122. Umhau, J.C.; Schwandt, M.L.; Usala, J.; Geyer, C.; Singley, E.; George, D.T.; Heilig, M. Pharmacologically
induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is
insensitive to acamprosate. Neuropsychopharmacology 2011, 36, 1178–1186, doi:10.1038/npp.2010.253.
123. Berman, S.; Suyenobu, B.; Naliboff, B.D.; Bueller, J.; Stains, J.; Wong, H.; Mandelkern, M.; Fitzgerald, L.;
Ohning, G.; Gupta, A.; et al. Evidence for alterations in central noradrenergic signaling in irritable bowel
syndrome. Neuroimage 2012, 63, 1854–1863, doi:10.1016/j.neuroimage.2012.08.028.
124. Li, S.; Zou, S.; Coen, K.; Funk, D.; Shram, M.J.; Lê, A.D. Sex differences in yohimbine-induced increases in
the reinforcing efficacy of nicotine in adolescent rats. Addict. Biol. 2014, 19, 156–164, doi:10.1111/j.1369-
125. Lê, A.D.; Funk, D.; Coen, K.; Li, Z.; Shaham, Y. Role of corticotropin-releasing factor in the median raphe
nucleus in yohimbine-induced reinstatement of alcohol seeking in rats. Addict. Biol. 2013, 18, 448–451,
Pharmaceuticals 2020, 13, 309 44 of 52
126. Anderson, C.; Anderson, D.; Harre, N.; Wade, N. Case study: Two fatal case reports of acute yohimbine
intoxication. J. Anal. Toxicol. 2013, 37, 611–614, doi:10.1093/jat/bkt057.
127. Stopponi, S.; De Guglielmo, G.; Somaini, L.; Cippitelli, A.; Cannella, N.; Kallupi, M.; Ubaldi, M.; Heilig, M.;
Demopulos, G.; Gaitanaris, G.; et al. Activation of PPAR c by Pioglitazone Potentiates the Effects of
Naltrexone on Alcohol Drinking and Relapse in msP Rats. Alcohol. Clin. Exp. Res. 2013, 37, 1351–1360,
128. Moran-Santa Maria, M.M.; McRae-Clark, A.; Baker, N.L.; Ramakrishnan, V.; Brady, K.T. Yohimbine
administration and cue-reactivity in cocaine-dependent individuals. Psychopharmacology 2014, 231, 4157–
4165, doi:10.1007/s00213-014-3555-9.
129. Li, Q.; Lin, J.; Zhang, Y.; Liu, X.; Chen, X.Q.; Xu, M.Q.; He, L.; Li, S.; Guo, N. Differential behavioral
responses of zebrafish larvae to yohimbine treatment. Psychopharmacology 2015, 232, 197–208,
130. Ball, K.T.; Jarsocrak, H.; Hyacinthe, J.; Lambert, J.; Lockowitz, J.; Schrock, J. Yohimbine reinstates
extinguished 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) seeking in rats with prior exposure
to chronic yohimbine. Behav. Brain Res. 2015, 294, 1–6, doi:10.1016/j.bbr.2015.07.056.
131. Vo, L.; Hood, S.; Drummond, P.D. Involvement of Opioid Receptors and α 2-Adrenoceptors in Inhibitory
Pain Modulation Processes: A Double-Blind Placebo-Controlled Crossover Study. J. Pain 2016, 17, 1164–
1173, doi:10.1016/j.jpain.2016.07.004.
132. Moran-Santa Maria, M.M.; Baker, N.L.; McRae-Clark, A.L.; Prisciandaro, J.J.; Brady, K.T. Effects of
yohimbine and drug cues on impulsivity and attention in cocaine-dependent men and women and sex-
matched controls. Drug Alcohol Depend. 2016, 162, 56–63, doi:10.1016/j.drugalcdep.2016.02.021.
133. Kluen, L.M.; Agorastos, A.; Wiedemann, K.; Schwabe, L. Noradrenergic Stimulation Impairs Memory
Generalization in Women. J. Cogn. Neurosci. 2017, 29, 1279–1291, doi:10.1162/jocn_a_01118.
134. Vo, L.; Drummond, P.D. Effect of combined opioid receptor and α2-adrenoceptor blockade on anxiety and
electrically evoked startle responses. J. Psychopharmacol. 2017, 31, 722–729, doi:10.1177/0269881116689259.
135. Herman, A.M.; Critchley, H.D.; Duka, T. The impact of Yohimbine-induced arousal on facets of behavioural
impulsivity. Psychopharmacology 2019, 236, 1783–1795, doi:10.1007/s00213-018-5160-9.
136. Prescott, J.; Jamieson, D.; Emdur, N.; Duffield, P. Acute effects of kava on measures of cognitive
performance, physiological function and mood. Drug Alcohol Rev. 1993, 12, 49–57,
137. Wheatley, D. Stress-induced insomnia treated with kava and valerian: Singly and in combination. Hum.
Psychopharmacol. 2001, 16, 353–356, doi:10.1002/hup.299.
138. Connor, K.M.; Davidson, J.R.; Churchill, L.E. Adverse-Effect Profile of Kava. CNS Spectr. 2001, 6, 848–853,
139. Meseguer, E.; Taboada, R.; Sánchez, V.; Mena, M.A.; Campos, V.; García De Yébenes, J. Life-threatening
parkinsonism induced by kava-kava. Mov. Disord. 2002, 17, 195–196, doi:10.1002/mds.1268.
140. Gastpar, M.; Klimm, H.D. Treatment of anxiety, tension and restlessness states with Kava special extract
WS® 1490 in general practice: A randomized placebo-controlled double-blind multicenter trial.
Phytomedicine 2003, 10, 631–639, doi:10.1078/0944-7113-00369.
141. Cairney, S.; Maruff, P.; Clough, A.R.; Collie, A.; Currie, J.; Currie, B.J. Saccade and cognitive impairment
associated with kava intoxication. Hum. Psychopharmacol. 2003, 18, 525–533, doi:10.1002/hup.532.
142. Cagnacci, A.; Arangino, S.; Renzi, A.; Zanni, A.L.; Malmusi, S.; Volpe, A. Kava-Kava administration reduces
anxiety in perimenopausal women. Maturitas 2003, 44, 103–109, doi:10.1016/S0378-5122(02)00317-1.
143. Shinomiya, K.; Inoue, T.; Utsu, Y.; Tokunaga, S.; Masuoka, T.; Ohmori, A.; Kamei, C. Effects of kava-kava
extract on the sleep-wake cycle in sleep-disturbed rats. Psychopharmacology 2005, 180, 564–569,
144. Perez, J.; Holmes, J.F. Altered mental status and ataxia secondary to acute Kava ingestion. J. Emerg. Med.
2005, 28, 49–51, doi:10.1016/j.jemermed.2004.10.003.
145. Sarris, J.; Kavanagh, D.J.; Deed, G.; Bone, K.M. St. John’s wort and Kava in treating major depressive
disorder with comorbid anxiety: A randomised double-blind placebo-controlled pilot trial. Hum.
Psychopharmacol. 2009, 24, 41–48, doi:10.1002/hup.994.
146. Sarris, J.; Stough, C.; Teschke, R.; Wahid, Z.T.; Bousman, C.A.; Murray, G.; Savage, K.M.; Mouatt, P.; Ng,
C.; Schweitzer, I. Kava for the treatment of generalized anxiety disorder RCT: Analysis of adverse reactions,
liver function, addiction, and sexual effects. Phyther. Res. 2013, 27, 1723–1728, doi:10.1002/ptr.4916.
Pharmaceuticals 2020, 13, 309 45 of 52
147. Sarris, J.; Stough, C.; Bousman, C.A.; Wahid, Z.T.; Murray, G.; Teschke, R.; Savage, K.M.; Dowell, A.; Ng,
C.; Schweitzer, I. Kava in the treatment of generalized anxiety disorder: A double-blind, randomized,
placebo-controlled study. J. Clin. Psychopharmacol. 2013, 33, 643–648, doi:10.1097/JCP.0b013e318291be67.
148. Malhotra, N.; Starkey, N.J.; Charlton, S.G. Driving under the influence of drugs: Perceptions and attitudes
of New Zealand drivers. Accid. Anal. Prev. 2017, 106, 44–52, doi:10.1016/j.aap.2017.05.011.
149. Wang, D.; Yang, L.E.; Wang, J.; Hu, G.; Liu, Z.Y.; Yan, D.; Serikuly, N.; Alpyshov, E.T.; Demin, K.A.;
Galstyan, D.S.; et al. Behavioral and physiological effects of acute and chronic kava exposure in adult
zebrafish. Neurotoxicol. Teratol. 2020, 79, 106881, doi:10.1016/
150. Fragoulis, A.; Siegl, S.; Fendt, M.; Jansen, S.; Soppa, U.; Brandenburg, L.O.; Pufe, T.; Weis, J.; Wruck, C.J.
Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer’s disease.
Redox Biol. 2017, 12, 843–853, doi:10.1016/j.redox.2017.04.024.
151. Da Silva, A.L.; Bardini, S.; Nunes, D.S.; Elisabetsky, E. Anxiogenic properties of Ptychopetalum olacoides
Benth. (Marapuama). Phyther. Res. 2002, 16, 223–226, doi:10.1002/ptr.825.
152. Da Silva, A.L.; Silva Martins, B. Da; Linck, V.D.M.; Herrmann, A.P.; Mai, N.; Nunes, D.S.; Elisabetsky, E.
MK801- and scopolamine-induced amnesias are reversed by an Amazonian herbal locally used as a “brain
tonic.” Psychopharmacology 2009, 202, 165–172, doi:10.1007/s00213-008-1272-y.
153. Chiu, S.; Gericke, N.; Farina-Woodbury, M.; Badmaev, V.; Raheb, H.; Terpstra, K.; Antongiorgi, J.; Bureau,
Y.; Cernovsky, Z.; Hou, J.; et al. Proof-of-concept randomized controlled study of cognition effects of the
proprietary extract sceletium tortuosum (Zembrin) targeting phosphodiesterase-4 in cognitively healthy
subjects: Implications for Alzheimer’s dementia. Evidence-Based Complement. Altern. Med. 2014, 2014,
682014, doi:10.1155/2014/682014.
154. Huang, Y.J.; Jiann, B.P. Association of Areca Nut Chewing With Risk of Erectile Dysfunction. Sex. Med.
2017, 5, e163–e168, doi:10.1016/j.esxm.2017.05.002.
155. Bales, A.; Peterson, M.J.; Ojha, S.; Upadhaya, K.; Adhikari, B.; Barrett, B. Associations between betel nut
(Areca catechu) and symptoms of schizophrenia among patients in Nepal: A longitudinal study. Psychiatry
Res. 2009, 169, 203–211, doi:10.1016/j.psychres.2008.06.006.
156. Chu, N.S. Neurological aspects of areca and betel chewing. Addict. Biol. 2002, 7, 111–114,
157. Lo Faro, A.F.; Di Trana, A.; La Maida, N.; Tagliabracci, A.; Giorgetti, R.; Busardò, F.P. Biomedical analysis
of New Psychoactive Substances (NPS) of natural origin. J. Pharm. Biomed. Anal. 2020, 179, 112945,
158. Norton, S.A. Betel: Consumption and consequences. J. Am. Acad. Dermatol. 1998, 38, 81–88,
159. Gupta, P.C.; Warnakulasuriya, S. Global epidemiology of areca nut usage. Addict. Biol. 2002, 7, 77–83,
160. Agostini-Costa, T. da S. Bioactive compounds and health benefits of some palm species traditionally used
in Africa and the Americas—A review. J. Ethnopharmacol. 2018, 224, 202–229, doi:10.1016/j.jep.2018.05.035.
161. Srimany, A.; George, C.; Naik, H.R.; Pinto, D.G.; Chandrakumar, N.; Pradeep, T. Developmental patterning
and segregation of alkaloids in areca nut (seed of Areca catechu) revealed by magnetic resonance and mass
spectrometry imaging. Phytochemistry 2016, 125, 35–42, doi:10.1016/j.phytochem.2016.02.002.
162. Peng, W.; Liu, Y.J.; Wu, N.; Sun, T.; He, X.Y.; Gao, Y.X.; Wu, C.J. Areca catechu L. (Arecaceae): A review of
its traditional uses, botany, phytochemistry, pharmacology and toxicology. J. Ethnopharmacol. 2015, 164,
340–356, doi:10.1016/j.jep.2015.02.010.
163. Liu, Y.J.; Peng, W.; Hu, M.B.; Xu, M.; Wu, C.J. The pharmacology, toxicology and potential applications of
arecoline: A review. Pharm. Biol. 2016, 54, 2753–2760, doi:10.3109/13880209.2016.1160251.
164. Gheddar, L.; Ricaut, F.X.; Ameline, A.; Brucato, N.; Tsang, R.; Leavesley, M.; Raul, J.S.; Kintz, P. Testing for
Betel Nut Alkaloids in Hair of Papuans Abusers using UPLC-MS/MS and UPLC-Q-Tof-MS. J. Anal. Toxicol.
2020, 44, 41–48, doi:10.1093/jat/bkz045.
165. Gupta, A.K.; Tulsyan, S.; Thakur, N.; Sharma, V.; Sinha, D.N.; Mehrotra, R. Chemistry, metabolism and
pharmacology of carcinogenic alkaloids present in areca nut and factors affecting their concentration.
Regul. Toxicol. Pharmacol. 2020, 110, 104548, doi:10.1016/j.yrtph.2019.104548.
166. Salehi, B.; Konovalov, D.A.; Fru, P.; Kapewangolo, P.; Peron, G.; Ksenija, M.S.; Cardoso, S.M.; Pereira, O.R.;
Nigam, M.; Nicola, S.; et al. Areca catechu—From farm to food and biomedical applications. Phyther. Res.
2020, 34, 2140–2158, doi:10.1002/ptr.6665.
Pharmaceuticals 2020, 13, 309 46 of 52
167. Horenstein, N.A.; Quadri, M.; Stokes, C.; Shoaib, M.; Papke, R.L. Cracking the betel nut: Cholinergic
activity of areca alkaloids and related compounds. Nicotine Tob. Res. 2019, 21, 805–812,
168. Thiele, A. Muscarinic Signaling in the Brain. Annu. Rev. Neurosci. 2013, 36, 271–294, doi:10.1146/annurev-
169. Coppola, M.; Mondola, R. Potential action of betel alkaloids on positive and negative symptoms of
schizophrenia: A review. Nord. J. Psychiatry 2012, 66, 73–78, doi:10.3109/08039488.2011.605172.
170. Meltzer, L.T.; Rosecrans, J.A. Discriminative stimulus properties of arecoline: A new approach for studying
central muscarinic receptors. Psychopharmacology 1981, 75, 383–387, doi:10.1007/BF00435858.
171. Avery, E.E.; Baker, L.D.; Asthana, S. Potential Role of Muscarinic Agonists in Alzheimer’s Disease. Drugs
Aging 1997, 11, 450–459, doi:10.2165/00002512-199711060-00004.
172. Chandradasa, M.; Rathnayake, L. Socio-cultural and neurobiological perspectives of betel nut chewing in
schizophrenia. Asian J. Psychiatr. 2018, 37, 38–39, doi:10.1016/j.ajp.2018.08.002.
173. Kuruppuarachchi, K.; Williams, S. Betel use and schizophrenia. Br. J. Psychiatry 2003, 182, 455,
174. Sullivan, R.J.; Andres, S.; Otto, C.; Miles, W.; Kydd, R. The Effects of an Indigenous Muscarinic Drug, Betel
Nut (Areca catechu), on the Symptoms of Schizophrenia: A Longitudinal Study in Palau, Micronesia. Am.
J. Psychiatry 2007, 164, 670–673, doi:10.1176/appi.ajp.164.4.670.
175. Moran, S.P.; Maksymetz, J.; Conn, P.J. Targeting Muscarinic Acetylcholine Receptors for the Treatment of
Psychiatric and Neurological Disorders. Trends Pharmacol. Sci. 2019, 40, 1006–1020,
176. Chu, N.S. Effects of Betel chewing on the central and autonomic nervous systems. J. Biomed. Sci. 2001, 8,
229–236, doi:10.1007/bf02256596.
177. Molinengo, L.; Cassone, M.C.; Orsetti, M. Action of arecoline on the levels of acetylcholine, norepinephrine
and dopamine in the mouse central nervous system. Pharmacol. Biochem. Behav. 1986, 24, 1801–1803,
178. Manzanares, J.; Julian, M.; Carrascosa, A. Role of the Cannabinoid System in Pain Control and Therapeutic
Implications for the Management of Acute and Chronic Pain Episodes. Curr. Neuropharmacol. 2006, 4, 239–
257, doi:10.2174/157015906778019527.
179. Garg, A.; Chaturvedi, P.; Gupta, P.C. A review of the systemic adverse effects of areca nut or betel nut.
Indian J. Med. Paediatr. Oncol. 2014, 35, 3–9, doi:10.4103/0971-5851.133702.
180. Boucher, B.J.; Mannan, N. Metabolic effects of the consumption of Areca catechu. Addict. Biol. 2002, 7, 103–
110, doi:10.1080/13556210120091464.
181. Johnston, G.; Krogsgaard-Larsen, P.; Stephanson, A. Betel nut constituents as inhibitors of gamma-
aminobutyric acid uptake. Nature 1975, 258, 627–628, doi:10.1038/258627a0.
182. Lodge, D.; Johnston, G.A.R.; Curtis, D.R.; Brand, S.J. Effects of the Areca nut constituents arecaidine and
guvacine on the action of GABA in the cat central nervous system. Brain Res. 1977, 136, 513–522,
183. Volgin, A.D.; Bashirzade, A.; Amstislavskaya, T.G.; Yakovlev, O.A.; Demin, K.A.; Ho, Y.J.; Wang, D.;
Shevyrin, V.A.; Yan, D.; Tang, Z.; et al. DARK Classics in Chemical Neuroscience: Arecoline. ACS Chem.
Neurosci. 2019, 10, 2176–2185, doi:10.1021/acschemneuro.8b00711.
184. Wu, M.; Fang, M.; Hu, Y.; Wang, X. Four types of traditional Chinese medicine inducing epileptic seizures.
Seizure 2012, 21, 311–315, doi:10.1016/j.seizure.2012.02.010.
185. Shih, Y.T.; Chen, P.S.; Wu, C.H.; Tseng, Y.T.; Wu, Y.C.; Lo, Y.C. Arecoline, a major alkaloid of the areca nut,
causes neurotoxicity through enhancement of oxidative stress and suppression of the antioxidant
protective system. Free Radic. Biol. Med. 2010, 49, 1471–1479, doi:10.1016/j.freeradbiomed.2010.07.017.
186. Mannucci, C.; Calapai, F.; Cardia, L.; Inferrera, G.; D’Arena, G.; Di Pietro, M.; Navarra, M.; Gangemi, S.;
Spagnolo, E.V.; Calapai, G. Clinical pharmacology of citrus aurantium and citrus sinensis for the treatment
of anxiety. Evid.-Based Complement. Altern. Med. 2018, 2018, 3624094, doi:10.1155/2018/3624094.
187. Dosoky, N.S.; Setzer, W.N. Biological activities and safety of citrus spp. Essential oils. Int. J. Mol. Sci. 2018,
19, 1966, doi:10.3390/ijms19071966.
Pharmaceuticals 2020, 13, 309 47 of 52
188. Moraes, T.M.; Kushima, H.; Moleiro, F.C.; Santos, R.C.; Rocha, L.R.M.; Marques, M.O.; Vilegas, W.;
Hiruma-Lima, C.A. Effects of limonene and essential oil from Citrus aurantium on gastric mucosa: Role of
prostaglandins and gastric mucus secretion. Chem. Biol. Interact. 2009, 180, 499–505,
189. Stohs, S.J. Safety, Efficacy, and Mechanistic Studies Regarding Citrus aurantium (Bitter Orange) Extract
and p-Synephrine. Phyther. Res. 2017, 31, 1463–1474, doi:10.1002/ptr.5879.
190. Suntar, I.; Khan, H.; Patel, S.; Celano, R.; Rastrelli, L. An overview on citrus aurantium L.: Its functions as
food ingredient and therapeutic agent. Oxid. Med. Cell. Longev. 2018, 2018, 7864269,
191. Teneva, D.; Denkova-Kostova, R.; Goranov, B.; Hristova-Ivanova, Y.; Slavchev, A.; Denkova, Z.; Kostov, G.
Chemical composition, antioxidant activity and antimicrobial activity of essential oil from Citrus
aurantium L zest against some pathogenic microorganisms. Z. Naturforsch. C. J. Biosci. 2019, 74, 105–111,
192. Tejada, S.; Pinya, S.; Martorell, M.; Capó, X.; Tur, J.A.; Pons, A.; Sureda, A. Potential Anti-inflammatory
Effects of Hesperidin from the Genus Citrus. Curr. Med. Chem. 2018, 25, 4929–4945,
193. Wolffenbüttel, A.N.; Zamboni, A.; Becker, G.; dos Santos, M.K.; Borille, B.T.; de Cássia Mariotti, K.;
Fagundes, A.C.; de Oliveira Salomón, J.L.; Coelho, V.R.; Ruiz, L.V.; et al. Citrus essential oils inhalation by
mice: Behavioral testing, GCMS plasma analysis, corticosterone, and melatonin levels evaluation. Phyther.
Res. 2018, 32, 160–169, doi:10.1002/ptr.5964.
194. González-Mas, M.C.; Rambla, J.L.; López-Gresa, M.P.; Amparo Blázquez, M.; Granell, A. Volatile
compounds in citrus essential oils: A comprehensive review. Front. Plant Sci. 2019, 10, 12,
195. Mahato, N.; Sharma, K.; Koteswararao, R.; Sinha, M.; Baral, E.R.; Cho, M.H. Citrus essential oils: Extraction,
authentication and application in food preservation. Crit. Rev. Food Sci. Nutr. 2019, 59, 611–625,
196. Escamilla-García, M.; Calderón-Domínguez, G.; Chanona-Pérez, J.J.; Mendoza-Madrigal, A.G.; Di Pierro,
P.; García-Almendárez, B.E.; Amaro-Reyes, A.; Regalado-González, C. Physical, structural, barrier, and
antifungal characterization of chitosan-zein edible films with added essential oils. Int. J. Mol. Sci. 2017, 18,
2370, doi:10.3390/ijms18112370.
197. Moslemi, F.; Alijaniha, F.; Naseri, M.; Kazemnejad, A.; Charkhkar, M.; Heidari, M.R. Citrus aurantium
Aroma for Anxiety in Patients with Acute Coronary Syndrome: A Double-Blind Placebo-Controlled Trial.
J. Altern. Complement. Med. 2019, 25, 833–839, doi:10.1089/acm.2019.0061.
198. de Sousa, D.P.; de Almeida Soares Hocayen, P.; Andrade, L.N.; Andreatini, R. A systematic review of the
anxiolytic-like effects of essential oils in animal models. Molecules 2015, 20, 18620–18660,
199. Costa, C.A.R.A.; Cury, T.C.; Cassettari, B.O.; Takahira, R.K.; Flório, J.C.; Costa, M. Citrus aurantium L.
essential oil exhibits anxiolytic-like activity mediated by 5-HT1A-receptors and reduces cholesterol after
repeated oral treatment. BMC Complement. Altern. Med. 2013, 13, 42, doi:10.1186/1472-6882-13-42.
200. Akhlaghi, M.; Shabanian, G.; Rafieian-Kopaei, M.; Parvin, N.; Saadat, M.; Akhlaghi, M. Citrus Aurantium
Blossom and Preoperative Anxiety. Rev. Bras. Anestesiol. 2011, 61, 702–712, doi:10.1016/S0034-
201. Bahr, T.A.; Rodriguez, D.; Beaumont, C.; Allred, K. The effects of various essential oils on epilepsy and
acute seizure: A systematic review. Evid. Based Complement. Altern. Med. 2019, 2019, 6216745,
202. Komiya, M.; Takeuchi, T.; Harada, E. Lemon oil vapor causes an anti-stress effect via modulating the 5-HT
and DA activities in mice. Behav. Brain Res. 2006, 172, 240–249, doi:10.1016/j.bbr.2006.05.006.
203. Ghiasi, A.; Bagheri, L.; Haseli, A. A Systematic Review on the Anxiolytic Effect of Aromatherapy during
the First Stage of Labor. J. Caring Sci. 2019, 8, 51–60, doi:10.15171/jcs.2019.008.
204. Jabri Karoui, I.; Marzouk, B. Characterization of bioactive compounds in Tunisian bitter orange (Citrus
aurantium L.) peel and juice and determination of their antioxidant activities. Biomed Res. Int. 2013, 2013,
345415, doi:10.1155/2013/345415.
Pharmaceuticals 2020, 13, 309 48 of 52
205. Hansen, D.K.; George, N.I.; White, G.E.; Abdel-Rahman, A.; Pellicore, L.S.; Fabricant, D. Cardiovascular
toxicity of Citrus aurantium in exercised rats. Cardiovasc. Toxicol. 2013, 13, 208–219, doi:10.1007/s12012-013-
206. Brown, A.C. Heart Toxicity Related to Herbs and Dietary Supplements: Online Table of Case Reports. Part
4 of 5. J. Diet. Suppl. 2018, 15, 516–555, doi:10.1080/19390211.2017.1356418.
207. Bae, K.; Kwon, N. ji; Han, E. A review on the abuse of three NPS (synthetic cannabinoids, kratom, poppers)
among youths in Asia. Forensic Sci. Int. 2018, 292, 45–49, doi:10.1016/j.forsciint.2018.09.008.
208. Singh, D.; Müller, C.P.; Vicknasingam, B.K.; Mansor, S.M. Social Functioning of Kratom (Mitragyna
speciosa) Users in Malaysia. J. Psychoact. Drugs 2015, 47, 125–131, doi:10.1080/02791072.2015.1012610.
209. Brown, P.N.; Lund, J.A.; Murch, S.J. A botanical, phytochemical and ethnomedicinal review of the genus
Mitragyna korth: Implications for products sold as kratom. J. Ethnopharmacol. 2017, 202, 302–325,
210. Prozialeck, W.C. Update on the pharmacology and legal status of Kratom. J. Am. Osteopath. Assoc. 2016,
116, 802–809, doi:10.7556/jaoa.2016.156.
211. Matsumoto, K.; Horie, S.; Ishikawa, H.; Takayama, H.; Aimi, N.; Ponglux, D.; Watanabe, K. Antinociceptive
effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai
medicinal herb Mitragyna speciosa. Life Sci. 2004, 74, 2143–2155, doi:10.1016/j.lfs.2003.09.054.
212. Yamamoto, L.T.; Horie, S.; Takayama, H.; Aimi, N.; Sakai, S.I.; Yano, S.; Shan, J.; Pang, P.K.T.; Ponglux, D.;
Watanabe, K. Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with
mitragynine derived from Thai medicinal plant Mitragyna speciosa. Gen. Pharmacol. 1999, 33, 73–81,
213. LaBryer, L.; Sharma, R.; Chaudhari, K.S.; Talsania, M.; Scofield, R.H. Kratom, an Emerging Drug of Abuse,
Raises Prolactin and Causes Secondary Hypogonadism: Case Report. J. Investig. Med. High Impact Case Rep.
2018, 6, doi:10.1177/2324709618765022.
214. Matsumoto, K.; Horie, S.; Takayama, H.; Ishikawa, H.; Aimi, N.; Ponglux, D.; Murayama, T.; Watanabe, K.
Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from
the Thai medicinal herb Mitragyna speciosa. Life Sci. 2005, 78, 2–7, doi:10.1016/j.lfs.2004.10.086.
215. Trakulsrichai, S.; Sathirakul, K.; Auparakkitanon, S.; Krongvorakul, J.; Sueajai, J.; Noumjad, N.; Sukasem,
C.; Wananukul, W. Pharmacokinetics of mitragynine in man. Drug Des. Devel. Ther. 2015, 9, 2421–2429,
216. Veltri, C.; Grundmann, O. Current perspectives on the impact of Kratom use. Subst. Abus. Rehabil. 2019, 10,
23–31, doi:10.2147/sar.s164261.
217. Fluyau, D.; Revadigar, N. Biochemical benefits, diagnosis, and clinical risks evaluation of kratom. Front.
Psychiatry 2017, 8, 62, doi:10.3389/fpsyt.2017.00062.
218. Liu, L.; Xu, F.-R.; Wang, Y.-Z. Traditional uses, chemical diversity and biological activities of Panax L.
(Araliaceae): A review. J. Ethnopharmacol. 2020, 263, 112792, doi:10.1016/j.jep.2020.112792.
219. Won, H.J.; Kim, H. Il; Park, T.; Kim, H.; Jo, K.; Jeon, H.; Ha, S.J.; Hyun, J.M.; Jeong, A.; Kim, J.S.; et al. Non-
clinical pharmacokinetic behavior of ginsenosides. J. Ginseng Res. 2019, 43, 354–360,
220. Chen, W.; Balan, P.; Popovich, D.G. Chapter 6—Comparison of the ginsenoside composition of Asian
ginseng (Panax ginseng) and American ginseng (Panax quinquefolius L.) and their transformation
pathways. In Bioactive Natural Product, 1st ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2019; Volume
63, pp. 161–195.
221. Leung, K.W.; Wong, A.S. Ginseng and male reproductive function. Spermatogenesis 2013, 3, e26391,
222. Mancuso, C.; Santangelo, R. Panax ginseng and Panax quinquefolius: From pharmacology to toxicology.
Food Chem. Toxicol. 2017, 107, 362–372, doi:10.1016/j.fct.2017.07.019.
223. Ellis, J.M.; Reddy, P. Effects of Panax ginseng on quality of life. Ann. Pharmacother. 2002, 36, 375–379,
224. Lee, S.-T.; Chu, K.; Sim, J.-J.; Heo, J.-H.; Kim, M. Panax ginseng enhances cognitive performance in
Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008, 22, 222–226, doi:10.1097/WAD.0b013e31816c92e6.
225. Heo, J.-H.; Lee, S.-T.; Oh, M.J.; Park, H.-J.; Shim, J.-Y.; Chu, K.; Kim, M. Improvement of cognitive deficit in
Alzheimer’s disease patients by long term treatment with Korean red ginseng. J. Ginseng Res. 2011, 35, 457–
461, doi:10.5142/jgr.2011.35.4.457.
Pharmaceuticals 2020, 13, 309 49 of 52
226. Lee, N.-H.; Yoo, S.-R.; Kim, H.-G.; Cho, J.-H.; Son, C.G. Safety and tolerability of panax ginseng root extract:
A randomized, placebo-controlled, clinical trial in healthy Korean volunteers. J. Altern. Complement. Med.
2012, 18, 1061–1069, doi:10.1089/acm.2011.0591.
227. Steiner, G.Z.; Yeung, A.; Liu, J.X.; Camfield, D.A.; de Blasio, F.M.; Pipingas, A.; Scholey, A.B.; Stough, C.;
Chang, D.H. The effect of Sailuotong (SLT) on neurocognitive and cardiovascular function in healthy
adults: A randomised, doubleblind, placebo controlled crossover pilot trial. BMC Complement. Altern. Med.
2016, 16, 15, doi:10.1186/s12906-016-0989-0.
228. Keshavan, M.; Jones, D.A.; Dube, S.; Grabowski, J.; Bell, J.; Sitaram, N. Cardioacceleratory responses to
arecoline infusion during sleep in depressive, anxious, and normal subjects. Biol. Psychiatry 1987, 22, 1473–
1477, doi:10.1016/0006-3223(87)90106-5.
229. Coon, J.T.; Ernst, E. Panax ginseng: A systematic review of adverse effects and drug interactions. Drug Saf.
2002, 25, 323–344, doi:10.2165/00002018-200225050-00003.
230. Woroń, J.; Siwek, M. Unwanted effects of psychotropic drug interactions with medicinal products and diet
supplements containing plant extracts. Psychiatr. Pol. 2018, 52, 983–996, doi:10.12740/PP/OnlineFirst/80998.
231. Choi, M.K.; Song, I.S. Interactions of ginseng with therapeutic drugs. Arch. Pharm. Res. 2019, 42, 862–878,
232. Liu, Y.; Yu, H.Y.; Xu, H.Z.; Liu, J.J.; Meng, X.G.; Zhou, M.; Ruan, H.L. Alkaloids with Immunosuppressive
Activity from the Bark of Pausinystalia yohimbe. J. Nat. Prod. 2018, 81, 1841–1849,
233. Sun, J.; Baker, A.; Chen, P. Profiling the indole alkaloids in yohimbe bark with ultra-performance liquid
chromatography coupled with ion mobility quadrupole time-of-flight mass spectrometry. Rapid Commun.
Mass Spectrom. 2011, 25, 2591–2602, doi:10.1002/rcm.5158.
234. Raman, V.; Avula, B.; Galal, A.M.; Wang, Y.H.; Khan, I.A. Microscopic and UPLC-UV-MS analyses of
authentic and commercial yohimbe (Pausinystalia johimbe) bark samples. J. Nat. Med. 2013, 67, 42–50,
235. Cohen, P.A.; Wang, Y.H.; Maller, G.; Desouza, R.; Khan, I.A. Pharmaceutical quantities of yohimbine found
in dietary supplements in the USA. Drug Test. Anal. 2016, 8, 357–369, doi:10.1002/dta.1849.
236. Uhde, T.W.; Boulenger, J.P.; Post, R.M.; Siever, L.J.; Vittone, B.J.; Jimerson, D.C.; Roy-Byrne, P.P. Fear and
anxiety: Relationship to noradrenergic function. Psychopathology 1984, 17 (Suppl. 3), 8–23,
237. Cai, L.; Bakalli, H.; Rinaman, L. Yohimbine anxiogenesis in the elevated plus maze is disrupted by
bilaterally disconnecting the bed nucleus of the stria terminalis from the central nucleus of the amygdala.
Neuroscience 2012, 223, 200–208, doi:10.1016/j.neuroscience.2012.08.008.
238. Tam, S.W.; Worcel, M.; Wyllie, M. Yohimbine: A clinical review. Pharmacol. Ther. 2001, 91, 215–243,
239. Owen, J.A.; Nakatsu, S.L.; Fenemore, J.; Condra, M.; Surridge, D.H.C.; Morales, A. The pharmacokinetics
of yohimbine in man. Eur. J. Clin. Pharmacol. 1987, 32, 577–582, doi:10.1007/BF02455991.
240. Berlan, M.; Le, Verge, R.; Galitzky, J.; Le Corre, P. α 2-Adrenoceptor antagonist potencies of two
hydroxylated metabolites of yohimbine. Br. J. Pharmacol. 1993, 108, 927–932, doi:10.1111/j.1476-
241. Kearney, T.; Tu, N.; Haller, C. Adverse drug events associated with yohimbine-containing products: A
retrospective review of the California poison control system reported cases. Ann. Pharmacother. 2010, 44,
1022–1029, doi:10.1345/aph.1P060.
242. Shannon, M.; Neuman, M.I. Yohimbine. Pediatr. Emerg. Care 2000, 16, 49–50, doi:10.1097/00006565-
243. Rothschild, A.J. New directions in the treatment of antidepressant-induced sexual dysfunction. Clin. Ther.
2000, 22, A42–A57, doi:10.1016/S0149-2918(00)80072-7.
244. Shamloul, R. Natural aphrodisiacs. J. Sex. Med. 2010, 7, 39–49, doi:10.1111/j.1743-6109.2009.01521.x.
245. West, E.; Krychman, M. Natural Aphrodisiacs-A Review of Selected Sexual Enhancers. Sex. Med. Rev. 2015,
3, 279–288, doi:10.1002/smrj.62.
246. Cimolai, N.; Cimolai, T. Yohimbine use for physical enhancement and its potential toxicity. J. Diet. Suppl.
2011, 8, 346–354, doi:10.3109/19390211.2011.615806.
Pharmaceuticals 2020, 13, 309 50 of 52
247. Yang, H.L.; Yang, T.Y.; Gowrisankar, Y.V.; Liao, C.H.; Liao, J.W.; Huang, P.J.; Hseu, Y.C. Suppression of
LPS-Induced Inflammation by Chalcone Flavokawain A through Activation of Nrf2/ARE-Mediated
Antioxidant Genes and Inhibition of ROS/NF κ B Signaling Pathways in Primary Splenocytes. Oxid. Med.
Cell. Longev. 2020, 2020, 3476212, doi:10.1155/2020/3476212.
248. Baker, J.D. Pills, potions, products: Kava’s transformations in new and nontraditional contexts. Contemp.
Pac. 2012, 24, 233–265, doi:10.1353/cp.2012.0026.
249. Xuan, T.D.; Fukuta, M.; Wei, A.C.; Elzaawely, A.A.; Khanh, T.D.; Tawata, S. Efficacy of extracting solvents
to chemical components of kava (Piper methysticum) roots. J. Nat. Med. 2008, 62, 188–194,
250. Teschke, R.; Qiu, S.X.; Lebot, V. Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B,
and mould hepatotoxins as primarily assumed culprits. Dig. Liver Dis. 2011, 43, 676–681,
251. Baum, S.S.; Hill, R.; Rommelspacher, H. Effect of kava extract and individual kavapyrones on
neurotransmitter levels in the nucleus accumbens of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998,
22, 1105–1120, doi:10.1016/S0278-5846(98)00062-1.
252. Boonen, G.; Ferger, B.; Kuschinsky, K.; Häberlein, H. In vivo effects of the kavapyrones (+)-
dihydromethysticin and (±)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-
hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Med. 1998, 64, 507–510,
253. Anke, J.; Ramzan, I. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper
methysticum Forst. f.). J. Ethnopharmacol. 2004, 93, 153–160, doi:10.1016/j.jep.2004.04.009.
254. Mathews, J.M.; Etheridge, A.; Valentine, J.L.; Black, S.R.; Coleman, D.P.; Patel, P.; So, J.; Burka, L.T.
Pharmacokinetics and disposition of the kavalactone kawain: Interaction with kava extract and
kavalactones in vivo and in vitro. Drug Metab. Dispos. 2005, 33, 1555–1563,
255. Fu, P.P.; Xia, Q.; Guo, L.; Yu, H.; Chan, P.C. Toxicity of kava kava. J. Environ. Sci. Health C Environ. Carcinog.
Ecotoxicol. Rev. 2008, 26, 89–112, doi:10.1080/10590500801907407.
256. Clough, A.R.; Bailie, R.S.; Currie, B. Liver Function Test Abnormalities in Users of Aqueous Kava Extracts.
J. Toxicol. Clin. Toxicol. 2003, 41, 821–829, doi:10.1081/CLT-120025347.
257. White, C.M. The Pharmacology, Pharmacokinetics, Efficacy, and Adverse Events Associated With Kava. J.
Clin. Pharmacol. 2018, 58, 1396–1405, doi:10.1002/jcph.1263.
258. de Vargas, F.S.; Almeida, P.D.O.; de Boleti, A.P.A.; Pereira, M.M.; de Souza, T.P.; de Vasconcellos, M.C.;
Nunez, C.V.; Pohlit, A.M.; Lima, E.S. Antioxidant activity and peroxidase inhibition of Amazonian plants
extracts traditionally used as anti-inflammatory. BMC Complement. Altern. Med. 2016, 16, 83,
259. Siqueira, I.R.; Fochesatto, C.; Da Silva, A.L.; Nunes, D.S.; Battastini, A.M.; Netto, C.A.; Elisabetsky, E.
Ptychopetalum olacoides, a traditional Amazonian “nerve tonic”, possesses anticholinesterase activity.
Pharmacol. Biochem. Behav. 2003, 75, 645–650, doi:10.1016/S0091-3057(03)00113-8.
260. Siqueira, I.R.; Lara, D.R.; Silva, D.; Gaieski, F.S.; Nunes, D.S.; Elisabetsky, E. Psychopharmacological
properties of Ptycopetalum olacoides Bentham (Olacaceae). Pharm. Biol. 1998, 36, 327–334,
261. Pankow, E.; Auterhoff, H. Contents of Muira puama. 2. Arch. Pharm. Ber. Dtsch. Pharm. Ges. 1969, 302, 209–
212, doi:10.1002/ardp.19693020309.
262. Novello, C.R.; Marques, L.C.; Miyazaki, C.R.; Milaneze-Gutierre, M.A.; Carneiro-Torres, D.S.; Sarragiotto,
M.H.; de Mello, J.C.P. Morphoanatomy and pharmacognostic study of the wood of Croton echioides, the
Northeastern Marapuama. Braz. J. Pharmacogn. 2012, 22, 946–956, doi:10.1590/S0102-695X2012005000062.
263. Vaz, Z.R.; Mata, L.V.; Calixto, J.B. Analgesic effect of the herbal medicine Catuama in thermal and chemical
models of nociception in mice. Phyther. Res. 1997, 11, 101–106, doi:10.1002/(SICI)1099-
264. Muszyńska, B.; Łojewski, M.; Rojowski, J.; Opoka, W.; Sułkowska-Ziaja, K. Natural products of relevance
in the prevention and supportive treatment of depression. Psychiatr. Pol. 2015, 49, 435–453,
Pharmaceuticals 2020, 13, 309 51 of 52
265. Dimpfel, W.; Franklin, R.; Gericke, N.; Schombert, L. Effect of Zembrin® and four of its alkaloid constituents
on electric excitability of the rat hippocampus. J. Ethnopharmacol. 2018, 223, 135–141,
266. Manda, V.K.; Avula, B.; Ashfaq, M.K.; Abe, N.; Khan, I.A.; Khan, S.I. Quantification of mesembrine and
mesembrenone in mouse plasma using UHPLC-QToF-MS: Application to a pharmacokinetic study.
Biomed. Chromatogr. 2017, 31, e3815, doi:10.1002/bmc.3815.
267. Zhao, J.; Khan, I.A.; Combrinck, S.; Sandasi, M.; Chen, W.; Viljoen, A.M. 1H-NMR and UPLC-MS
metabolomics: Functional tools for exploring chemotypic variation in Sceletium tortuosum from two
provinces in South Africa. Phytochemistry 2018, 152, 191–203, doi:10.1016/j.phytochem.2018.03.013.
268. Smith, M.T.; Crouch, N.R.; Gericke, N.; Hirst, M. Psychoactive constituents of the genus Sceletium N.E.Br.
and other Mesembryanthemaceae: A review. J. Ethnopharmacol. 1996, 50, 119–130, doi:10.1016/0378-
269. Cashman, J.R.; Voelker, T.; Johnson, R.; Janowsky, A. Stereoselective inhibition of serotonin re-uptake and
phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg. Med. Chem. 2009, 17, 337–
343, doi:10.1016/j.bmc.2008.10.065.
270. Loria, M.J.; Ali, Z.; Abe, N.; Sufka, K.J.; Khan, I.A. Effects of Sceletium tortuosum in rats. J. Ethnopharmacol.
2014, 155, 731–735, doi:10.1016/j.jep.2014.06.007.
271. Harvey, A.L.; Young, L.C.; Viljoen, A.M.; Gericke, N.P. Pharmacological actions of the South African
medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. J. Ethnopharmacol.
2011, 137, 1124–1129, doi:10.1016/j.jep.2011.07.035.
272. Smith, C. The effects of Sceletium tortuosum in an in vivo model of psychological stress. J. Ethnopharmacol.
2011, 133, 31–36, doi:10.1016/j.jep.2010.08.058.
273. Carpenter, J.M.; Jourdan, M.K.; Fountain, E.M.; Ali, Z.; Abe, N.; Khan, I.A.; Sufka, K.J. The effects of
Sceletium tortuosum (L.) N.E. Br. extract fraction in the chick anxiety-depression model. J. Ethnopharmacol.
2016, 193, 329–332, doi:10.1016/j.jep.2016.08.019.
274. Stafford, G.I.; Pedersen, M.E.; van Staden, J.; Jäger, A.K. Review on plants with CNS-effects used in
traditional South African medicine against mental diseases. J. Ethnopharmacol. 2008, 119, 513–537,
275. Terburg, D.; Syal, S.; Rosenberger, L.A.; Heany, S.; Phillips, N.; Gericke, N.; Stein, D.J.; Van Honk, J. Acute
effects of sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human
amygdala and its connection to the hypothalamus. Neuropsychopharmacology 2013, 38, 2708–2716,
276. Coetzee, D.D.; López, V.; Smith, C. High-mesembrine Sceletium extract (TrimesemineTM) is a monoamine
releasing agent, rather than only a selective serotonin reuptake inhibitor. J. Ethnopharmacol. 2016, 177, 111–
116, doi:10.1016/j.jep.2015.11.034.
277. Bennett, A.C.; Smith, C. Immunomodulatory effects of Sceletium tortuosum (TrimesemineTM) elucidated in
vitro: Implications for chronic disease. J. Ethnopharmacol. 2018, 214, 134–140, doi:10.1016/j.jep.2017.12.020.
278. Krstenansky, J.L. Mesembrine alkaloids: Review of their occurrence, chemistry, and pharmacology. J.
Ethnopharmacol. 2017, 195, 10–19, doi:10.1016/j.jep.2016.12.004.
279. Beharry, S.; Heinrich, M. Is the hype around the reproductive health claims of maca (Lepidium meyenii
Walp.) justified? J. Ethnopharmacol. 2018, 211, 126–170, doi:10.1016/j.jep.2017.08.003.
280. Quandt, P.; Puga, M. Manic episode secondary to maca. Eur. Psychiatry 2016, 33, S339,
281. Ingawale, D.S.M.; Namdeo, A.G. Pharmacological evaluation of Ashwagandha highlighting its healthcare
claims, safety, and toxicity aspects. J. Diet. Suppl. 2020, 1–44, doi:10.1080/19390211.2020.1741484.
282. Tandon, N.; Yadav, S.S. Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human
ailments. J. Ethnopharmacol. 2020, 255, 112768, doi:10.1016/j.jep.2020.112768.
283. Estrada-Reyes, R.; Carro-Juárez, M.; Martínez-Mota, L. Pro-sexual effects of Turnera diffusa Wild
(Turneraceae) in male rats involves the nitric oxide pathway. J. Ethnopharmacol. 2013, 146, 164–172,
284. María, D.-B.A.; María, V.V.R.; Lilian, M.-N.; Lucía, M.-M.; Oscar, G.-P.; Rosa, E.R. Neurobehavioral and
toxicological effects of an aqueous extract of Turnera diffusa Willd (Turneraceae) in mice. J. Ethnopharmacol.
2019, 236, 50–62, doi:10.1016/j.jep.2019.02.036.
Pharmaceuticals 2020, 13, 309 52 of 52
285. Vilgiate, T. The Invention of Voacanga africana as a Ceremonial Psychedelic|Environment & Society Portal
Available online:
ceremonial-psychedelic (accessed on 27 August 2020).
286. Alper, K.R.; Lotsof, H.S.; Kaplan, C.D. The ibogaine medical subculture. J. Ethnopharmacol. 2008, 115, 9–24,
287. Kombian, S.B.; Saleh, T.M.; Fiagbe, N.I.Y.; Chen, X.; Akabutu, J.J.; Buolamwini, J.K.; Pittman, Q.J. Ibogaine
and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic
transmission in the rat parabrachial nucleus in vitro. Brain Res. Bull. 1997, 44, 603–610, doi:10.1016/S0361-
288. Currais, A.; Chiruta, C.; Goujon-Svrzic, M.; Costa, G.; Santos, T.; Batista, M.T.; Paiva, J.; Do Céu Madureira,
M.; Maher, P. Screening and identification of neuroprotective compounds relevant to Alzheimer’s disease
from medicinal plants of S. Tomé e Príncipe. J. Ethnopharmacol. 2014, 155, 830–840,
289. Yuan, H.; Ma, Q.; Ye, L.; Piao, G. The traditional medicine and modern medicine from natural products.
Molecules 2016, 21, 559, doi:10.3390/molecules21050559.
290. Ko, R.J. Adulterants in Asian patent medicines. N. Engl. J. Med. 1998, 339, 847,
291. World Health Organization (WHO). WHO Traditional Medicine Strategy 2014–2023. Available online:;jsessionid=55A97B8E89F5
867AF5301067143BA683?sequence=1 (accessed on 27 August 2020).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (
... Native Khoi and San tribes of South Africa have been traditionally using "Kanna" plants as a pain reliever by chewing the plant material directly and smoking the residue after chewing [12,66,70]. However, recently, this chewable plant has been prepared in various forms such as capsules, gel caps, resin, teas, and tinctures, which can be used as a snuff and smoked [70][71][72]. Despite the extensive documented history of the psychological and biological effect, few studies have proved that the Sceletium plant possesses useful analgesic properties [10,28,66,70]. ...
Full-text available
Sceletium tortuosum (L.) N.E.Br. (Mesembryanthemaceae), commonly known as kanna or kougoed, is an effective indigenous medicinal plant in South Africa, specifically to the native San and Khoikhoi tribes. Today, the plant has gained strong global attraction and reputation due to its capabilities to promote a sense of well-being by relieving stress with calming effects. Historically, the plant was used by native San hunter-gatherers and Khoi people to quench their thirst, fight fatigue and for healing, social, and spiritual purposes. Various studies have revealed that extracts of the plant have numerous biological properties and isolated alkaloids of Sceletium tortuosum are currently being used as dietary supplements for medicinal purposes and food. Furthermore, current research has focused on the commercialization of the plant because of its treatment in clinical anxiety and depression, psychological and psychiatric disorders, improving mood, promoting relaxation and happiness. In addition, several studies have focused on the isolation and characterization of various beneficial bioactive compounds including alkaloids from the Sceletium tortuosum plant. Sceletium was reviewed more than a decade ago and new evidence has been published since 2008, substantiating an update on this South African botanical asset. Thus, this review provides an extensive overview of the biological and pharmaceutical properties of Sceletium tortuosum as well as the bioactive compounds with an emphasis on antimicrobial, anti-inflammatory, anti-oxidant, antidepressant, anxiolytic, and other significant biological effects. There is a need to critically evaluate the bioactivities and responsible bioactive compounds, which might assist in reinforcing and confirming the significant role of kanna in the promotion of healthy well-being in these stressful times.
Dietary supplements (DSs) are used by 50% of Americans and 70% of United States military service members (SMs); some have adverse effects (AEs). This cross-sectional investigation examined AEs associated with specific DSs. A stratified random sample of SMs from the Air Force, Army, Marine Corps, and Navy was obtained. Volunteers completed a questionnaire reporting AEs for 96 generic and 62 specific DSs. The highest prevalence (≥1 AE) in specific DS categories was 35% prohormones, 33% weight loss supplements, 26% pre/post workout supplements, 14% herbal products, 12% multivitamin/multiminerals, 11% protein/amino acids, 9% muscle building supplements, 7% other DSs, 6% joint health products, and 5% individual vitamins/minerals. Specific DSs of concern (with proportion reporting AEs) included: Libido Max® (35%), Hydroxycut Hardcore® (33%), OxyElite® (33%), Roxylean® (31%), Growth Factor 9® (30%), Super HD® (29%), Hydroxycut Advanced® (29%), Lipo 6® (28%), The Ripper® (27%), Test Booster® (27%), Xenadrine Xtreme Thermogenic® (27%), C4 Extreme® (26%), and C4 Origional® (25%). Products marketed for weight loss, use before/after workout, and prohormones had the highest AE prevalence. DSs can contain substances with independent/additive AEs and/or interact with other ingredients or prescribed medications. Methods described here could provide a continuous surveillance system detecting dangerous DSs entering the market.
Herbal products are being increasingly used all over the world for preventive and therapeutic purposes because of the belief of their safety. They have become an important part of health care system in many countries since they can easily be purchased in the health food stores or online. However, the lack of sufficient study on their efficacy and toxicity, inadequate controls of their availability, reduce their safety. Unlike conventional drugs, herbal products are not regulated for purity and potency. Herbal products contain substances which can induce or inhibit enzymes that take part in drug metabolism. Therefore the concurrent use of drugs with some medicinal plants can cause serious adverse effects and can also decrease the efficacy of the therapy. Particularly, drugs with narrow therapeutic index and plants which can affect drug metabolizing enzymes when used together, may lead to unpredictable adverse reactions. Impurities, contaminants and adulterants found in the herbal products, are the most common malpractises in herbal raw-material trade. In this review the unpredictable adverse effects of herbal products due to their possible interactions with drugs and also due to the adulteration and contamination with prohibited chemicals will be discussed in detail.
Complementary and alternative medicine is used worldwide. The use of plant-based medicines for the prevention or treatment of disease is prevalent but not regulated or studied. Multiple countries are implementing pharmacovigilance systems to monitor the use and safety of dietary supplements. Reporting mechanisms continue to be sporadic and inconsistent, based mainly on consumer or healthcare provider reports outlining individual adverse effects (AEs) from dietary supplements. Supplement product ingredient lists may be inaccurate, claims biased, and Evidence-Based information regarding risks and benefits lacking. Healthcare providers should familiarize themselves with complementary medicine practices, the benefits and associated risks to best care for their patient populations. A global pandemic marked 2020 with the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A short review of vitamin and plant-based prevention, treatment, and associated ramifications with use of these products for coronavirus disease 2019 (COVID-19) is provided. Another world-wide dilemma is food security. Nutrieconomics and the socioeconomic ramifications of food are reviewed from a wider timeframe. Reports and reviews from 2020 describe AEs of complementary and alternative medicine and herbal dietary supplements. These are listed alphabetically by plant or supplement name.
Full-text available
Dopamine receptors are widely distributed within the brain where they play critical modulator roles on motor functions, motivation and drive, as well as cognition. The identification of five genes coding for different dopamine receptor subtypes, pharmacologically grouped as D1- (D1 and D5) or D2-like (D2S, D2L, D3, and D4) has allowed the demonstration of differential receptor function in specific neurocircuits. Recent observation on dopamine receptor signaling point at dopamine—glutamate-NMDA neurobiology as the most relevant in schizophrenia and for the development of new therapies. Progress in the chemistry of D1- and D2-like receptor ligands (agonists, antagonists, and partial agonists) has provided more selective compounds possibly able to target the dopamine receptors homo and heterodimers and address different schizophrenia symptoms. Moreover, an extensive evaluation of the functional effect of these agents on dopamine receptor coupling and intracellular signaling highlights important differences that could also result in highly differentiated clinical pharmacology. The review summarizes the recent advances in the field, addressing the relevance of emerging new targets in schizophrenia in particular in relation to the dopamine – glutamate NMDA systems interactions.
Full-text available
Oxidative stress is an important contributing factor for inflammation. Piper methysticum, also known as Kava-kava, is a shrub whose root extract has been consumed as a drink by the pacific islanders for a long time. Flavokawain A (FKA) is a novel chalcone derived from the kava plant that is known to have medicinal properties. This study was aimed at demonstrating the antioxidant molecular mechanisms mediated by FKA on lipopolysaccharide- (LPS-) induced inflammation in BALB/c mouse-derived primary splenocytes. In vitro data show that the nontoxic concentrations of FKA (2-30 μM) significantly suppressed the proinflammatory cytokine (TNF-α, IL-1β, and IL-6) release but induced the secretion of interleukin-10 (IL-10), an anti-inflammatory cytokine. It was also shown that FKA pretreatment significantly downregulated the LPS-induced ROS production and blocked the activation of the NFκB (p65) pathway leading to the significant suppression of iNOS, COX-2, TNF-α, and IL-1β protein expressions. Notably, FKA favored the nuclear translocation of Nrf2 leading to the downstream expression of antioxidant proteins HO-1, NQO-1, and γ-GCLC via the Nrf2/ARE signaling pathway signifying the FKA’s potent antioxidant mechanism in these cells. Supporting the in vitro data, the ex vivo data obtained from primary splenocytes derived from the FKA-preadministered BALB/c mice (orally) show that FKA significantly suppressed the proinflammatory cytokine (TNF-α, IL-1β, and IL-6) secretion in control-, LPS-, or Concanavalin A- (Con A-) stimulated cells. A significant decrease in the ratios of pro- and anti-inflammatory cytokines (IL-6/IL-10; TNF-α/IL-10) showed that FKA possesses strong anti-inflammatory properties. Furthermore, BALB/c mice induced with experimental pancreatitis using cholecystokinin- (CCK-) 8 showed decreased serum lipase levels due to FKA pretreatment. We conclude that with its potent antioxidant and anti-inflammatory properties, chalcone flavokawain A could be a novel therapeutic agent in the treatment of inflammation-associated diseases. 1. Introduction Inflammation is characterized as a protective biological response with complicated mechanisms and implicates immune cells and molecular mediators secreted from the cells that act against pathogens, damaged cells, or other irritants. The inflammation process rules out the initial causes of cell injury, cleans away necrotic cells, and begins tissue repairs [1]. There is a dynamic and ever-shifting balance exits between pro- and anti-inflammatory components of the immune system [2]. An uncontrolled shift of this balance towards excessive production of proinflammatory cytokines causes several major cellular events that lead to the pathogenesis and progression of inflammatory responses. Splenocytes are a type of white blood cells from the splenic origin that consists of a variety of T and B lymphocytes, dendritic cells, and macrophages which have different immune functions and release various factors in response to inflammatory and anti-inflammatory agents [3]. Various transcription factors and cellular signaling pathways are involved in the expression of proinflammatory genes in macrophages [4]. LPS (the main component of gram-negative bacterial endotoxin) is one of the primary causes of sepsis. The administration of LPS in laboratory animals duplicates that of an experimental inflammatory response. During an inflammation process, the MAPKs p38, JNK, and ERK are involved in the expression of proinflammatory genes. NFκB is a crucial factor and plays a major role in the regulation of gene expression patterns of various genes in both innate and adaptive immunities. Upon stimulation with LPS, the activated MAPKs mediate the signaling cascades leading to the activation of NFκB in activated macrophages [4, 5]. Further, LPS-mediated splenocyte activation can initiate oxygen uptake to drive oxidative stress-induced inflammation in the immune cells leading to ROS production [6]. Mulder et al. suggested that in response to activation with interferon-γ (IFN-γ) and lipopolysaccharide (LPS), spleen-derived macrophages readily acquired a proinflammatory status (M1 type) indicated by the upregulation of nitric oxide (NO) production, prostaglandin E2 (PEG2), tumor necrosis factor-α (TNF-α), and interleukins through NFκB activation [7, 8]. These proinflammatory molecules participate in the development of inflammatory reactions [9, 10]. The expression levels of cytoprotective enzymes, which are a response to oxidative stress, are primarily regulated at the transcriptional level. The Nrf2/ARE pathway controls a network of cytoprotective genes that defend against the damaging effects of oxidative and electrophilic stress and inflammation [11]. Nrf2 is an important protein that participates in the coordination of transcriptional induction for various antioxidant enzymes, which also protects them from LPS-stimulated inflammation [12]. Nrf2 is a member of the basic leucine zipper (bZIP) family of transcriptional activator proteins, and it is activated by endogenous products of oxidative stress. Nrf2 is bound to Keap-1 and stays in the cytoplasm. Due to the ‘inducers,’ Nrf2-Keap1 complex disrupts and Nrf2 undergoes rapid translocation to the nucleus, binds to antioxidant response elements (ARE), and induces the expression of antioxidant and phase II enzymes, such as heme oxygenase-1 (HO-1), NAD(P)H-quinone oxidoreductase-1 (NQO-1), gamma-glutamylcysteine synthetase (γ-GCLC), glutathione (GSH), and glutathione S-transferase A2 (GST-A2) [13]. This group of enzymes has cytoprotective, antioxidant, and anti-inflammatory effects in endotoxin-induced macrophages. Several new and natural compounds and crude herbal extracts of medicinal herbs induced the expression of phase II detoxifying enzymes in different cell types has been reported. A few of these reports, Nrf2-mediated genes employ antioxidant and anti-inflammatory activities [14]. Therefore, an effective strategy would be to reverse the negative effects of LPS-induced ROS generation through the exogenous supplementation of antioxidants. Kava-kava, scientifically known as Piper methysticum, is a shrub belonging to the pepper family Piperaceae. It is widely cultivated in various parts of the world, mainly in the Pacific islands. The aqueous root extract of kava has been consumed as a drink that has a strong odor and a pungent taste with sedative, anesthetic, and euphoriant properties. Kavalactones and chalcones are two major phytochemical ingredients present in this plant. The chalcones are derived from flavonoids with a basic molecular structure of two aromatic rings linked by an unsaturated three-carbon bridge. Chalcones in the kava plant can be recognized by their yellow appearance and are named flavokawains. Flavokawain A (FKA) is the major constituent of chalcones (0.46%) derived from kava extracts [15]. Splenocytes consist of a variety of cell populations such as T and B lymphocytes, monocytes, and macrophages, which have different immune functions and release different factors in response to the inflammatory and anti-inflammatory agents. A previous study indicated that FKA suppresses iNOS and COX-2 expression via blockade of NFκB and AP-1 activation in RAW 264.7 macrophages [16]. However, little is known about the anti-inflammatory activity of FKA in splenocytes. In this study, we further demonstrated the molecular signaling pathways associated with FKA-mediated antioxidant and anti-inflammatory properties in primary splenocytes isolated from the BALB/c mice that were challenged to the LPS-induced inflammation. 2. Materials and Methods 2.1. Reagents and Antibodies This study bought Roswell Park Memorial Institute (RPMI)-1640, fetal bovine serum (FBS), Dulbecco’s Modified Eagle’s medium (DMEM), and penicillin/streptomycin/amphotericin from Gibco BRL/Invitrogen (Carlsbad, CA, USA). We obtained LPS (from Escherichia coli 055: B5), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and 2,7-dihydrofluorescein-diacetate (DCFH2-DA) from Sigma-Aldrich (St. Louis, MO, USA). We purchased flavokawain A (FKA, %) from LKT Laboratories, Inc. (St. Paul, MN, USA). We obtained the antibodies for p65 NFκB, histone H3from Cell Signaling Technology Inc. (Danvers, MA). We purchased antibodies against iNOS, COX-2, Nrf2, NQO-1, and β-actin from Santa Cruz (Heidelberg, Germany). We procured mouse monoclonal antibodies against TNF-α, and IL-1β from Abcam (Cambridge, UK). We obtained anti-γ-GCLC and HO-1 antibodies from Gene Tex Inc. (San Antonio, TX, USA). We obtained all other chemicals and general lab equipment from either Merck & Co., Inc. (Darmstadt, Germany) or Sigma-Aldrich (St. Louis, MO, USA). 2.2. Laboratory Animals We purchased 6–8-week-old female BALB/c mice (20-25 g) from the National Animal Center (Taipei, Taiwan). They were maintained in a pathogen-free set up with a 12-h/12-h light/dull cycle. There was free access to water and rat chow (Oriental Yeast Co. Ltd., Tokyo, Japan) for all mice [17]. In accordance with “The Guidelines for the Care and Use of Laboratory Animals” suggested by the Chinese Society of Animal Science, Taiwan, all animal experiments in this study were performed as indicated. The animal conventions were endorsed by the Institutional Animal Care and Use Committee (IACUC) of China Medical University. 2.3. Primary Splenocyte Preparation Primary splenocytes were aseptically isolated from the 8–12-week-old female BALB/c mice and kept in the RPMI-1640 medium. This medium was supplemented with 0.1% of the penicillin-streptomycin-amphotericin solution and 2% of 50x tissue culture medium (TCM, a serum substitution purchased from Protide Pharmaceuticals, Inc., Lake Zurich, IL) [18]. Suitable cell numbers were evaluated using the trypan blue exclusion method and a hemocytometer. Segregated splenocytes from every animal were acclimated to a cell density of cells/mL of the RPMI-1640 medium. We procured RAW264.7 (the murine macrophage cell line) from the American Type Culture Collection (ATCC, Rockville, MD, USA). It was then cultured in 1% penicillin-streptomycin, DMEM containing 2 mM glutamine, and 10% heat-inactivated FBS at 37°C in a humidified atmosphere with 5% CO2. 2.4. In Vitro Stimulation Assays The primary splenocyte or RAW264.7 macrophage cultures were pretreated with FKA for 2 h. After incubation, PBS washed cells were exposed to the fresh medium supplemented with or without LPS (prepared in pH 7.2 PBS). Liu et al. reported that higher concentrations of (5–20 μg/mL) LPS cause significant cytotoxicity to the cells [19]. Also, Kwon et al. demonstrated the inflammation studies in RAW267.4 macrophages by using 1 μg/mL of LPS [16]. Based on this 2.5 μg/mL and 1 μg/mL concentrations of LPS were used for splenocytes and RAW264.7 cells, respectively, in the entire study. For the measurement of TNF-α, IL-1β, IL-2, IL-6, or IL-10 levels in the cell culture medium, approximately cells/well of splenocytes were cultured in a 12-well plate. These cells were either treated with FKA (0-30 μM, 72 h) to measure the effect of FKA on cytokine secretion (or) pretreated with FKA (0-30 μM, 2 h) followed by LPS (2.5 μg/mL, 72 h) to measure the protective effect of FKA on cytokine secretion from LPS-stimulated cells using the ELISA method. The cytokines, TNF-α, IL-1β, IL-2, IL-6, or IL-10 were quantified by their respective ELISA kits (R&D Systems, Minneapolis, MN, USA) using the manufacturer’s protocols [20]. 2.5. MTT Assay MTT colorimetric assay measured the effect of FKA on cell viability [21]. Splenocytes ( cells/mL in 96-well plate) or macrophages ( cells/mL in 12-well plate) were pretreated with FKA for 2 h, followed by treatment with or without LPS (2.5 or 1 μg/mL) for 72 h. After treatment, MTT (0.5 mg/mL) was added to each well and incubated at 37°C for 4 h. After the incubation period, using the 400 μL DMSO, MTT formazan crystals were dissolved and the absorbance (A570) was measured through an ELISA microplate reader (μ-Quant, Winooski, VT, USA). The cell viability was expressed as a percentage using the following formula: . 2.6. Measurement of Intracellular ROS Accumulation The intracellular ROS accumulation was measured by the DCFH2-DA fluorescence dye method [22]. Briefly, cells/mL were seeded in a 6-well plate (primary splenocytes) or cells/mL were seeded in a 12-well plate (RAW 264.7 macrophages) and then pretreated with different concentrations of FKA (for 2 h) followed by treatment with or without LPS. After incubation, 10 μM of DCFH2-DA was added to the culture medium and the incubation was continued for 30 min at 37°C. The intracellular ROS, as indicated by the dichlorofluorescein (DCF) fluorescence intensity, was measured using a Becton-Dickinson FACSCalibur flow cytometer for suspended primary splenocytes (Becton Dickinson, NJ) or fluorescence microscopy for adherent RAW 264.7 macrophages (200x magnification, Olympus, Center Valley, PA, USA). The ROS levels were measured by comparing the exhibited fluorescence intensity from any treated cells compared to the vehicle-treated cells and were assigned to 1-fold arbitrarily. 2.7. Preparation of Cell Extracts and Western Blot Analysis Approximately cells/mL of primary splenocytes (seeded in 60 mm dish) or cells/mL of RAW264.7 macrophages (seeded in a 100 mm dish) pretreated with different concentrations of FKA (2.5–30 μM) for 2 h followed by exposing to LPS (2.5 or 1 μg/mL) at different time points (1–24 h). The untreated cells were the control cells. After treatment, the cytoplasmic, nuclear fractions of the proteins were harvested using protein extracting reagents (Pierce Biotechnology, Rockford, IL, USA). The concentrations of extracted protein fractions were measured using the BCA protein assay method (Bio-Rad, Hercules, CA, USA). Equal quantities of denatured proteins (50 μg) were resolved on 8–15% gradient SDS-PAGE, followed by transfer on to PVDF membranes. Blocking buffer was used to block these (5% nonfat dry milk for 30 min) and then incubation with various primary antibodies overnight. On the next day, membranes were washed and incubated with secondary antibodies for 2 h. After the incubation, PBS-washed membranes were developed and the protein bands were visualized using a chemiluminescence substrate (Pierce Biotechnology, Rockford, IL, USA). Using AlphaEase (Genetic Technology Inc. Miami, FL, USA) densitometric analysis was carried out and the protein expression data were represented as fold over control. Throughout the western blot experiments, either β-actin (for cytosolic proteins) or histone (for nuclear proteins) proteins were considered internal protein controls [23]. 2.8. In Vivo Demonstration of Pro- and Anti-inflammatory Cytokine Levels in Control-, LPS-, or Con A-Stimulated Splenocytes Isolated from the FKA-Administered BALB/c Mice Eight BALB/c mice were randomly segregated into two groups of four mice each. These mice were orally administered with 0 (control) or 30 mg/kg of FKA (solubilized in 0.1% DMSO) for 4 h. At the end of the incubation period, all mice were sacrificed and primary splenocytes were aseptically isolated as per the procedure described above [18]. Primary splenocytes were seeded in 12-well plates ( cells/mL) and were stimulated with control (saline), LPS (2.5 μg/mL), or concanavalin A (Con A, 2.5 μg/mL) for 72 h. After the incubation period, the concentrations of secreted TNF-α, IL-1β, IL-2, IL-6, or IL-10 levels in the control-, LPS-, or Con A- stimulated cell culture medium were measured using the ELISA kits (R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer’s protocol. 2.9. Determination of Serum Lipase Concentrations in Cholecystokinin-8- (CCK-8-) Induced Experimental Pancreatitis of BALB/c Mice Twenty BALB/c mice were randomly placed into five different groups and each group was made up of four mice. The mice were administered either oral administration of FKA (in 0.1% DMSO) and/or intraperitoneal (IP) injections of cholecystokinin-8 (CCK-8). The treatments were as follows: (a) vehicle (0.1% DMSO), (b) 100 μg/kg of CCK-8 alone, (c) 15 mg/kg of FKA+100 μg/kg of CCK-8, (d) 30 mg/kg of FKA+100 μg/kg of CCK-8, and (e) 30 mg/kg of FKA alone. In the case of groups ‘c’ and ‘d,’ CCK-8 was injected into the mice for 0.5, 1.5, 2.5, and 4 h after the oral administration of FKA [22]. After the CCK-8 injections, the blood samples for the mice were collected from the retroorbital sinus and the serum lipase levels were measured by using a commercial serum lipase ELISA kit (R&D System, Minneapolis, MN, USA). 2.10. Statistical Analyses In this study, data were represented as () of three or more independent experiments. All data were analyzed using analysis of variance (ANOVA), followed by Dunnett’s test for pairwise comparison. Statistical significance was assigned as , , and compared to the untreated control cells and #,##, and ### compared to the LPS-treated group. 3. Results 3.1. FKA Mediated Differential Secretion Patterns of Pro- and Anti-inflammatory Cytokines in Primary Splenocytes We first determined the subtoxic dosage of FKA (Figure 1(a)) on primary splenocytes derived from the BALB/c mice. Primary splenocytes were treated with increasing concentrations of FKA (1 to 60 μM) or 2.5 μg/mL of LPS for 72 h. After incubation has concluded, an MTT assay was conducted to determine cell viability. The data showed that compared with control cells, splenocytes exposed to FKA did not enhance the proliferative state of splenocytes and did not induce any significant toxicity as well [24]. Based on these observations, 30 μM FKA has been used as the maximum concentration in the entire study (Figure 1(b)). Later, we tested the effect of FKA concentration on the secretion patterns of pro- and anti-inflammatory cytokines in the FKA-stimulated primary splenocyte cell culture medium. ELISA data showed that FKA dose dependently and significantly suppressed the release of proinflammatory TNF-α, IL-1β, and IL-2 but upregulated the release of anti-inflammatory IL-10 from primary splenocytes (Figures 1(c)–1(f)). This data suggested that FKA showed anti-inflammatory properties in primary splenocytes. (a)
Full-text available
Ethnopharmacological relevance Panax L. (Araliaceae) is globally-recognized plant resource suitable for the globalization of traditional Chinese medicines. It has traditionally been used as tonic agents in various ethnomedicinal systems of East Asia, especially in China. It is often used to regulate bodily functions and considered as adjuvant therapy for tumor, resuscitation of traumatic hemorrhagic shock, etc. Aim of this review This review systematically summarized the information on distributions, botanical characteristics, traditional uses, chemical components and biological activities of the genus Panax, in order to explore and exploit the therapeutic potential of this plant. Materials and methods The available information about genus Panax was collected via the online search on Web of Science, Google Scholar, PubMed, Baidu Scholar, Science Direct, China National Knowledge Infrastructure and Springer search. The keywords used include Panax, saponin, secondary metabolites, chemical components, biological activity, pharmacology, traditional medicinal uses, safety and other related words. The Plant List ( and Catalogue of Life: 2019 Annual Checklist ( databases were used to provide the scientific names, subspecies classification and distribution information of Panax. Results Panax is widely assessed concerning its phytochemistry and biological activities. To date, at least 760 chemical compounds from genus Panax were isolated, including saponins, flavonoids, polysaccharides, steroids and phenols. Among them, triterpenoid saponins and polysaccharides were the representative active ingredients of Panax plants, which have been widely investigated. Modern pharmacological studies showed that these compounds exhibited a wide range of biological activities in vitro and in vivo including antineoplastic, anti-inflammatory, hepatorenal protective, neuroprotective, immunoregulatory, cardioprotective and antidiabetic activities. Many studies also confirmed that the mechanisms of organ-protective were closely related to molecular signaling pathways, the expression of related proteins and antioxidant reactions. To sum up, genus Panax has high medicinal and social value, deserving further investigation. Conclusions The genus Panax is very promising to be fully utilized in the development of nutraceutical and pharmaceutical products. However, there is a lack of in-depth studies on ethnomedicinal uses of Panax plants. In addition, further studies of single chemical component should be performed based on the diversity of chemical structure, significant biological activities and clinical application. If the bioactive molecules and multicomponent interactions are discovered, it will be of great significance to the clinical application of Panax plants. It is an urgent requirement to carry out detailed phytochemical, pharmacology and clinical research on Panax classical prescriptions for the establishment of modern medication guidelines. Exploring the molecular basis of herbal synergistic actions may provide a new understanding of the complex disease mechanisms and accelerate the process of pharmaceutical development.
Full-text available
Objective: The purpose of the present study was to evaluate the efficacy of omega-3 and Korean red ginseng on improving attention deficit hyperactivity disorder (ADHD) symptoms and cognitive function in children with ADHD. Methods: A total of 40 children aged 6 to 12 years diagnosed with ADHD participated in this open-label trial. Participants received daily supplements containing 500 mg of omega-3 (eicosapentaenoic acid, 294 mg; docosahexaenoic acid, 206 mg) and 3 mg of Korean red ginseng extract (combination of ginsenoside Rg1, Rb1, and Rg3) for 12 weeks. No psychotropic drug was allowed during the study period. ADHD symptoms were assessed using the ADHD Rating Scale (ADHD-RS) and Clinical Global Impression-Severity (CGI-S) scale. Neuropsychological tests on sustained attention, short-term memory, and executive function were also assessed. Results: After 12 weeks, participants showed significant improvements on ADHD-RS (31.12 ± 8.82 at baseline, 24.15 ± 11.45 at endpoint; p < 0.001) and CGI-S (3.38 ± 1.18 at baseline, 2.94 ± 1.00 at endpoint; p < 0.001). On the Continuous Performance Test, commission errors significantly decreased, while reaction time significantly increased. Immediate recall and delayed recall on both Auditory Verbal Learning Test and Complex Figure Test showed significant improvements. Scores of Color-Word Task from Stroop Color-Word Test also showed significant improvements after the treatment. The supplement was well tolerated. Conclusion: The results of this pilot study suggest that the combination of omega-3 and Korean red ginseng may improve ADHD symptoms and cognitive function including attention, memory, and executive function in children with ADHD. Future randomized placebo-controlled trials with a larger sample is warranted.
The family Arecaceae includes 181 genera and 2,600 species with a high diversity in physical characteristics. Areca plants, commonly palms, which are able to grow in nearly every type of habitat, prefer tropical and subtropical climates. The most studied species Areca catechu L. contains phytochemicals as phenolics and alkaloids with biological properties. The phenolics are mainly distributed in roots followed by fresh unripe fruits, leaves, spikes, and veins, while the contents of alkaloids are in the order
Withania somnifera, commonly known as "Ashwagandha" or "Indian ginseng" is an essential therapeutic plant of Indian subcontinent regions. It is regularly used, alone or in combination with other plants for the treatment of various illnesses in Indian Systems of Medicine over the period of 3,000 years. Ashwagandha (W. somnifera) belongs to the genus Withania and family Solanaceae. It comprises a broad spectrum of phytochemicals having wide range of biological effects. W. somnifera has demonstrated various biological actions such as anti-cancer, anti-inflammatory, anti-diabetic, anti-microbial, anti-arthritic, anti-stress/adaptogenic, neuro-protective, cardio-protective, hepato-protective, immunomodulatory properties. Furthermore, W. somnifera has revealed the capability to decrease reactive oxygen species and inflammation, modulation of mitochondrial function, apoptosis regulation and improve endothelial function. Withaferin-A is an important phytoconstituents of W. somnifera belonging to the category of withanolides been used in the traditional system of medicine for the treatment of various disorders. In this review, we have summarized the active phytoconstituents, pharmacologic activities (preclinical and clinical), mechanisms of action, potential beneficial applications, marketed formulations and safety and toxicity profile of W. somnifera.
Kava kava (Piper methysticum) is a medicinal plant containing kavalactones that exert potent sedative, analgesic and anti-stress effects. However, their pharmacological effects and molecular targets remain poorly understood. The zebrafish (Danio rerio) has recently emerged as a powerful new model organism for neuroscience research and drug discovery. Here, we evaluate the effects of acute and chronic exposure to kava and kavalactones on adult zebrafish anxiety, aggression and sociality, as well as neurochemical, neuroendocrine and genomic responses. Supporting evolutionarily conserved molecular targets, acute kava and kavalactones evoked dose-dependent behavioral inhibition, upregulated brain expression of early protooncogenes c-fos and c-jun, elevated brain monoamines and lowered whole-body cortisol. Chronic 7-day kava exposure evoked similar behavioral effects, did not alter cortisol levels, and failed to evoke withdrawal-like states upon discontinuation. Chronic kava upregulated several microglial (iNOS, Egr-2, CD11b), astrocytal (C3, C4B, S100a), epigenetic (ncoa-1) and pro-inflammatory (IL-1β, IL-6, TNFa) biomarker genes, downregulated CD206 and IL-4 and did not affect major apoptotic genes. Collectively, this study supports evolutionarily conserved behavioral and physiological effects of kava and kavalactones in zebrafish, implicates brain monoamines in their acute effects, and provides novel important insights into potential role of neuroglial and epigenetic mechanisms in long-term kava use.
Ethnopharmacological relevance Withania somnifera popularly known as Aswagandha or Indian Ginseng/Poison Gooseberry have thousands years of history of use in Indian traditional medicine. Besides, finding place root of the plant as Indian Ginseng, Ayurveda also uses root of this plant as general health tonic, adaptogenic, nootropic, immunomodulatoryetc. With its widespread and growing use, it becomes prudent to scientifically evaluate and document both the efficacy and safety of this plant in humans. Aim of the study Aswagnadha root is rapidly gaining popularity abroad for use as medicine. Current article attempts to primarily review the human efficacy and safety of Aswagandha generated through clinical trials. Methods A systematic search both for indexed and non-indexed literature was made for W. somnifera using various search engines and databases and the details of research articles pertaining to all clinical trials/human studies, animal studies addressing safety issues of CNS, CVS, general toxicity, mutagenicity, genotoxicity, reproductive safety and herb-drug interactions were reviewed and compiled comprehensively from full texts. Results A total of 69 (39 pre-clinical and 30 clinical) studies documenting efficacy and safety aspects were identified and the desired information of these studies is comprehensively presented in this review. Retrieved thirty(30) human studies demonstrated reasonable efficacy of root preparations in subclinical hypothyroidism (1), schizophrenia (3), chronic stress (2), insomnia (2), anxiety (1), memory and cognitive improvement (2), obsessive-compulsive disorder (1), rheumatoid arthritis (2), type-2 diabetes (2), male infertility (6), fertility promotion activity in females (1), adaptogenic (3), growth promoter in children (3) and chemotherapy adjuvant (1). Reasonable safety of root preparations of Aswagandha has been established by these retrieved 30 human trials. No serious adverse events or any changes in haematological, biochemical or vital parameters were reported in these human studies. Only mild and mainly transient type adverse events of somnolence, epigastric pain/discomfort and loose stools were reported as most common (>5%); and giddiness, drowsiness, hallucinogenic, vertigo, nasal congestion (rhinitis), cough, cold, decreased appetite, nausea, constipation, dry mouth, hyperactivity, nocturnal cramps, blurring of vision, hyperacidity, skin rash and weight gain were reported as less common adverse events. Pre-clinical chronic toxicity studies conducted up to 8 months also found root extracts to be safe. No mutagenicity or genotoxicity was reported for the root; only mild CNS depression and increase in thyroxine (T4) levels were reported with rootby some studies. Further, there was no in vitro and in vivo inhibition seen for CYP3A4 and CYP2D6, the two major hepatic drug metabolizing enzymes. Conclusion Root of the Ayurvedic drug W. somnifera (Aswagandha) appears a promising safe and effective traditional medicine for management of schizophrenia, chronic stress, insomnia, anxiety, memory/cognitive enhancement, obsessive-compulsive disorder, rheumatoid arthritis, type-2 diabetes and male infertility, and bears fertility promotion activity in females adaptogenic, growth promoter activity in children and as adjuvant for reduction of fatigue and improvement in quality of life among cancer patients undergoing chemotherapy. Properly designed, randomized-controlled, large-size, prospective trials with standardized preparations are needed to ascertain efficacy of Aswagandha root in previously studied and other new indications.
Kratom (Mitragyna speciosa), an indigenous medicinal plant of Southeast Asia, is believed to be harmful. We compared the perceptions toward kratom use among kratom users and non-users in Malaysia. 356 respondents (137 kratom users and 219 non-users) were recruited for this cross-sectional study. The majority of respondents were male (60%, n = 212/356), Malays (88%), and 51% were ≥37 years old. Non-users showed higher unadjusted odds of reporting a perception that kratom use can cause addiction (OR = 6.72, CI: 3.91–11.54, p < .0001), withdrawal symptoms (OR = 7.58, CI: 4.62–12.42, p < .0001), illicit drug use problems (OR = 10.12, CI: 6.14–16.68, p < .0001), impaired social-functioning (OR = 12.05, CI: 7.24–20.05, p < .0001), and health problems (OR = 10.44, CI: 6.32–17.24, p < .0001). Similarly, non-users viewed kratom policies differently from kratom users, displaying increased odds of reporting the belief that kratom use and sales must be regulated with stringent laws (OR = 5.75, CI: 3.61–9.18, p < .0001), and kratom should be regulated instead under the Dangerous Drugs Act 1952 to overcome kratom use problems (OR = 8.26, CI: 4.94–13.82, p < .0001). Because of the disconnect in kratom use perceptions and personal experiences between kratom users and non-users, hastily criminalizing kratom without investigating carefully its scientific merits can significantly impede future kratom research.
Introduction Erectile dysfunction (ED) is the inability to attain or sustain an erection for sexual intercourse. Affected men endorse difficulties with intimacy and feelings of guilt and shame. Although medical treatments are available, patients are reluctant to discuss ED with physicians and often use dietary supplements to attempt to treat their ED. As such, there is a need to better understand the effects of ingredients used in nutraceuticals for ED treatment. Objectives To summarize the literature on the efficacy and safety of the most common ingredients used in ED supplements. Methods 10 of the most common ingredients in ED supplements were reviewed using PubMed-indexed literature to assess their efficacy and safety in treating ED. Key findings were summarized to include historical use, active ingredients, prior animal studies, human studies, and toxicity. Results Nutraceuticals used in ED treatment include a variety of ingredients. Although L-arginine is a safe supplement with clinical data supporting improved erectile function, limited data exist on the efficacy of other ingredients in the treatment of ED. Conclusion Despite the growing use of supplements for treatment of sexual dysfunction, ED supplements remain poorly studied, with limited data demonstrating efficacy of individual ingredients. Further study is required to definitively determine the efficacy of nutraceuticals in ED treatment. Srivatsav A, Balasubramanian A, Pathak UI, et al. Efficacy and Safety of Common Ingredients in Aphrodisiacs Used for Erectile Dysfunction: A Review. J Sex Med 2020;XX:XXX–XXX.